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Abstract	
Therapies	capable	of	inducing	and	maintaining	endoscopic	mucosal	healing	(MH)	in	Crohn’s	Disease	
(CD)	are	vital,	as	emerging	data	suggest	that	rapid	early	and	sustained	MH	in	CD	is	associated	with	
less	frequent	clinical	relapses,	fewer	hospitalisations	and	reduced	intestinal	resections	(IR).	(1)	Use	
of	 Exclusive	 Enteral	 Nutrition	 (EEN)	 induction	 over	 corticosteroids	 (CS)	 in	 children	 with	 CD	 is	
associated	with	better	early	MH	rates,	but	medium	to	long-term	benefits	are	not	well	established.	
We	hypothesised	that	early	complete	mucosal	recovery	after	EEN	induction	therapy	will	 lead	to	a	
greater	relapse	free	survival	and	reduction	 in	need	for	CS	and	anti-TNF	use.	 	 	The	primary	aim	of	
thesis	is	to	investigate	benefits	of	EEN	and	early	maintenance	thiopurines	(TP)	use	on	early	mucosal	
recovery,	and	 its	 impact	on	the	subsequent	clinical	course.	Secondary	aims	were	to	relate	clinical	
disease	activity,	biomarker	response	and	mucosal	microbiome	characteristics	of	children	with	early	
mucosal	recovery	(responders)	vs.	mucosal	non-responders	to	EEN.	
This	thesis	is	comprised	of	five	main	studies.		
Study	one:	 Importance	of	 initial	 induction	 therapy	on	medium-term	outcomes	with	 routine	early	
thiopurines	(TP)	use	is	not	well	documented	in	Paediatric	CD;	whether	choice	of	EEN	induction	over	
CS	 reduces	 relapses,	 need	 for	 rescue	 CS	 or	 Infliximab	 (IFX)	 and	 intestinal	 resection	 (IR)	 remains	
unclear.	In	this	retrospective	study	of	89	children	with	CD,	completing	induction	therapy	either	with	
CS	or	EEN,	we	compared	relapses,	need	for	rescue	CS	or	Infliximab	(IFX)	and	intestinal	resection	(IR)	
over	 the	 first	 two	 years.	 Choice	 of	 EEN	 over	 CS	 in	 the	 setting	 of	 early	 optimised	 TP	 use	 was	
associated	 with	 reduced	 growth	 failure	 (7%	 vs.	 26%,	 p=0.02),	 less	 CS	 dependency	 (7%	 vs.	 43%,	
p=0.002)	and	a	sustained	response	to	IFX	(86%	vs.	68%,	p=0.02).	CS/IFX-free	remission	and	IR	were	
similar.	
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Study	 two:	 	EEN	 induces	 superior	MH	 in	CD,	however,	 the	 impact	of	 EEN	 induced	early	MH	and	
early	 TP	 use	 on	 subsequent	 clinical	 outcomes	 needs	 prospective	 evaluation.In	 this	 prospective	
study	of	 twenty-six	 children,	we	 investigate	 frequency	of	early	 clinical,	biochemical,	mucosal	 and	
transmural	 remission	 of	 new	 diagnosis	 Paediatric	 CD	 following	 an	 induction	 course	 of	 EEN	with	
routine	early	TP	use.	We	compared	outcomes	of	early	responders	(Simple	Endoscopic	Score-CD	£3)	
vs.	 non-responders	 (SES-CD>3)	 at	 12	 months.	 We	 confirmed	 early	 good	 endoscopic	 response	
(Simple	 Endoscopic	 Score	 for	 CD,	 0-3)	 was	 associated	 with	 reduction	 in	 endoscopic	 confirmed	
relapse	(53%	vs.	100	%,	p	=	0.02),	anti-TNF	use	(33%	vs.	88	%,	p	=	0.01)	and	hospitalisation	(40	vs.	
88	%)	at	1	year.		
Study	three:	Repeat	endoscopy	to	document	mucosal	inflammation	following	CD	induction	therapy	
is	invasive.	Paediatric	studies	using	proxies	of	mucosal	inflammation	like	Paediatric	Crohn’s	Disease	
activity	 (PCDAI),	 C	 reactive	 protein	 (CRP)	 and	 Faecal	 Calprotectin	 (FC)	 against	 a	 validated	
endoscopic	 disease	 activity	 tool	 are	 not	 available.	 In	 this	 prospective	 sub-study,	 twenty-four	
children	 (<16	 years)	 with	 CD	 and	 a	 complete	 Ileo-colonoscopy	 at	 diagnosis	 and	 after	 induction	
therapy	 (EEN=20,	 CS=4)	 were	 included.	 Endoscopic	 disease	 activity	 was	 quantified	 using	 simple	
endoscopic	 score	 for	 CD	 (SES-CD).	 	 PCDAI	 had	 poor	 correlation	 (r=0.33);	 CRP	 (r=0.54)	 and	 FC	
(r=0.46)	 had	moderate	 correlation	with	 SES-CD	 at	 diagnosis.	 After	 induction	 therapy:	 13/24	with	
active	endoscopic	disease	(SES-CD≥3)	were	in	biological	remission	(PCDAI	<	10	and	CRP	<	5mg/L).	FC	
had	the	best	individual	correlation	(r=0.50)	in	predicting	endoscopic	disease	inactivity.	FC<500	μg/g	
of	stool	(Positive	likelihood	ratio,	3.2)	and	FC	drop	>50%	(PLR	3.8)	had	a	greater	predictive	value	for	
inactive	disease	(SES-CD<3).	
Study	four:	 In	this	extension	study,	we	reported	 longitudinal	outcomes	of	early,	EEN	induced	MH	
for	predicting	sustained	biological	 remission	 (SR)	on	 Immuno-modulators	 (IM's)	without	 the	need	
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for	 additional	 therapies	 including	 CS,	 IFX	 or	 Intestinal	 resection	 (IR).	 Fifty-four	 newly	 diagnosed	
children	 completing	 at	 least	 6	 weeks	 EEN	 with	 paired	 clinical	 (PCDAI),	 biochemical	 (CRP)	 and	
endoscopy	scores	(SES-CD)	at	diagnosis	and	post	EEN	were	analysed.	All	commenced	IM's	early	and	
had	minimum	1	 year	 follow	up.	 Primary	outcome	was	 SR.	 Complete	MH	was	 SES-CD=0	and	 SES-
CD≥1	ascribed	active	endoscopic	disease	(aED).	Complete	MH	was	observed	 in	18/54	(33%),	near	
complete	MH	(SES=1-3)	in	10/54(19%).	SR	was	superior	in	those	with	complete	MH	vs.	aED;	13/18,	
(72%)	vs.	10/36	(28%),	p=0.003	at	1	year,	8/16,	(50%)	vs.	3/24,	(8%),	p=0.008	at	2	years	and	(8/16,	
(50%)	vs.	1/19,	(6%),	p=0.005)	at	3	years.	
Study	 five:	 Faecal	 microbiome	 studies	 report	 EEN	 induced	 remission	 coincides	 with	 reduced	
bacterial	 diversity,	 however	 the	 mucosa-associated	 microbiome	 (MAM)	 is	 distinct	 and	 poorly	
reflected	 in	 faeces.	We	characterised	 the	MAM	of	pinch	biopsies	collected	at	diagnosis	and	after	
completion	of	EEN	from	eight	treatment	naïve	children	diagnosed	with	CD;	and	relate	changes	 in	
profiles	with	correspondent	SES-CD.	16S	rRNA	gene	amplicon	libraries	of	MAM	communities	were	
produced	and	sequenced	using	Illumina	MiSeq	platforms	and	analysed	using	QIIME	packages.	Gross	
alterations	 in	MAM	profiles	after	EEN	were	similar	to	those	found	in	previous	faecal	studies.	 	We	
demonstrated	 that	 microbial	 diversity	 post	 EEN	 in	 those	 with	 complete	 MH	 not	 only	 shows	 a	
greater	contraction	in	microbial	diversity	but	a	shift	in	the	Firmicutes	family	from	Ruminococcaceae	
to	Lachnospiraceae,	a	reduction	in	presumptive	protective	bacteria	F.prausnitzii	and	an	increase	in		
genus	Dorea.	
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Conclusion:	
Through	a	number	of	peer-reviewed	publications	arising	from	this	Ph.D.,	this	thesis	demonstrates	
that	EEN	provides	excellent	clinical,	biomarker	and	endoscopic	mucosal	healing	and	early,	complete	
endoscopic	MH	 is	associated	with	sustained	remission	on	 Immuno-modulators	 (IM's)	without	 the	
need	for	additional	therapies	including	CS,	IFX	or	IR.	
We	also	demonstrate	EEN	therapy,	when	compared	to	induction	therapy	with	CS,	is	associated	with	
reduced	growth	failure,	reduced	steroid	dependency	over	the	next	2	years	and	improved	sustained	
response	 rates	 in	 those	children	 later	 treated	with	 infliximab.	We	demonstrate	 the	 limitations	of	
currently	used	non-invasive	markers	 to	accurately	predict	MH	after	EEN.	 	We	conclude	with	sub-
analysis	 of	 the	 pre-	 &	 post	 EEN	 mucosal	 associated	 microbiome,	 which	 demonstrates	 gross	
alterations	 in	 mucosal	 microbiota	 similar	 to	 stool	 microbiome	 following	 EEN	 as	 reported	 by	
previous	studies.		We	demonstrate	the	novel	finding	that	microbial	diversity	post	EEN	in	those	with	
complete	MH	not	only	shows	contraction	in	microbial	diversity	but	a	shift	in	the	Firmicutes	family	
from	 Ruminococcaceae	 to	 Lachnospiraceae,	 a	 reduction	 in	 presumptive	 protective	 bacteria	 F	
prausnitzii	 and	 an	 increase	 in	 presumptive	 genus	 Dorea.	 The	 relevance	 of	 these	 MAM	 findings	
needs	 to	be	validated	 in	a	 larger	sample	size	but	our	pilot	data	challenges	 the	hitherto	simplistic	
assumption	 that	 mucosal	 recovery	 depends	 on	 correction	 of	 reduced	 microbial	 diversity	 and	
supports	 the	 concept	 of	 encouraging	 the	 recovery	 of	 certain	 microbial	 species	 for	 improved	
outcomes.	
This	thesis	adds	significant	and	practice	changing	clinical	and	preliminary	microbiological	data	in	the	
field	 of	 Inflammatory	 Bowel	 Disease	 by	 highlighting	 the	 value	 and	 utility	 of	 EEN	 in	 the	 optimal	
management	of	Crohn’s	disease	in	children	and	by	extension,	in	adults.		
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Chapter	1	
Introduction	and	Literature	review	
	
	
	
The	purpose	of	this	chapter	is	to:	
1. Epidemiology	and	Pathogenesis		
2. Highlight	key	differences	between	Paediatric	vs.	Adult	Onset	CD.	
3. Review	efficacy	of	Exclusive	Enteral	Nutrition	therapy	in	Crohn’s	Disease.	
4. Review	mechanisms	of	action	of	EEN	in	CD	
5. Discuss	the	importance	of	attaining	early	mucosal	healing	in	Crohn's	disease.	
6. Provide	hypotheses	and	frame	study	questions.	
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Introduction:	
Crohn’s	Disease	(CD)	is	a	chronic,	debilitating	gut	disorder	affecting	growth,	well-being,	education,	
and	employment	and	nearly	5-10	%	of	patients	are	diagnosed	before	16	years	of	age.	(2)	Paediatric	
onset	 Crohn's	 disease	 is	 a	 more	 severe	 phenotype	 with	 the	 additional	 issues	 of	 growth	 failure,	
delayed	puberty,	poor	bone	density	and	the	consequences	of	a	chronic	disease	commencing	at	a	
vulnerable	 period	 of	 psychosocial	 development.	 Cohort	 studies	 comparing	 the	 clinical	 course	 of	
paediatric	 vs.	 adult-onset	 CD	 confirm	 the	 more	 aggressive	 nature	 with	 extensive	 intestinal	
involvement,	rapid	progression	and	increased	disease	activity	 index,	year	by	year,	despite	the	use	
of	more	immunosuppression	(3-5).	These	observations	demand	the	need	for	both	better	treatment	
endpoints	 and	 interventions	 in	 the	 paediatric	 population.	 Mucosal	 healing	 has	 emerged	 as	 an	
important	end-point,	which	when	achieved	in	the	first	year,	leads	to	less	frequent	clinical	relapses,	
fewer	 hospitalisations,	 reduced	 surgical	 resections	 and	 lower	 risk	 of	 fistulising	 disease	 (5-7).	
Treatments	 for	 induction	 of	 remission	 in	 CD	 include	 EEN	 (exclusive	 enteral	 nutrition),	
corticosteroids	 (CS)	 and	 biologic	 agents.	 High-quality	 studies	 and	 those	 in	 paediatric	 cohorts	
comparing	steroids	and	EEN	for	induction	of	clinical	remission	show	them	to	be	equally	effective	in	
up	to	80%	of	patients	(9).	However,	clinical	remission	indicated	by	improved	symptom	control	alone	
is	 inadequate.	 Not	 only	 is	mucosal	 disease	 very	 active	 in	 the	majority	 of	 asymptomatic	 patients	
treated	with	steroids	(10)	but	treatment	to	this	endpoint	over	the	past	20	years	has	failed	to	avert	
the	progressive	and	complicated	course	of	CD	(4),	particularly	 in	children.	Studies	have	confirmed	
superior	early	endoscopic	remission	with	EEN	in	CD	but	the	role	of	this	early	endoscopic	healing	on	
future	 outcomes	 beyond	 12	months	 has	 not	 been	 studied.	 (11,12).	 The	major	 hypothesis	 of	 this	
thesis	 is	 that	 inducing	 early,	mucosal	 healing(MH)	with	 EEN	 followed	by	 an	 early	 introduction	of	
conventional	 Immunomodulators	 (<	 8	weeks)	may	 lead	 to	 sustained	 remission(SR)	 and	 improved	
medium	and	long-term	outcomes.			
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Poor	 concordance	 between	 Crohn’s	 clinical	 disease	 activity	 index	 (CDAI)	 and	 endoscopic	 disease	
activity	is	well	established	in	adults	with	active	CD	with	up	to	70%	of	patients	in	clinical	remission	
having	significant	mucosal	lesions.	(10,13)	The	Paediatric	Crohn’s	Disease	activity	index	(PCDAI)	is	a	
clinical	 tool	 like	 CDAI,	 that	 includes	 subjective	 variables	 and,	 unlike	 CDAI,	 PCDAI	 has	 not	 been	
validated	against	established	endoscopic	disease	activity	scores.	The	purpose	of	our	study	was	also	
to	 correlate	 these	 proxies	 with	 simple	 endoscopic	 score	 (SES-CD)	 at	 diagnosis	 and	 assess	 their	
performance	 in	predicting	endoscopic	disease	scores	after	primary	 induction	therapy	with	EEN	or	
steroids.		
Despite	 the	success	of	EEN,	 little	 is	known	about	 the	mechanisms	of	EEN	promoting	MH,	or	why	
some	 patients	 are	 non-responders.	 In	 that	 context,	 our	 understanding	 how	 the	 gut	 mucosa-
associated	 microbiota	 (MAM)	 is	 affected	 by	 EEN	 is	 relatively	 deficient.	 Many	 recent	 studies	
exploring	 the	 stool	microbiota	 during	 EEN	 in	 paediatric	 CD	 demonstrate	 reductions	 in	microbial	
diversity,	along	with	improvement	in	clinical	disease	(symptom)	activity	scores.	(14-16)	
However,	 not	 only	 is	 the	 mucosa-associated	 microbiome	 (MAM)	 distinct	 as	 it	 is	 often	 poorly	
reflected	in	stools,	but	clinical	symptom	control	does	not	equate	to	endoscopic	healing.	(10,	17-18).	
Therefore,	 an	 understanding	 of	 changes	 in	 the	 MAM	 in	 response	 to	 EEN	 intervention,	 and	 its	
relationships	 with	 endoscopic	 mucosal	 healing	 are	 essential.	 There	 are	 no	 published	 studies	
correlating	 post	 EEN	 induction	 endoscopic	 disease	 scores	 with	 MAM	 shifts.	 We	 sought	 to	
characterise	the	MAM	of	treatment	naïve	children	with	CD,	at	diagnosis	and	after	8	weeks	EEN;	and	
relate	changes	in	these	MAM	profiles	with	correspondent	endoscopic	disease	activity	scores	(SES-
CD).		
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Literature	review	
1a.	Epidemiology	and	Pathogenesis		
Crohn’s	 Disease	 and	 Ulcerative	 Colitis	 are	 two	 major	 groups	 of	 chronic	 inflammatory	 bowel	
disorders	 (IBD)	affecting	almost	75,000	Australians	 (Crohn’s	Colitis	Australia,	March	2013).	 IBD	 in	
Australia	 is	more	common	than	road	traffic	accidents	and	almost	as	common	as	Type	1	Diabetes	
with	 the	estimated	economic	cost	of	 IBD	 to	Australia	of	over	2.7	Billion	 (“The	Economic	Costs	of	
Crohn’s	Disease	and	Ulcerative	Colitis”,	Access	Economics,	9	June	2007).		
Comprehensive	 systemic	 reviews	 of	 international	 incidence	 trends	 confirm	 a	 global	 increase	 in	
Paediatric	Onset	IBD	(19).	More	recently	another	cohort	study	reported	a	steadily	rising	incidence	
of	Paediatric	CD	in	Scotland	from	2.86/100,000/year	in	(1990-1995)	to	4.75/100,000	in	(2003-2008)	
(20).	Similar	observations	have	been	reported	in	Australian	children	with	an	over	fifteen-fold	rise	of	
CD	from	0.18/100,000	(1976-80)	to	2.09/100,000	in	(1996-2001)	(21).		
The	world-wide	rise	in	CD,	particularly	in	developing	countries	as	they	adopt	western	lifestyles	and	
low	twin	concordance	rate	of	27%	underscore	the	importance	of	lifestyle	factors	(22,	23).	There	are	
multiple	 lifestyle	 factors	 linked	 with	 risk	 of	 developing	 CD	 such	 as	 method	 of	 birth,	 antibiotic	
exposure,	smoking	and	diet.	Recent	prospective	lifestyle	and	dietary	risk	cohort	studies	suggests	a	
preventative	 role	 for	 fiber	 intake	 from	 fruits,	 vegetables	 and	 an	 increase	 risk	 of	 CD	with	 animal	
protein	 intake	 (24,	 25).	 Diet	 is	 the	 most	 frequently	 reported	 risk	 factor	 associated	 with	
inflammatory	bowel	disease	flare	by	patients,	yet	there	is	a	paucity	of	prospective	data	examining	
the	 role	 of	 dietary	 factors	 in	 perpetuating	 inflammation	 in	 CD	 (26).	 Recent	 bench	mark	 studies	
linking	dietary	factors	with	epithelial	barrier	dysfunction	associated	with	aberrant	mucosal	immune	
response	and	alterations	in	microbiota	profile	have	rekindled	interest	in	examining	the	therapeutic	
role	of	diet	in	CD	(27-29).	
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Pathogenesis	of	Crohn’s	disease	
A	widely	 accepted	 hypothetical	model	 of	 CD	 pathophysiology	 suggest	 it	 is	 an	 immune	mediated	
chronic	progressive	 inflammatory	gut	disorder	that	 is	triggered	by	a	complex	 interaction	between	
environment	exposure	(the	“exposome”)	in	a	genetically	predisposed	individual	leading	to	mucosal	
epithelial	barrier	dysfunction,	aberrant	gut	microbiota	and	immune	dysfunction.			
	
	
(Figure	1.1)		
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Figure	1.2	Pathogenesis	of	IBD	
	
	
	
Figure	1.2	Diagram	demonstrating	complex	interplay	of	genes,	environmental	factors,	microbiota	
and	 immune	 system	 contributing	 to	 pathogenesis	 of	 CD	 –	 adopted	 from	Boyapati	 (F1000Prime	
rep.)30	
	
A	 significant	 progress	 has	 been	made	 in	 genetics	 of	 CD,	with	 over	 160	 genetic	 susceptibility	 loci	
described	with	 the	 help	 of	 large	 population	 based	GWAS.	 These	 genetic	 variants	 are	 involved	 in	
diverse	 immune	 pathways	 such	 as	 paneth	 cell	 function	 (NOD2),	 autophagy	 (ATG16L1),	 epithelial	
barrier	 function	 (PTGER4)	 innate	 immunity	 (MST1,	 MAST3,	 CARD9),	 phagocytosis	 NCF4,	 NCF2,	
adaptive	immunity	(Il23R,	NKX2-3)	and	antigen	presentation	(DENND1B,	LRRK2)	(30).		Advances	in	
high	 throughput	 sequencing	 have	 also	 enhanced	 our	 understanding	 of	 how	 microbiota	 can	
contribute	 to	 pathophysiology	 of	 IBD.	 Reduction	 in	 microbial	 diversity	 have	 been	 consistently	
processing of intracellular bacteria such as Listeria
monocytogenes [18]. In humans, a cohort study found a
significant association between NOD2 risk alleles and
increased abundance of Enterobacteriaceae [39]. In
mice, NOD2 deficiency is also associated with ileal
dysbiosis [40–42] but this is not consistently replicated
[43,44]. NOD2 facilitates autophagic targeting of
bacterial pathogens via binding to the autophagy
protein ATG16L1, to be discussed later [22,45].
The NOD2 interactome is incredibly complex (Table 1),
and all respective network functions and interactions are
potentially important in CD, as they are potential novel
therapeutic or ‘druggable’ targets [12,27,46–50]. Overall,
Figure 2. Molecular mechanisms in the pathogenesis of Crohn’s disease (CD)
(A) A number of CD susceptibility genes have been identified (see text). Of these, NOD2 has the strongest association. (B) Microbial dysbiosis is
characterized by decreased diversity and changes in abundance of particular bacterial species. Increased levels of AIEC with adherent (via CEACAM6)
and invasive properties are resistant to subsequent phagocytic killing, leading to cytokine responses and inflammation. (C) Environmental (and genetic)
factors affect microbial dysbiosis and lead to epithelial barrier dysfunction, including affecting the secreted barrier. (D) One major theory of how
defective NOD2 le ds to CD: nor ally, NOD2 se ses MDP activating a number of innate immune responses and bacterial kil ing; defective NOD2 leads
to defects in these pathways, resulting in persistence of intracellular bacteria and effects on antimicrobial functions in the lumen. (E) Another major
theory on NOD2: activation via MDP leads to modulating effects on the innate immune system, including suppression of cytokine effects (for example,
IL-23-driven Th17 respons s), suppression of o her PRRs (for example, TLR-2 and TLR-4 responses), and induction of tolerance (via IL-10 and decreased
TGF-b). (F) Increased IL-23 production can lead to increased Th17 responses through a number of pathways, including ILC and CD4+ T cells via the
IL-12Rb1/IL-23R receptor. IL-23 inhibits Treg cell/IL-10 responses, which are responsible for mucosal homeostasis as well as suppressive effects on
B cells, T cells, and monocytes. NOD2 may suppress IL-23-driven Th17 responses, but in defective NOD2 these may be unrestrained; see (E).
(G) Specific microbes (such as SFB and Clostridium) as well as microbial products (such as butyrate and PSA) can induce particular innate immune
responses. SFB preferentially induces Th17 responses; Clostridium (reduced in CD), butyrate, and PSA (produced by Firmicutes and Bacteroidetes, which
are reduced in CD) potently induce Treg cell responses. (H) NOD2 recruits ATG16L1 to the plasma membrane to initiate xenophagy. Normal PC
function, including release of AMP, relies on autophagy; the T300A variant in ATG16L1 seen in some CD patients leads to increased cleavage and
defective autophagy. (I) UPR and autophagy help regulate ER stress as compensatory mechanisms. Excessive ER stress can overwhelm autophagy, leading
to defective PC function. Arrows ↑ and ↓ indicate findings in CD. AMP, anti-microbial peptide; ATG16L1, autophagy-related 16-like 1 gene; CD, Crohn’s
disease; CEACAM6, carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross-reacting antigen); ER, endoplasmic reticulum;
IL, interleukin; ILC, innate lymphoid cell; MDP, muramyl dipeptide; NOD2, nucleotide-binding oligomerization domain containing 2; PC, plasma cell;
PRR, pattern recognition receptor; PSA, polysaccharide A; SFB, segmental filamentous bacteria; TGFb, transforming growth factor-beta; Th17, T helper
17; TLR, Toll-like receptor; Treg, regulatory T; UPR, unfolded protein response.
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demonstrated	 in	 CD	 with	 specific	 taxonomic	 shifts	 with	 reduced	 abundance	 of	 firmicutes	 and	
bacteroidetes,	although	it	is	unclear	if	these	microbiota	changes	are	the	cause	or	effect	of	disease.		
Emerging	 evidence	 does	 suggest	 a	 causal	 role	 for	 dysbiosis	 in	 the	 development	 of	 CD-like	 ileal	
inflammation	in	germ	free	mice	(31).	
	
	
1b.	Natural	History	of	Crohn’s	Disease	
CD	is	a	progressive,	chronic,	destructive	 intestinal	disorder	progressing	 in	the	majority	of	patients	
from	inflammatory	to	stenosing	and/or	penetrating	behaviour	ultimately	requiring	surgery	that	 is	
not	curative	(32,33).	Thereafter	many	patients	experience	disease	recurrence	and	rerun	the	same	
disease	course	resulting	in	second	and	third	surgeries.	Paediatric	onset	Crohn's	disease	(PO-CD)	has	
a	 distinct	 phenotype	 when	 compared	 to	 Adult-onset	 CD	 (AO-CD),	 with	 the	 additional	 issues	 of	
growth	 failure,	 delayed	 puberty,	 poor	 bone	 density	 and	 the	 consequences	 of	 a	 chronic	 disease	
commencing	 at	 a	 vulnerable	 period	 of	 psychosocial	 development.	 We	 briefly	 outline	 the	 key	
differences	and	natural	history	of	 (PO-CD)	 in	comparison	 to	 (AO-CD)	with	 further	details	 in	Table	
1.1,	1.2.		
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Table	1.1.	Cohort	studies	reporting	natural	history	of	Paediatric	Crohn’s	Disease	(PO-CD)	in	the	pre-biologics	Era	
	
Study		
(time	period)	
Design	 Number	 Median	FU	in	years		 Main	Outcomes	of	Interest	
Puntis	(34)	
1935-80	
Prospective	
Clinic	visits	
67	
Ileum+/-	
Colon=38	
Colonic=18	
16.5	
(1.5-47)	
Ileum+/-	Colonic	
• 1	resection=36(94%)	
• 2	resections=	19(50%)		
• 3	resections=9(25%)		
Colonic=18	
• 15/18	resection	
Wheelan	(35)	
1955-74	
Retrospective	 513		
(60%,	16-20	yrs.)	
7.7	 69%	required	surgery	
Castile	(36)	
1950-73	
Retrospective	 177	 8.8	 	67%	required	surgery	
Likelihood	of	second	surgery		
• 36%	at	5	yrs.	FU	
• 48%	at	10	yrs.	FU	
Gryboski	(37)	
1966-76	
Retrospective	
Clinics	
86	 	 Ileo-colonic	most	common	phenotype	52%	
Langholz	(38)	
1962-87	
Retrospective	 103	 12	 Disease	 course/prognosis	 of	 Childhood-onset	 CD	
similar	to	Adults	
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Table	1.2	Recent	Paediatric	Cohort	studies	comparing	the	course	of	(PO-CD)	vs.	(AO-CD).	
	
Study	 Design	 Number	 Median	 FU	 in	
yrs.	
Main	Outcomes	of	Interest	
Vernier	
Massouille	
2008	(3)	
Retrospective	 404		
PO-CD	
7	yrs.		
(4.3-10.3)	
Natural	History	of	PO-CD	
• Disease	extension	31%	
• Complicated	behaviour	29%	at	diagnosis,59%	at	FU	
• Cumulative	risk	of	surgery	20%	at	3	yrs,34%	at	5yrs	
Van	 Limbergen	
J	
2008	(4)	
Retrospective	 416	
276		
PO-CD	
	 Natural	history	of	PO-CD		
• 39%	anatomical	extension	<	2	yrs	
• Complicated=9%	diagnosis,	24%	<	4	years	
PO-CD	vs.	AO-CD	
• Extensive	[L3+L4];	43%	vs.	3%;	P	<	.0001)	
• Median	time	to	surgery	longer	(13.7	vs.	7.8	yr)	
Pigneur	B	(5)	
2010	
Retrospective	 	206	PO-CD	 14.7		
(10.8-45.2)	yrs.	
PO-CD	Vs.	AO-CD	
PO-CD	has	
• Actuarial	risk	of	IR	&	permanent	stoma	at	30.	
• Year-Year	Disease	activity.		
• IM	use		
• Similar	10yr	risk	(24-25%)	of	stricture,	perforation	&	perianal	
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fistula	to	AO-CD.		
Guariso	G	
(39)	
2010	
Retrospective	
prospective	
IBD	312	
CD=132	
PO-CD	67	
AO-CD	65	
Mean	4.8	yrs.	 PO-CD	Vs.	AO-CD	
More	common	in	PO-CD.	
• EIM	(50.4%	vs.34.6%,	P	0.005)		
• PD	(44.8%	vs.21%,P	0.006)		
EIM=	Extra-intestinal	manifestations,	PD=Perianal	Disease	
Jackobsen	(40)	
2011	
Prospective	
Small	sample	
29(PO-CD)	
vs	 67(AO-
CD)	
4.8	yrs	 PO-CD	vs.AO-CD	
No	difference	in	disease	course		
5-year	surgical	rates	(18%	vs.	21%)	
Peneau*	(41)	
2012		
	
	
*Abstract		
EPIMAD	
Registry	
Natural	 Hx	 of	
PO-	CD	
	
538	 11.5(7-15,	IQR)	 • 11%	anatomic	extension	
• 28%(24%	B2+4%B3)	at	diagnosis	
• 58%	(39%	B2+19%B3)	at	last	FU	
Cumulative	Probability	for:	
• IM:	66%	-10yrs,	74%	at	20	yrs.	
• Biologicals:	29%-	10	yrs.	,49%	at	20	y	
• First	IR:	31%	at	10	yrs,	54%	20	yr.	
Abraham	 2012,	
J	 Clin		
Gastroenetrol.	
(42)	
Systematic	
review	 of	
Paediatric	
Onset	CD	
3505	
(PO-CD)	
	 During	 a	 FU	 of	 6	 to	 10	 years,	 four	 clinic/hospital-based	 PO-CD	
studies	 report	stricture	24%	-43%,	14%	-27%	fistulising	disease	and	
25%	-	30%	developing	perianal	disease.	
Cumulative	surgical	resection	rates	for	PO-	CD	=10%	and	72%		
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1c.	Phenotype	difference	of	Paediatric	vs.	Adult	onset	Crohn’s	Disease		
Cohort	 studies	 comparing	 the	 clinical	 course	 of	 paediatric	 vs.	 adult-onset	 CD	 confirm	 a	 more	
aggressive	 nature	 with	 pan-enteric	 involvement	 (Ileo-colonic	 and	 Upper	 GI	 disease),	 rapid	
progression	 and	 increased	 disease	 activity	 index,	 year	 by	 year,	 despite	 use	 of	 more	
immunosuppression	(3-5).	 In	another	prospective	study,	extra-intestinal	 involvement	and	perianal	
disease	were	more	prevalent	in	Paediatric	onset	CD	(39).			Cumulative	risk	of	intestinal	resection	at	
30	years	(48%	vs.	14%)	and	permanent	stoma	(12%	vs.	1%)	are	much	greater	 in	PO-CD	vs.	AO-CD	
(5).	Not	only	is	the	disease	phenotype	severe,	there	are	additional	issues	of	growth	failure,	delayed	
puberty,	poor	bone	density	and	psychosocial	impact	at	a	vulnerable	period	of	life.		
	
1d.	Natural	History	of	Paediatric	Onset	CD	
One	 in	 three	 children	 will	 have	 stricturing	 or	 fistulising	 disease	 behaviour	 at	 diagnosis	 with	 a	
cumulative	probability	of	this	doubling	over	the	next	7-11	yrs	(3,	41).	Anatomical	extension	of	the	
disease	 is	reported	in	31-39%	children	during	follow	up	(3,	41).	A	recent	French	Paediatric	cohort	
study	 reported	 a	 cumulative	 probability	 of	 one	 in	 three	 and	 one	 in	 two	 of	 coming	 to	 surgical	
resection	at	10	and	20	years	from	diagnosis	(41).	A	systematic	review	of	paediatric	studies	with	>	5	
year	follow	up	documents	rapid	progression;	anatomical	extension	with	Ileo-colonic	involvement	in	
up	to	70%,	stricturing	in	43%,	fistulae	in	27%,	perianal	disease	in	30%	and	cumulative	probability	of	
surgery	10-72%	(42).		
Large	paediatric	cohort	studies	with	similar	follow	up	from	the	1970’s	to	1980’s	demonstrated	an	
even	higher	risk	of	surgical	resection	(69%)	vs.	(50%)	compared	to	more	recent	longitudinal	studies	
(35,42).	This	is	likely	related	to	different	study	design,	with	earlier	studies	including	mainly	tertiary	
referral	populations.		
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Nevertheless,	increased	use	of	Immuno-modulators	(IM’s),	biologics	and	less	reliance	on	CS	in	the	
last	two	decades	could	have	contributed	to	overall	reduced	resection	rates	(5,	36-42).	However,	it	is	
also	important	to	note	that	despite	similar	rates	of	complicating	disease	and	intestinal	resections,	
irrespective	 of	 age	 of	 onset	 in	 CD,	 a	 significantly	 higher	 actuarial	 risk	 of	 surgery	 and	 permanent	
stoma	are	seen	in	PO-	CD	(5).		
	
1e.	Impaired	Linear	Growth	in	Paediatric	Onset	CD	(PO-CD)	
While	faltering	linear	growth	velocity	at	diagnosis	and	during	the	treatment	is	a	reflection	of	poorly	
controlled	disease	activity,	loss	of	final	adult	height	is	an	irreversible	and	serious	adverse	event.	The	
reported	prevalence	of	linear	growth	failure	at	diagnosis	in	Paediatric	CD	ranges	from	19%	to	88	%	
(40-44).	 	Wide	 variations	 in	 linear	 growth	 delay	 could	 be	 secondary	 to	 heterogeneity	 including;	
study	 designs	 (population	 vs.	 tertiary	 referral);	 definitions	 (Ht.	 <	 2	 SD,	 Ht	 Velocity	 <	 2	 SD)	 and	
inclusion	at	different	stages	of	puberty.		Despite	these	limitations,	linear	growth	failure	in	PO-CD	is	
a	major	problem,	with	a	1	 in	2	probability	of	reduction	 in	height	velocity	before	the	onset	of	any	
intestinal	symptoms	(43)	and	at	least	1	in	5	chance	of	never	reaching	full	potential	adult	height	(46).	
Growth	faltering	in	CD	is	attributed	to	poor	control	of	the	chronic	inflammatory	state	and	possibly	
the	 use	 of	 steroids.	 Using	 different	 criteria,	 impaired	 final	 adult	 height	 is	 reported	 in	 19-36%	 of	
Children	(45-52).	In	a	large	retrospective	study	from	the	UK,	almost	20%	of	Paediatric	onset	CD	did	
have	final	adult	height	>	8.0	cm	below	their	target	height	strongly	correlating	to	delay	in	diagnosis	
and	 presence	 of	 extensive	 small	 bowel	 disease	 (46).	 Another	 recent	 prospective	 US	 longitudinal	
growth	cohort	study	in	Paediatric	Onset	CD	concluded	that	only	11%	remain	stunted	in	adulthood	
with	 an	 average	 final	 adult	 height	 loss	 of	 5.2	 cm	 (51).	 Authors	 of	 this	 study	 found	 that	 parental	
height	and	not	disease	phenotypes	or	treatment	choices	significantly	affect	final	adult	height.	It	was	
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intriguing	to	note	that	prevalence	of	growth	failure	(22%	in	this	study)	remains	unchanged	despite	
improving	treatment	paradigms	over	the	last	two	decades.	However,	in	this	study	final	adult	height	
was	 not	 recorded	 in	 almost	 half	 (28,	 43%)	 of	 their	 growth	 impaired	 IBD	 cohort	 (n=65)	 thus	
potentially	underestimating	the	true	prevalence	of	stunting	in	adulthood.	It	is	also	well	known	that	
choice	 of	 EEN	 over	 CS,	 leads	 to	 positive	 growth	 outcome	 in	 a	 short	 term	 but	 long	 term	 studies	
evaluating	final	adult	growth	potential	are	lacking.		Adult	height	Z	scores	were	found	to	be	similar	(-
0.39	vs.	-0.29)	between	a	recent	North	American	and	a	previous	English	cohort	study,	where	EEN	is	
preferred	 induction	 therapy	 (46,	 51).	 It	 is	 however	 noteworthy	 that	 in	 both	 cohort	 studies	
cumulative	steroid	dose	was	not	calculated.	A	recent	retrospective	study	from	Australia	with	follow	
up	beyond	2	years	concluded	that	mean	height	Z	scores	of	those	treated	with	EEN	were	better	than	
CS	(p=.01)	(52).		Finally,	benefit	of	early	IFX	use	over	early	IM	or	CS	use	on	linear	growth	in	children	
was	 demonstrated	 in	 a	 large	 propensity	 matched	 cohort	 study	 possibly	 due	 to	 rapid	 and	 early	
effective	control	of	mucosal	Inflammation	(53).	
	
2a.	EEN	in	CD	
EEN	 is	not	only	effective	 in	 inducing	clinical	 remission	but	provides	superior	mucosal	healing	and	
significantly	better	nutrition	and	bone	mineral	density.	(11,	12,	54)	Over	the	last	four	decades	there	
have	been	numerous	randomised	and	non-randomised	studies	demonstrating	the	effectiveness	of	
various	 elemental,	 semi-elemental	 and	 polymeric	 liquid	 diets	 as	 the	 sole	 source	 of	 nutrition	 in	
achieving	 remission	 in	 Crohn's	 disease.(11,12,66-81)	 Despite	 initial	 studies	 and	 systemic	 reviews	
suggesting	EEN	to	be	less	efficacious	than	traditional	therapy	with	CS	at	inducing	clinical	remission,	
two	 recent	 systematic	 paediatric	 reviews	demonstrated	both	 to	be	equally	 effective	 in	 achieving	
clinical	remission	(relative	risk,	RR	0.97,	95%	CI	0.7–1.4).	(9,54).	In	the	following	section,	role	of	EEN	
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in	the	induction	of	remission	in	CD,	variation	of	practices,	effect	of	formula	composition,	mode	of	
administration	and	its	proposed	mechanisms	of	action	is	reviewed.		
	
	
i.	Variation	in	Practice		
Despite	 being	 established	 as	 a	 safe,	 effective	 non-pharmacological	 therapy	with	 greater	mucosal	
healing	 EEN	 is	 not	 uniformly	 adopted	 as	 a	 primary	 induction	 therapy	 for	 children	 with	 CD.	
International	 surveys	 clearly	 demonstrate	 contrasting	 practices	 with	 only	 4%	 of	 North	 American	
Paediatric	 Gastroenterologists	 using	 EEN	 as	 therapy	 for	 CD	 compared	 to	 two-thirds	 of	 their	
European	Colleagues	(55).	The	diverse	prescribing	behaviour	of	EEN	was	also	noted	by	an	Australian	
survey	of	Paediatric	Gastroenterologist	 identifying	compliance,	costs,	resources	and	experience	 in	
training	as	some	of	the	barriers	to	its	use	(56).	In	addition,	lack	of	formal	consensus	also	exists	for	
use	of	concomitant	medications	and	duration	of	 induction	and	maintenance	EEN	therapy	(54-55).	
The	 Enteral	 nutrition	 working	 group	 of	 North	 American	 Society	 of	 Paediatric	 Gastroenterology	
recently	 reviewed	evidence	 to	provide	practical	 consensus	 statements	advocating	 the	use	of	 this	
much	safer	and	equally	effective	alternative	treatment	to	steroids	for	the	Paediatric	CD	(59).	
	
ii.	Exclusive	EN	vs.	Partial	EN	vs.	TPN	
It	was	first	speculated	that	TPN	may	aid	in	process	of	intestinal	healing,	and	thus	clinical	remission,	
by	providing	 complete	bowel	 rest	 separate	 from	nutritional	 restitution.	 This	 putative	mechanism	
was	first	challenged	by	a	randomised	controlled	trial	in	a	small	number	of	Adults	reporting	similar	
clinical	 remission	 in	 those	 on	 TPN	with	 complete	 bowel	 rest	 vs.	 TPN	with	 low	 residue	 diet	 (60).	
Equivalent	 clinical	 remission	at	discharge	and	at	1	 year	 follow	up	were	demonstrated	 in	 another	
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RCT	 with	 a	 larger	 sample	 size	 comparing	 patients	 with	 TPN	 and	 bowel	 rest	 (n=17)	 vs.	 exclusive	
polymeric	diet	(n=19)	(61).	
	
	
iii.	Total	EN	vs.	Partial	EN	
These	controlled	trials	in	groups	of	medically	resistant	CD	patients	confirmed	that	nutrition	support	
with	 or	 without	 bowel	 rest	 promotes	 clinical	 remission	 in	 a	majority	 of	 patients.	 Partial	 enteral	
nutrition	 (PEN)	with	 normal	 eating	 is	 obviously	more	 acceptable	 than	 the	 complete	 exclusion	 of	
normal	diet	and	its	role	in	Crohn's	Disease	was	studied	in	a	Paediatric	RCT.	Authors	examining	this	
approach	concluded	significantly	inferior	clinical	remission	rates	(4/26,	15%	in	PEN	vs.	10/24,	42%	
in	EEN)	and	no	significant	changes	in	surrogate	markers	(haemoglobin,	platelet	count,	ESR,	CRP,	or	
albumin)	of	inflammation.	(62)	
	
iv.	Method	of	Administration	
One	 of	 the	 major	 limitations	 of	 EEN	 is	 poor	 oral	 acceptance	 due	 to	 non-palatability.	 NG	
supplementation	can	overcome	the	palatability	 issues	thereby	improving	compliance	and	possibly	
remission	rates.	 	However,	 in	a	recent	retrospective	study,	similar	clinical	remission	(85%	vs.75%)	
and	compliance	rates	(90	vs.	87%)	were	found	irrespective	of	oral	or	NG	administration	of	EEN	(63).	
v.	Efficacy	between	enteral	formulas		
Enteral	Nutrition	formulae	are	classified	as	elemental,	semi-elemental	or	polymeric	based	on	their	
source	 of	 nitrogen.	 Enteral	 diets	 differ	 in	 their	 protein	 and	 fat	 composition;	 elemental	 diets	 are	
hypoallergenic	containing	amino	acids,	glucose	polymers,	and	low	fat.	Semi-elemental	formulae	are	
partially	hydrolysed	with	small	oligo-peptides	and	medium	chain	triglycerides	whereas	Polymeric	or	
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standard	formula	has	whole,	 intact	protein	typically	derived	from	milk	but	also	from	egg	and	soy.	
One	of	 the	 first	 controlled	 trial	 by	O'Moráin	 and	 colleagues	demonstrated	 the	 similar	 efficacy	of	
elemental	diet	(ED)	to	CS	and	suggested	that	ED	avoids	continuous	foreign	antigenic	stimulation	to	
a	 breached	 intestinal	 barrier	 in	 those	with	 CD,	 thus	 avoiding	 a	 cascade	 of	 uncontrolled	mucosal	
inflammatory	 response	 (64).	 This	 hypothesis	 was	 disproven	 by	 further	 controlled	 trials	 and	 a	
subsequent	 systemic	 review	confirmed	similar	 remission	with	elemental	 and	non-elemental	diets	
(Odds	 ratio	 1.10;	 95%	 CI	 0.69%–1.75%)	 (64).	 Non-	 elemental	 diets	 are	 less	 expensive,	 more	
palatable	 and	 less	 often	 requires	 NG	 tube	 insertion	 promoting	 better	 acceptance	 and	 greater	
weight	gain.	(66-69)	
	
vi.	Fat	composition	of	enteral	formulation	
The	 contention	 that	 quantity	 and	 quality	 of	 fat	 in	 EEN	 potentially	 impacts	 pro	 and	 anti-
inflammatory	cytokine	pathways	and	thus	influence	therapeutic	response	has	also	been	subjected	
to	 trial.	 Initial	 RCT	 and	 systematic	 analysis	 concluded	 that	 an	 EEN	 induced	 therapeutic	 response	
bears	a	negative	correlation	(r	=	-0.97,	p	=	0.016)	with	LCT.	However,	a	meta-analysis	of	six	trials	did	
not	reveal	significant	clinical	difference	between	those	treated	with	low	LCT	(n	=	111)	or	high	LCT	(n	
=	99)	formula,	with	an	OR	1.39,	95%	CI	0.78-2.48	(65).	The	possibility	that	fat	quality	may	promote	a	
pro-inflammatory	environment	warrants	further	investigation	in	light	of	a	recent	publication	linking	
gene,	 diet	 and	microbiome	 to	 inflammatory	 bowel	 disease.	 This	 study	 in	 genetically	 susceptible	
mice	 demonstrated	 that	 a	 saturated	 milk	 diet	 promotes	 pathological	 prevalence	 of	 Bilophila	
wadsworthia,	a	pathobiont	contributing	to	the	intestinal	mucosal	barrier	dysfunction	triggering	pro-
inflammatory	responses	and	colitis	(28).	
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vii.	New	Vs.	Relapsed	Disease		
EEN	induction	therapy	leads	to	greater	clinical	remission	in	those	with	a	new	diagnosis	CD	(80-87%)	
compared	 to	 those	 with	 long-standing	 disease	 (50-58%),	 although	 recent	 studies	 report	 similar	
induction	remission	and	relapse	rates	(66,69-72).	Cameron	et	al.	reported	a	greater	improvement	in	
weight	Z	score	with	first	vs.	second	course	of	EEN	(181).	When	considering	re-induction	therapy	at	
disease	 relapse,	 it	 should	 be	 remembered	 that	 there	 is	 no	 comparative	 outcome	 data	 between	
second	course	of	CS	vs.	EEN.	Nevertheless,	remission	rates	of	repeat	course	of	EEN	are	high	enough	
to	consider	this	induction	therapy	at	relapse	in	those	with	established	CD.	(72,181)	(Table	1.3)	
	
viii.	Efficacy	of	EEN	based	on	CD	phenotypes	
In	a	single	prospective	study,	better	efficacy	of	EEN	was	demonstrated	in	those	with	the	Ileo-colonic	
disease	 compared	 to	 isolated	 colonic	 disease	 (73).	 Further	 studies	 have	 not	 replicated	 similar	
results	 suggesting	 disease	 location	 does	 not	 necessarily	 affect	 clinical,	 endoscopic	 or	 histological	
remission	with	EEN	(11,	12,	74).	The	data	is	summarised	in	Table	1.4.	
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Table	1.3			Efficacy	of	EEN	in	inducing	remission	in	new	vs.	relapsed	CD	
Study		 Objective	 	 Other	results	 Outcome	of	interest	
Ludvigsson	
2004	(66)		
Comparison	 of	 ED	
(n=16)	
Vs.	 PD	 (n=17)	 on	
disease	
activity	
	
Multicenter	
RCT	
No	 difference	 in	
remission	rates;		
69%	 in	 ED	 vs	
82%PD	
No	 difference	 between	
new	and	relapse	disease	
Gorard	
1993	(69)	
ED	 (n=22)	 vs.	 CS	
(n=20);	 remission	
at	 4	 weeks	 &	
follow	up	at	1	year	
or	until	relapse	
	
RCT	 including	
Adults	with	new	
and	old	CD	
Remission	 (10/22	
on	 ED	 vs.	 17/20	
CS)	 (9/22	 did	 not	
tolerate	EEN,	
1yr	 remission	 less	
in	EEN	vs.	CS	(1/11	
vs.	6/19)	
Similar	 significant	
improvement	 in	 disease	
activity	in	new	vs.	old	CD	
	
Day	 et	 al	
2006	(70)	
Effect	 of	 EEN	 on	
PCDAI	
n=27	 (15	 new	 ,12	
old)	
Retrospective	 No	 association	 of	
efficacy	 with	
disease	 location;	
wt.	 increased	 but	
less	 in	 non-
responders	
	
Remission	 rate	 (12/15,	
80%	in	new	diagnosis	vs.	
7/12	 (58%)	 with	 old	 CD	
(concomitant	 treatment	
continued)	
Seidman	
(71)	
1993	
Abstract	
ED	Vs.CS	N=68	 RCT	 Remission	with	ED	
vs.	Steroids	
	26/34	vs.	31/34	
Remission	 higher	 with	
new	vs.	old	(21/24,	
87%	vs.	5/10,	50%)	in	ED	
group.	
	
Cameron	FL	
(181)	2013	
	
First	 &Second	
course	 of	 EEN	 on	
44	patients	
Retrospective	
Single	centre	
29/44	vs.	25/44	
(p=0.51)	
Remission	 similar,	
greater	 improvement	 in	
weight	z-score	 with	 the	
first	vs.	second	course	of	
EEN	(P	<	0.0001)	
	
Frivolt		
(72)	2014	
	EEN	 use	 over	 7.5	
years.		
excluded	 if	
exposed	 to	 anti-
TNFα	 or	 CS	 3	
months	 prior	 to	
EEN.	
Retrospective	
single	center	
Higher	 wPCDAI	 at	
start	in	those	with	
first	 vs.	 second	
course	 of	 EEN	 (59	
vs.	40,	P	<	0.0001)		
higher	 3	 months.	
remission	 in	 those	 with	
first	vs.	second	course	of	
EEN	 (92%	 vs.	 77%,	 n.s.),	
similar	 1-year	 relapse	
rates	(67%	vs.	70%,		
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Table	1.4	Efficacy	of	EEN	in	inducing	remission	based	on	disease	location.	
Study	 Main	Objective	 Design	 Other	results	 Main	 outcome	 of	
Interest	
Afzal	 2005	
(73)	
Efficacy	 of	 EEN	
on	 disease	
activity	
Prospective,	
n=65	
Endoscopic	 &	
histologic	
improvement	 in	
Ileocolonic	 (P	 <	 .01)	
but	 not	 colonic	 (P	 =	
ns).	
Remission	 rate	 lower	
in	 isolated	 colonic	 vs.	
Ileal	 or	 Ileocolonic	
disease	 50%,	 vs.	
91.7%	vs.82.1)	
Borelli	2006	
(11)	
Comparison	 of	
EEN	vs.	Steroids	
RCT,	 n=37	
(EEN=19)	
Clinical	 remission	
between	 EEN	 &	 Cs	
(79%	vs	67%)	
Mucosal	Healing	74%	
vs.	30%)	
Endoscopic	
improvement	 in	 ileum	
13/15	 (87%)	 vs.	 colon	
9/12	(75%)		
	
Buchanan	
2009	(74)	
Efficacy	 of	 EEN	
on	 disease	
remission	
Retrospective	
N=110	
80%	achieved	clinical	
remission	
Remission	 lower	 in	
isolated	 Ileal	 disease	
(n=4,1/4)	
Remission	 rate	 similar	
in	 isolated	 colonic	 vs.	
Ileocolonic	 (15/19,	
79%	vs.25/29,	86%)	
Yamamoto	
2005	(12)	
Efficacy	of	ED	on	
mucosal	
inflammation	 in	
Adults	
Prospective	 No	
comparison	
group	(n=28)	
	 Endoscopic	 and	
histological	 healing	
44%	&19%	in	Ileum	vs.	
39%	and	20%	in	Colon	
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EEN	induced	Clinical	and	Biochemical	remission	
2b.	Exclusive	Enteral	Nutrition	vs.	Steroids	in	adults	with	CD		
The	role	of	elemental	diet	as	a	primary	therapy	in	active	CD	was	first	described	four	decades	ago	
with	 studies	 reporting	 enteric	 fistula	 closure,	 clinical	 remission	 and	 reduced	 surgical	 resection	 in	
medically	 refractory	 adults	 with	 CD	 (75-76).	 In	 1984,	 the	 first	 controlled	 trial	 ascertained	 the	
comparable	efficacy	of	elemental	diet	to	steroids	reporting	clinical	remission	rates	of	80	%	in	both	
arms	 (61).	 Following	 this,	 other	 controlled	 trials	 in	 adults	 with	 larger	 numbers	 (except	 for	 one	
study)	 did	 not	 validate	 these	 findings	 (64,75-81)	 and	 a	 Cochrane	 review	 stated	 "including	 192	
patients	treated	with	EN	and	160	treated	with	steroids	yielded	pooled	OR	(0.33,	95%	CI	0.21-0.53)"	
thus	 favouring	 steroids	 over	 EEN	 in	 inducing	 clinical	 remission	 (65).	 The	 limitations	 of	 the	 above	
conclusions	are;	high	EEN	withdrawal	 rates	 (39%	 in	one	 large	RCT),	 concurrent	 intervention	with	
Sulphasalazine	in	those	on	corticosteroids	and	heterogeneous	definition	of	clinical	remission.	Also,	
one	 could	 argue	 that	 a	 negative	bias	 is	 introduced	when	 comparing	 EEN	 results	with	CS,	 only	 in	
those	 prepared	 to	 attempt	 EEN	 and	 not	 just	 randomised.	 On	 performing	 non–intention	 to	 treat	
analysis	aiming	to	estimate	the	true	effect	of	EEN	in	those	adhering	to	the	diet	we	calculated	similar	
clinical	 remission	 rates	between	CS	vs.	EEN	 in	adults	with	CD	 (100/148,	67.5%	vs.	135/172,	78%)	
and	NNT=	9.2	 (that	 for	every	9	patients	 treated	with	EEN,	1	will	not	enter	 into	clinical	 remission	
compared	to	steroids).	Therefore,	EEN	is	effective	in	inducing	clinical	remission	in	adults	with	CD	in	
48	%	(100/206)	of	those	attempting,	67	%(	100/148)	in	those	accepting	this	treatment	vs.	78%	with	
CS.	 A	 summary	 of	 published	 studies	 is	 outlined	 in	 table	 1.5
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Table	1.5	RCT	comparing	EEN	vs.	CS	as	induction	therapy	in	adults	with	CD	
	
Study		 Inclusion	
criteria	
No.	 Design	 Intervention	
Elemental	(ED)	
CS=Steroids	
ASA	
Withdrawal	 Time	
of		
review	
(weeks)	
Definition	 of	
remission	
Clinical	
Remission	
Response	rate	
Compliant		
Malchow	
1990	
(77)	
Adults	
CDAI>150	
	
95	 RCT	 ED=51	
	Vs.		
CS+ASA=44	
ED=29	
(20	unwilling)	
(9	failure)	
Vs.	
CS	=4	
6	 CDAI	drop	by	
100	 or	 40%	
after	6	weeks	
21/51	(44%)	
Vs.	
32/44	(73%)	
22	Completed,	
9	failures	
ED	 Response	
21/31	68%	
Co-intervention	
With	ASA	
	
Lochs	
1991	
(78)	
Adults	
CDAI>200	
107	 RCT	 ED=55	
Vs.	
CS/ASA=52	
SED=7	
Vs.	
Drugs=4	
6	
	
CDAI	drop	
100	 or	 40%	
after	6	weeks	
29/55	(52%)	
Vs.	
41/52	(78%)	
Co-intervention	
With	ASA	
Included	 all	
Patients	
Lindor	
1992	
(79)	
Adults	 19	 RCT	 ED=9	
Vs.	
CS=10	
EN=4	 unwilling	 to	
participate	or	 take	
it		
4		 CDAI	drop	 3/9	(33%)	
Vs.	
7/10	(70%)	
5	 completed	
course	
3/5=60%	vs.	
7/10=70%	
Gorard	
1993	
(80)	
Adults	 42	 RCT	 ED	(n=22)	
CS	(n=20);	
9/22	 did	 not	
tolerate	diet	
4	 DAI	 10/22,	(45%)	
17/20	(85%)	
Those	
completed	
course	
10/13(77%)	vs.	
17/20(85%)	
Gassull	
2002	
Adults	
VHAI>120	
62	 RCT	 Polymeric	
diet1=20	
PD=9	 unwilling	 or	
not	tolerating	
4	 VHAI	
<120	
16/43	(37%)	
Vs.	
16/34(47%)	
Vs.	
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(80)	 &	 2	
abnormal	
bloods	
Polymeric	 diet	
2=23	
Steroids=19	
15/19	(73%)	 15/19(73%)	
Gonzalez-
1993	
(81)	
Adults		
Van	 Hees	
Activity	
Index	>120	
32	 RCT	 Polymeric=15	
Vs.	
CS/ASA=17	
None	 4	 VHAI	
<120	 after	 4	
weeks	
12/15	(80%)	
Vs.	
15/17(88%)	
	
Similar	
response		
Good	
compliance		
	
O’Morain	
1984	
(64)	
Adults	 with	
active	CD	
21	 RCT	 ED=11	
CS=10	
ED=2	
CS=2	
4	 Simple	
Activity	index	
9/11(82%)	
Vs.	
8/10(80%)	
Similar	
remission		
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2c.	Exclusive	Enteral	Nutrition(EEN)	vs.	Steroids(CS)	in	Children	with	CD		
Despite	 conclusions	 of	 a	 Cochrane	 review	 suggesting	 EEN	 is	 inferior	 to	 CS	 to	 induce	 clinical	
remission,	 systematic	 reviews	 including	 children	 report	 the	 similar	 clinical	 efficacy	 of	 EEN	 vs.	 CS	
(9,54).	 A	 summary	 of	 all	 paediatric	 RCT	 comparing	 the	 efficacy	 of	 EEN	 vs.	 CS	 in	 CD	 are	 outlined	
below	(table	1.6),	with	almost	80%	clinical	remission	rates	on	EEN	(11,74,	82-86).	Although	these	
results	suggest	greater	benefits	of	EEN	over	corticosteroids	 in	the	acute	paediatric	CD,	the	higher	
withdrawal	rates	(1	in	3)	and	shorter	duration	of	therapy	could	account	for	lower	remission	rates	in	
adults.	
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Table	1.6	RCT’s	comparing	EEN	vs.	CS	as	induction	therapy	in	children	with	CD	
	
Study	 Inclusion	
Criteria	
Number	
New/Relapse	
Design	 Intervention	
ED=elemental	
diet	
PD=polymeric	
diet	
CS=Steroids	
	
Remission	time	
(wks)	&	
criteria	
Clinical	
remission	
Poor	
tolerance	
to	EEN	
Comments	
Sanderson	
1987	(83)	
Lloyd	 Still	
index	
17	relapsed	 RCT	 ED	Vs.	
CS+ASA	
(6	wks)	
	Lloyd	 Still	
Disease	Activity	
8/9	Vs	7/8		 0	 Concurrent	
Medication	
Seidman	
1991	(84)	
CDAI	
>150-450	
19	 RCT	 ED=10	Vs.	CS=9	 (3	wks)	
CDAI		
8/10	Vs.	6/9	 0	 6/10	at	9	wk	
9/9	at	9	wks		
Seidman	
1993	(71)	
CDAI	 >150-
450	
68	
46/22		
RCT	 SED=34	 Vs.	
CS=34	
4	(Wks)	 21/24	(New)	
5/10	(	old)		
Vs.	
21/22	(New)	
10/12	(Old)	
	
8	
	
On	follow	up	
relapse,	 hospitalisation	
similar	in	both	groups	
Ruuska	
1994	(85)	
PCDAI	 9/10	 RCT	 PD=10	Vs.	CS=9	 8	WKS	
PCDAI	
9/10	Vs.	8/9	 	 	
Terrin		
2002(86)	
	 20	 RCT	 SE=10	 Vs.	
CS/ASA=10	
8	Wks.	
PCADI	
9/10	 Vs.	
5/10	
0	 Concurrent	medication	
Borreli	
2006	(11)	
PCDAI	 37	 RCT	 PD	Vs.	CS	 10	Wks.	
PCDAI,	
MH	
15/19	 Vs.	
12/18	
0	 EEN	
Better	MH	over	CS	
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2d.	EEN	induced	mucosal	remission	(Table	1.7)	
The	endoscopic	disease	 remains	 active	 in	 the	majority	of	 asymptomatic	patients	 treated	with	CS	
(10,	87)	and	studies	have	also	confirmed	greater	endoscopic	and	histological	remission	in	CD	after	
treatment	 with	 EEN	 (11-12,63,	 88-90).	 A	 randomised	 controlled	 trial	 comparing	 endoscopic	
remission	 rates	 between	 CS	 and	 EEN	 (74%	 vs.	 33%	with	 steroids,	 p=<0.05)	 ascertained	 superior	
early	mucosal	healing	with	EEN	(11).	This	is	particularly	important	as	there	is	emerging	evidence	to	
suggest	medium	to	long-term	benefits	of	early	mucosal	healing.	Adult	CD	patients	with	MH	both	at	
week	10	and	54	weeks	of	Infliximab	(IFX)	did	not	require	any	hospitalisation,	and	those	with	MH	at	
only	one	visit	compared	to	those	without	MH	required	fewer	(18.8%	vs.	28%)	hospitalisations	(7).	In	
the	 EXTEND	 trial	 with	 Adalimumab	 for	 adults	with	moderate	 to	 severe	 CD,	 a	 positive	 predictive	
effect	of	early	(12	weeks)	mucosal	healing	on	Week-52	outcomes	was	demonstrated.		In	this	study,	
a	"1-point	increase	in	Week-12	SES-CD	score	was	associated	with	a	5.0-point	increase	in	Week-52	
CDAI	 score	 (p<0.05)".	 Conversely	 higher	 Week-12	 SES-CD	 scores	 were	 associated	 with	 reduced	
Odds	(OR=0.6,	p<0.05)	of	Week-52	remission	(91).	These	observations	highlight	the	importance	of	
choosing	 therapies	 capable	 of	 inducing	 mucosal	 healing	 early	 in	 the	 course	 of	 the	 disease	 to	
improve	future	clinical	outcomes.		
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Table	1.7	Summary	of	studies	evaluating	EEN	induced	endoscopic	remission	
Study	 Number	 Design	 Intervention	 Definition	of	MH	 Results	 Comment	
Fell	2000	
(88)	
29	 Prospective	
Uncontrolled	
Oral	PD	for	
8	weeks	
Macroscopic	 Healing	
and	Improvement	
Healing	
Ileum	8/22	
Colon=8/26	
Improvement	
Ileum=15/22	
Colon=13/26	
Histological	Healing	
Ileum=8/22	
Colon=	2/26		
Breese	
1995	(90)	
18	 Randomised	
between	
cyclosporine	 or	
EEN/Steroids	
	
Cyclosporine=6	
EEN=6	
Steroids=6	
Not	 defined	 used	
Histological	Healing	
EN=Significant	
Histological	
improvement		
(P	<	0.04).	
	
Endoscopy	 grading	
not	defined		
Afzal	
(89)2004	
26	 Prospective	
Uncontrolled	
Oral	PD	
8	wks	
Previously	 published	
non	
Validated	 Endoscopic	
Scoring	
Mean	score	2.38	
(s.d.	0.65)	
after	 treatment	
was	0.77	(s.d.	0.65)	
(P	<	0.01).	
No	 Correlation	
between	 endoscopic	
improvement	 with	
QOL	
Yamamoto	
2005	(12)	
28	 Prospective	
Uncontrolled	
ED	 Wardle	Score	
(Score	 =	 0	 as	
endoscopic	 healing	
(macroscopically	
normal)	
Endoscopic	 healing	
44%	Ileum	
39%	colon	
	
Histological	healing	
19%	Ileum	
20%	Colon	
Rubio	
2011	(63)	
106	
(16	 paired	
endoscopy)	
Retrospective	 ED	 Oral	
intermittent	or	NG	
continuous		
Not	defined	 12/16	 (only	 16	
underwent	 follow	
up	endoscopy)	
	
Borrelli	
2006	(11)	
37	 RCT	 EEN	=19	
vs.	Steroids=18	
CDEIS	 14/19=74%	
vs.6/18=33%	
,P<0.05	
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2e.	Medium	and	long-term	outcomes	of	EEN	in	Paediatric	CD	(Table	1.8)	
The	ultimate	benefit	of	any	treatment	 in	CD	would	be	 in	 its	ability	 to	mitigate	recurrent	relapses	
contributing	 to	 cumulative	 long-term	 bowel	 damage.	 Retrospective	 observational	 studies	 with	
longer	follow	up	comparing	CS	and	EEN	induction	therapy	suggest	sustained	clinical	remission,	40-
60%	 corticosteroid-free	 remission,	 better	 linear	 growth,	 reduced	 relapses	 and	 lower	 cumulative	
need	for	corticosteroids	with	EEN	(92-95).	However,	it	remains	unknown	if	the	early	choice	of	EEN	
over	 steroids	prevents	CD-related	 complications,	hospitalisation,	need	 for	 surgical	 resections	and	
better	final	adult	height.	
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Table	1.8	Medium	and	Long-term	outcomes	of	EEN	induction	therapy	in	Paediatric	CD	
Study	 DESIGN	 Intervention	 No.	 follow	up	 Outcome	of	interest	
Seidman(71)	 Prospective	 EEN	
Vs.	
CS	
	 5.2	±0.8		
vs.	
	6.18	 ±1	
years	
Relapse	per	patient	/yr	during	follow-up	similar	to	Steroids	
EN=	(1.25±	0.25)	vs.(0.88±	0.16)Steroids	
	
Knight	2005(92)	 Retrospective	
New	CD	
EEN	induction	
EEN	
maintenance	
44	 1-7	years	 4/44	Failed	EEN,	40	Responders	
			25/40	(60%)relapsed	median	54.4	(4-312	weeks)	
								10/25	first	relapse:	second	course	EEN	rest	Steroids	
									8/10	 in	 remission	 after	 the	 second	 course	 of	 EEN	 40%,15/40	
maintained	remission	till	the	last	fu	
47%-CS	free	remission	
Delayed	exposure	to	steroids		
	Berni	2006(93)	 Retrospective	 EEN	=37	
	CS=10	
47		 1	year	 							EEN	vs.	CS	
	
Endoscopic	remission	=26/37	(70%)	vs.	4/10	40%	
Relapse	rate	over	12	mo	=30%	EEN	vs.	70%	Steroids		
Better	linear	growth	EEN	
Lambert	
2012(94)	
Retrospective	 EEN=31	
CS=26	
57	 Over	 2	
years	
					EEN	vs.	Steroids	
Disease	Activity	at	6	mo,	1	&	2	years	
Lower	Relapse	at	1	and	2	years	
19	(61	%)	vs.20	(77	%)	at	12	mo	(NS)	
19	(61%)	vs.	23	(89%)	at	24	mo	(0.03)	
Mean	relapses	
	0.5	(0–2)	vs.	1.5	(	0–8),	p=.01	
	CS	exposure	and	(TP)	use	
	Lower	cumulative	steroids	in	EEN	group	0.0001.	
TP	use	over	2	yrs.:	12	(39	%)	vs.	21	(80	%)	(p	=	0.003).	
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2f.	EEN	in	combination	with	Immuno-modulators	(IM’s)	
	
A	 paediatric	 controlled	 study	 suggested	 a	 lower	 clinical	 relapse	 at	 18	months	 (9%	 Vs	 47	 %)	 for	
children	 started	 on	 early	 6MP	 (<8	weeks)	 vs.	 no	 6MP	 after	 CS	 induction	 therapy	 (96).	 However,	
more	 recent	 data	 is	 less	 convincing	 of	 benefits	 of	 early	 IM's	 use	 on	 subsequent	 outcomes.	 A	
prospective	randomised	study	in	147	adults	with	disabling	CD,	early	Azathioprine	therapy	vs	later,	
"on	demand"	Azathioprine	was	not	associated	with	better	outcomes	including;	remission	rate	(61%	
Vs	 50%,	 p=NS);	 anti	 TNF	 use,	 (29%	 Vs	 26%);	 and	 surgery	 (11%	 Vs	 21%,	 p=0.11)	 (98).	 However,	
prospective	 studies	 investigating	 the	 role	 of	 IM's	 with	 EEN	 are	 limited	 to	 a	 single	 observational	
paediatric	cohort	reporting	lower	incidence	of	surgery	and	growth	failure	with	the	introduction	of	
IM	with	EEN	(<	12	months	of	diagnosis)	versus	historical	cohorts	(use	of	 IM’s	beyond	12	months)	
(99).	
3a.	Mechanisms	of	action	of	EEN	in	CD	
Mechanisms	 behind	 EEN	 induced	 clinical	 and	mucosal	 remission	 in	 CD	 remain	 elusive.	 Proposed	
mechanistic	 pathways	 include	 anti-inflammatory	 action,	 restoring	 intestinal	 permeability,	 low	
antigenic	load,	and	modulation	of	the	microbiome.	(Figure	1.3)	
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1. Anti-inflammatory	(Table	1.9)	
Several	 studies	 have	 shown	 EEN	 induced	 clinical	 remission	 in	 CD	 closely	 parallels	 rapid	
improvement	of	surrogate	systemic	inflammatory	markers	like	CRP,	ESR,	and	Albumin	(85,	88,	92,	
100).	 	 The	 contention	 that	 resolution	 of	 the	 systemic	 inflammatory	 response	 in	 CD	 occurs	 as	 a	
consequence	 of	 improvement	 in	 gut	 inflammation	was	 further	 tested	 in	 several	 other	 paediatric	
and	 adult	 studies.	 Fell	 et	 al	 were	 the	 first	 to	 comprehensively	 demonstrate	 improvement	 of	
endoscopic	 and	 histological	 CD	 activity	 closely	 coincides	 with	 fall	 of	 mucosal	 pro-inflammatory	
cytokines	m-RNA	(IL-1,	IFN-γ,	IL-8)	in	children	before	and	after	8	weeks	of	EEN	(88).	Another	study	
in	adults	with	active	CD	also	demonstrated	reduced	mucosal	pro-inflammatory	cytokines	IL-1β,	IL-6,	
IL-8	 and	 TNF-α	 to	 normal	 healthy	 control	 levels	 after	 4	weeks	 of	 EEN	 (12).	 In	 addition,	 EEN	was	
shown	to	correct	perturbed	anti-inflammatory/pro-inflammatory	regulatory	responses	indirectly	by	
demonstrating	increasing	IL-1	ra	(IL-1	receptor	antagonist)/IL-1	β	ratio	in	those	with	endoscopic	and	
histological	healing	(12).	Another	in-vitro	study	incubating	elemental	diet	with	mucosal	biopsies	of	
EEN
Anti-
Inflammatory
Improves
Intestinal	
permeability
?	Immune-
modulating
Altered
microbiome
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adult	 patients	 with	 CD,	 UC	 and	 control	 samples	 observed	 an	 increased	 ratio	 of	 the	 anti-
inflammatory/pro-inflammatory	 cytokines	 (IL-1	 receptor	 antagonist/IL-1β)	 only	 in	 tissue	 with	 CD	
thus	providing	compelling	evidence	of	EEN's	direct	anti-inflammatory	properties	(100).	A	summary	
of	 effects	 of	 EEN	 on	 cytokines	 from	 various	 studies	 is	 summarised	 in	 the	Table	 1.9.	 Direct	 anti-
inflammatory	effect	of	polymeric	formula	(PFA)	was	further	elucidated	in	an	in	vitro	experiment	of	
intestinal	epithelial	cells	(IEC)	where	PFA	induced	anti-inflammatory	response	persisted	even	after	
the	separation	of	PFA	from	pro-inflammatory	stimuli	in	a	two	compartments	model	(101,102).		
	
	
Table	1.9,	EEN	induced	changes	in	Inflammatory	Cytokines	
	
Cytokine	Profile		 EEN	induced	change	 Relevance	
IL-185	 Fall	in	mucosal	level	 	
Il-1	ra11,98	 Increase	in	mucosal	level	 	
IFN-	γ85	 Fall	in	mucosal	level	 Th1	response	
IL-811,85,99	 Fall	in	mucosal	level	 	
IL1	β11,98	 Fall	in	mucosal	level	 	
IL-611	 Fall	in	mucosal	level	 Promotes	Th17	through	CD25+Tregs	
TNF	α11	 Fall	in	mucosal	level	 Th1	response	
TGF-	β1	117	 Increased	with	EEN	(Serum)	 Th17	response	
Ra=receptor	antagonist,	IL=Interleukin,	IFN=Interferon,	TNF=tumour	necrosis	factor	
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Anti-Inflammatory	effect	of	EEN,	improvement	in	Faecal	Calprotectin	(FC)	following	EEN		
There	is	growing	evidence	to	suggest	that	MH	in	CD	relates	to	favourable	long-term	outcomes.	The	
gold	 standard	 for	 assessing	 mucosal	 inflammation	 is	 endoscopy,	 however	 repeat	 endoscopy	 is	
invasive	 therefore	 surrogate	 markers	 are	 essential	 to	 assess	 therapeutic	 response.	 FC	 is	 an	
established	 surrogate	 faecal	 marker	 that	 strongly	 correlates	 with	 endoscopic	 and	 histological	
disease	 activity	 (103).	 Normalisation	 of	 FC	 is	 a	 dependable	 marker	 of	 MH,	 suggested	 by	 a	
colonoscopic	 study	 in	 asymptomatic	 adult	 CD	 patients	 where	 a	 normal	 FC	 reliably	 predicted	
histological	remission	in	85%	of	patients	(104).	There	is	limited	data	on	therapeutic	efficacy	or	risk	
prediction	analysis	based	on	FC	in	CD.		A	Finnish	study	examined	the	effect	of	CS	therapy	on	FC	in	
15	 children	 with	 inflammatory	 bowel	 disease	 and	 concluded	 that	 a	 majority	 of	 children	 had	
elevated	FC	despite	being	in	clinical	remission	(102)	In	a	large	prospective	multicentre	study	of	101	
children	with	UC,	 FC	 and	 other	 novel	 faecal	markers	 did	 not	 add	 further	 to	 the	 clinical	 index	 in	
predicting	corticosteroid	response	(106).	In	a	small	prospective	study	in	children	with	CD,	significant	
quantitative	 reduction	 in	 FC	 at	 1	 and	 2	 months	 after	 EEN	 correlated	 with	 complete	 clinical	
remission,	18%	drop	of	baseline	FC	at	1	month	predicted	a	successful	clinical	response	to	EEN	(107).	
Another	 small	paediatric	Spanish	study	 found	a	non-significant	 reduction	of	FC	 in	10/14	 (70%)	of	
clinical	responders	(108).	The	absence	of	endoscopic	correlation,	concurrent	medication	use,	small	
numbers	and	inclusions	of	new	and	relapsing	patients	limits	the	conclusions	from	all	studies	where	
clinical	 outcomes	 are	 the	 sole	 marker	 of	 remission.	 Further	 validation	 studies	 to	 examine	
quantitative	 drop	 in	 FC	 that	 reliably	 predicts	 endoscopic	 response	 to	 EEN	 is	 required;	 a	
homogenous	study	population	together	with	endoscopic	correlation	can	overcome	the	limitations	
of	these	studies.	
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2.	Altered	intestinal	permeability	
A	 healthy	 epithelium	 maintains	 a	 physical	 and	 immunological	 barrier	 to	 harmful	 bacteria	
adequately	 sensing	 and	 reacting	 to	 harmful	 stimuli.	 Impaired	 intestinal	 epithelium	 integrity	 is	
increasingly	 appreciated	 as	 a	 major	 factor	 contributing	 to	 CD	 pathogenesis	 as	 it	 represents	 an	
interface	of	genetic,	immune	and	environmental	factors.	Whether	a	defective	intestinal	epithelium	
barrier	 is	 a	 consequence	 of	 the	 inflammatory	 response	 or	 a	 primary	 epithelial	 defect,	 triggering	
secondary	inflammatory	response	is	not	clear.	It	appears	that	a	“leaky	gut”	is	an	early	phenomenon	
in	the	development	of	disease,	probably	genetically	driven	and	triggered	further	by	environmental	
factors	 such	 as	 luminal	 antigens	 or	 bacteria.	 Support	 for	 this	 comes	 from	 studies	 indicating	
increased	intestinal	permeability	in	healthy	relatives	of	patients	with	IBD	and	observations	that	this	
could	be	 related	 to	underlying	genetic	mutations	 (109-110).	Defects	 in	epithelial	barrier	 function	
are	indirectly	measured	by	oral	administration	of	a	non-absorbable	test	substance	and	subsequent	
measurement	 in	 urine.	 Children	 with	 active	 CD	 have	 perturbation	 of	 normal	 intestinal	 barrier	
function	 as	 suggested	 by	 abnormal	 lactose/rhamnose	 sugar	 permeability	 test	 (111).	 Impaired	
intestinal	 permeability	 also	 positively	 correlates	 with	 CD	 activity	 and	 is	 also	 associated	 with	
increases	likelihood	of	clinical	relapse	(112-114).	EEN	leads	to	rapid	and	significant	improvement	in	
lactose/rhamnose	permeability	ratio	normalizing	to	a	normal	 level	 in	almost	50%	of	children	with	
active	 CD	 (112).	 In	 vitro	 studies	 with	 EEN	 have	 demonstrated	 altered	 epithelial	 cell	 chemokine	
responses	to	the	pro-inflammatory	stimulation	in	a	two	compartments	model,	confirming	its	anti-
inflammatory	action	is	also	mediated	through	intracellular	signalling	processes	(112).	
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3.	Immune-modulating	response	(CD25+	FOXP3+	T	regulatory	cells)	
Exaggerated	Th1	and	Th17	mediated	responses	plays	a	major	role	in	the	immune-pathogenesis	of	
CD	as	 suggested	by	 increased	production	of	 interferon-γ	 (IFN-γ),	 tumor	necrosis	 factor-α	 (TNF-α)	
and	interleukin-17	(IL-17)	from	ileo-colonic	biopsies	of	patients	with	CD	(117).	FoxP3+	T	regs	cells	
can	modulate	the	Th1/Th2/Th17	response	(Figure	1.2)	hence	are	pivotal	in	maintaining	gut	immune	
tolerance;	 the	 number	 of	 CD25bright	and	 FoxP3+	cells	 are	 higher	 in	 the	 lamina	 propria	 of	 patients	
with	CD	than	in	normal	controls	and	an	increase	is	observed	in	those	with	active	CD	(115-116).		In	
one	 previous	 trial,	 mucosal	 FOXP3	 expression	 was	 significantly	 increased	 in	 those	 treated	 with	
Infliximab	vs.	EEN	(116).	EEN	therapy	also	leads	to	down-regulation	of	mucosal	IL-6	and	serum	TGF-	
β1	expression,	key	mediators	of	CD25+	T	regulatory	cells,	ultimately	impacting	Th1/Th17	helper	cell	
response;	 this	 observation	 and	 lack	 of	 paired	 data	 from	 previous	 studies	 warrant	 further	
investigation	to	determine	if	EEN	has	any	effect	on	mucosal	CD25+FoxP3+	cells	(116-117).	
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Figure	1.4.	Adopted	from	“Immunopathogenesis	of	Inflammatory	Bowel	disease”,	Shih	D,	Targan	
S.	World	J	Gastroenterol,	2008;21;14:390.	
“Differentiation	 of	 T-cell	 Subsets.	 Upon	 stimulation,	 naïve	 CD4+	 T-cells	 differentiate	 into	 3	main	
subsets,	 Th1,	 Th2,	 and	 Th17	 cell.	 IL-12	 induces	 the	 formation	 of	 IFN-γ	 producing	 Th1	 cells.	 IL-23	
promotes	the	development	of	an	IL-17	producing	CD4+	helper	T	cells.	IL-4	induces	STAT6	activation,	
promoting	 the	expression	of	GATA-3,	which	 feeds	 forward	 to	 induce	 IL-4	expression	and	Th2	cell	
differentiation.	An	EBI3-associated	cytokine	was	hypothesized	to	be	necessary	for	activation	of	IL-
13	 producing	NK	 T-cells.	 Tregs,	 an	 immune-modulating	 subset	 of	 CD4+	 T-cells,	 can	 suppress	 the	
differentiation	and	function	of	Th1	and	Th2	cells.	Interestingly,	in	the	presence	of	IL-6,	Treg-derived	
TGF-β	can	induce	the	differentiation	of	Th17	cells.	
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4.	Intestinal	Microbiome	in	Inflammatory	Bowel	Disease	and	its	modulation	by	EEN	
Despite	 enormous	 progress	 in	 understanding	 the	molecular	 pathogenesis	 of	 IBD	 its	 exact	 cause	
remains	 elusive.	 The	most	 accepted	mechanistic	 model	 is	 that	 chronic	 gut	 inflammation	 results	
from	 an	 intolerant	 innate	 and	 adaptive	 immune	 response	 to	 commensal	 or	 pathogenic	 enteric	
microflora	 gaining	 inappropriate	 access	 through	 the	 defective	 intestinal	 barrier	 in	 a	 genetically	
predisposed	host	(118).	There	is	abundant	experimental	and	clinical	evidence	to	implicate	a	major	
role	for	the	intestinal	microbiome	in	initiating	and	perpetuating	IBD.		
Experimental	Evidence	of	role	of	microbiome	in	IBD	
Failure	 to	 develop	 experimental	 colitis	 in	 various	 germ-free	murine	models	 and	 improvement	 of	
experimental	colitis	on	antibiotics	or	prebiotics	provide	compelling	evidence	 for	a	 role	of	 the	gut	
microbiome	in	the	pathogenesis	of	IBD	(119-124).	
	
Microbiome	in	CD	
There	 is	 enormous	evidence	 that	 "dysbiosis"	 contributes	 to	 the	pathogenesis	of	 IBD.	 The	human	
microbiota	 is	 characterised	 by	 four	major	 phylum	 Firmicutes,	 Bacteroidetes,	 Proteobacteria	 and	
Actinobacteria.	 CD	 is	 characterised	 by	 reduction	 in	 overall	 biodiversity	 and	 many	 studies	 have	
consistently	reported	an	overall	reduction	in	Firmicutes	and	increase	in	Proteobacteria	(Figure	1.3).	
16,126,208	There	are	significant	variations	across	studies	reporting	specific	microbiota	changes	in	CD,	
reflecting	difference	in	methodology	(gradient	gel	electrophoresis	to	more	recent	next	generation	
sequencing),	sample	size	and	type	(i.e.	stool	vs.	mucosa)	and	potentially	treatment	effects	(new	vs.	
established	CD).		A	recent	large	European	cohort	study	employing	high-throughput	DNA	sequencing	
confirmed	 stool	 microbiota	 signatures	 highly	 specific	 to	 adult	 CD,	 with	 predominant	 loss	 of	
beneficial	 Faecalibacterium,	 Christensenellaceae,	 Methanobrevibacter,	 Oscillospira	 and	 gain	 of	
pathobionts	 Fusobacterium	 and	Escherichia	(126).	 On	 the	 other	 hand,	 Gevers	et	 al.	 reported	 CD	
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specific	 mucosa	 associated	 microbiota	 (MAM)	 in	 treatment	 naive	 children	 with	 abundance	 of	
“pathobionts”	including	Enterobacteriaceae,	Pasteurellaceae	Fusobacteriaceae	and	Veillonellaceae	
and	 reduction	 in	 symbionts	 like	 Bifidobacteriaceae,	 Erysipelotrichales	 and	 Clostridiales	 (16).	
Together,	these	studies	provide	further	evidence	of	specific	gut	microbial	signatures	in	CD	providing	
a	clear	roadmap	to	understand	microbiota	modulation	as	a	potential	therapy	in	CD.	
	
Figure	1.5	
	
	
	
Clinical	and	experimental	evidence	of	microbiome	modulation	with	EEN	
Modification	of	 intestinal	microflora	 is	proposed	as	a	 therapeutic	mechanism	of	action	of	EEN	 in	
CD.	 Previous	 investigations	 relying	 on	 culture	 driven	 methods	 failed	 to	 confirm	 microbiota	
modification	 following	 EEN	 (127-128).	 However,	 availability	 of	 culture	 free	 techniques	 like	
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PCR/DGGE	and	PCR/TGGE	made	 it	 possible	 to	 further	 investigate	 this	 putative	mechanism	 (128).		
Most	 recent	 paediatric	 studies	 have	 utilised	 next	 generation	 sequencing	 targeting	 16SrRNA	
(13,15,132-134).	Multiple	 studies	exploring	utilising	 the	 stool	microbiota	during	EEN	 in	paediatric	
CD	 have	 reported	 reduction	 in	 bacterial	 diversity,	 loss	 of	 Firmicutes,	 Bacteroides/Prevotella	 and	
increase	 in	 Bacteroidetes	 (Table	 1.10).	 Another	 consistent	 but	 paradoxical	 report	 is	 the	 greater	
reduction	in	biodiversity	in	those	with	improvement	in	clinical	disease	activity	scores	(13-15).		
These	 alterations	 include	 the	 depletion	 of	 specific	 bacteria	 such	 as	 Faecalibacterium	 prausnitzii,	
which	 is	widely	 considered	 to	 be	 beneficial	 for	 its	 anti-inflammatory	 properties	 (13,14,135),	 and	
contrast	with	studies	by	Schwerd	et	al.	and	other	adult	CD	studies	(132,136).			
The	 mucosa-associated	 microbiome	 (MAM)	 is	 now	 accepted	 to	 be	 distinct	 from	 the	 faecal	
microbiome	 (16-17)	 and	 there	 are	 currently	 no	 published	 studies	 correlating	 post-EEN	 induction	
endoscopic	disease	activity	scores	and	parallel	changes	in	MAM.	A	single	case	report	described	the	
ileal	microbiome	 changes	 pre-	 and	post-EEN	 in	 a	 newly	 diagnosed	 child	with	 CD,	 compared	 to	 a	
single	 healthy	 control	 (137).	 The	 pre-EEN	MAM	 in	 the	 child	 with	 CD	 showed	 reduced	microbial	
diversity,	increased	levels	of	Proteobacteria	and	lower	levels	of	Bacteroidetes	species	compared	to	
the	 healthy	 control.	 These	 changes	 corrected	 post-EEN	 with	 a	 reduction	 in	 Proteobacteria	 and	
increase	in	Bacteroidetes	and	Firmicutes	phyla,	to	become	more	similar	to	healthy	controls.	These	
authors	concluded	that	EEN	restores	the	MAM	diversity,	but	this	is	in	contrast	with	the	two	recent,	
larger	studies	noted	above.		
In	summary,	while	EEN	promotes	MH	in	most	patients,	there	are	conflicting	results	arising	from	the	
limited	 studies	 of	 changes	 in	 stool	 microbiota	 and	MAM	 during	 EEN,	 and	 a	 lack	 of	 microbiome	
studies	paired	with	endoscopic	data.		
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Table	1.10	EEN	induced	changes	in	stool	microbiota	(13-15,129-136)	
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3b.	Mucosal	Healing	in	CD	
Adequate	 therapeutic	 end	 points	 for	 any	 lifelong	 chronic	 relapsing	 illness	 like	 CD	 is	 not	 just	 short-term	 symptomatic	 relief	 but	 long-term	
modification,	 amelioration	 of	 disease	 progression.	 In	 this	 chapter,	 we	 review	 the	 natural	 history	 of	 CD	 and	 its	 further	 relevance	 in	 the	
paediatric	 age	 group.	 	 Before	 choosing	 therapeutic	 targets	 in	 CD,	 it	 is	 important	 to	 conceptualise	 a	 theoretical	 stepwise	 progression	 of	
childhood-onset	 CD	 from	 an	 early	 pre-symptomatic	 stage	 possibly	 lasting	 for	 several	 years	 to	 a	 full-blown	 symptomatic	 disease	 before	
diagnosis	and	its	course	thereafter	(Figure	1.6)	
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Figure	1.6	Stepwise	progression	of	CD	
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CD	symptoms	do	not	correlate	with	intestinal	ulcers	
In	a	multicentre	prospective	study,	active	endoscopic	mucosal	lesions	were	detected	in	up	to	70%	of	subjects	who	achieved	clinical	remission	
with	 steroids	 (10).	 Another	 prospective	 study	 from	 the	 same	 group	 further	 reaffirmed	 the	 poor	 relationship	 between	 clinical	 recurrence,	
biochemical	 remission	 and	 endoscopic	 healing	 (138).	 In	 a	 retrospective	 cohort	 study,	 Allez	 et	 al.	 (139)	 concluded	 that	 severe	 endoscopic	
lesions	(deep	ulceration	of	>10%	mucosal	surface)	predict	a	higher	risk	of	colectomy.	Clinical	disease	activity	tools	like	PCDAI	include	variables	
like	 abdominal	 pain	 and	daily	 activities,	 easily	 influenced	by	 emotional	wellbeing	 and	 symptoms	 and	do	not	 necessarily	 correlate	with	 the	
degree	of	pathological	inflammation	(140).	Other	potential	problems	with	clinical	indices	are	an	overestimation	of	disease	activity	in	patients	
with	limited	anatomical	disease	involving	distal	colonic	segments	presenting	as	diarrhea	or	blood	loss,	and	potentially	underestimating	or	even	
missing	those	with	proximal	small	bowel	disease	presenting	as	anorexia	or	 fatigue.	This	discrepancy	clearly	explains	why	future	therapeutic	
trials	should	not	use	endpoints	like	clinical	remission	alone	given	the	significant	dis-association	of	symptoms	to	mucosal	inflammation.		
Defining	Mucosal	Healing	
Before	using	MH	as	treatment	endpoint,	it	is	important	to	know	how	it	should	be	defined	and	measured.	Endoscopic	lesions	in	CD	are	typically	
discontinuous	with	mucosal	appearance	ranging	from	erythema,	aphthous	ulcers,	edema	to	cobblestoning	deep	or	longitudinal	ulceration	and	
stenosis.	Although	variable	endoscopic	definitions	have	been	used	in	clinical	and	research	practice,	a	complete	absence	of	ulceration	in	both	
ileum	and	colon	appears	to	be	the	most	definite,	albeit	simplistic,	way	to	describe	MH	in	CD.	Validated	Quantitative	endoscopic	definitions	as	
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summarised	in	Table	1.11	have	been	used	in	clinical	trials	to	describe	the	extent	of	healing	in	CD	(141,142),	although	the	degree	of	endoscopic	
healing	required	to	improve	long-term	meaningful	outcomes	remains	to	be	proven.	
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Table	1.11,	Definition	of	Mucosal	Healing	
Endoscopic	
Score	
Variables	 Definition	of	Mucosal	Healing	 Comments	
CDEIS	(0-44)	 Deep	ulceration		
Superficial	ulceration	
Surface	 area	 of	
ulceration	
Surface	 area	 of	
diseased	segment	
Ulcerated/non-
ulcerated		stenosis		
Endoscopic	evidence	of	no	 lesion	
at	all	or	scarred	lesion		
Corresponding	 to	 CDEIS	 score	 of	
<3	
Gold	 Standard	 but	
time	 consuming	
and	complicated	
SES	(0-56)	 Size	of	Ulcers	
Ulcerated	surface	
Affected	Surface	
Presence	 of	
narrowing’s	
Score	of	“0”	=	Complete	
	
	
Simpleand	
Practical	
Strong	 correlation	
with	CDEIS	
Good	IO	variability	
Good	 correlation	
with	FC	
	
	
Impact	of	Endoscopic	Healing	on	the	natural	history	of	CD	
There	is	accumulating	evidence	that	MH	can	improve	outcomes	in	adults	with	CD.	Paediatric	data	
utilising	similar	endpoints	are	limited	to	an	Italian	study,	comparing	EEN	to	steroids	with	sustained	
clinical	remission	and	reduced	1-year	relapse	rate	(30%	vs.	70%)	in	those	with	greater	endoscopic	
remission	(EEN	70%	vs.	Steroids	40%).	(93).	MH	when	achieved	in	the	first	year	is	associated	with	
sustained	clinical	remission,	reduced	hospitalisation	and	reduced	surgical	resection.	Key	published	
evidence	from	adult	studies	are	briefly	summarise	in	Table	1.12.	
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Treatments	associated	with	mucosal	healing	(MH)	
Trials	evaluating	mucosal	healing	with	other	CD	 therapies,	 apart	 from	EEN,	are	 limited	 to	adults.		
There	are	no	placebo	controlled	trials	using	IM’s	or	biologics	with	similar	endpoints	 in	children.	A	
recent	 paediatric	 study	 including	 66	 moderate	 to	 severe	 CD	 patients	 failing	 steroids	 and	
conventional	 IM’s	 reported	 early	 complete	MH	at	 10	weeks	with	 Infliximab	 induction	 therapy	 in	
only	23%	with	an	overall	decrease	in	SES-CD	from	18	to	7.5,	p<0.05	(143).		In	Figure	1.4	below,	early	
mucosal	healing	rates	with	different	treatments	are	reported	with	further	details	in	Table	1.13	 (10-
11,145-155).	However,	directly	comparing	effectiveness	of	medical	therapies	to	induce	early	MH	(4-10	
weeks)	is	difficult	due	to	heterogeneous	study	designs,	population	and	definitions.	
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Table	1.12	Effect	of	mucosal	healing	on	long	term	outcomes		
	
Key	Outcomes	 Drug	 Results	 Followup	 Studies	
Sustained	 Clinical	
response	
Inflximab	
	
Inf+AZA	or		
Inf	/AZA	
	
EEN	vs.	Steroids	
	
	
Adalimumab	
With	MH	=64.8%	vs.	Without	MH=	39.5%,	p<.001	
	
MH	at	2	yrs	vs.	No	MH	at	2	yrs	associated	with						
sustained	Remission	at	3-4	yrs	=70.8%	vs.	27%,	p<.03		
	
	
Better	endoscopic	improvement	(EEN	65%	Vs	CS	40%)			leads	to	longer	
clinical	remission	and	reduced	1	yr	relapse	(30%	vs.	70%)	
	
MH	at	wk	12	patients	with	significant	reduction	in	
CDAI	at	week	52	by	46	points	(P	<	0.05).		
69	mo	
	
3-4	years	
	
	
	
12	mo	
	
	
12	mo	
Schnitzler	
2009	
	
Baert	2010	
	
	
	
Berni	2006	
	
	
Rutgeerts	
2012	
Reduced	
Hospitalisation	
Inflximab	
	
	
Inflximab	
	
MH	at	both	10	or	54	weeks	vs.	either	at	10	or	54	vs.	neither	at	10	or	54	
weeks	(0%	vs.18.8%	vs.28%)	
	
MH	vs.	No	MH	at	last	FU	(42%	vs.	59%)	
	
	
	
69	mo	
Rutgeerts	
2006	
	
Schnitzler	
2009	
	
Less	 Penetrating	
Disease	
No	clear		
evidence	
	
	
Presence	of	deep	ulceration	associated	with	higher	risk	of	penetrating	
disease	
52	mo	 Allez	2002	
Less	 Surgical	
resection	
Population	 based	
cohort	
	
Inflximab	
	
MH	vs.	No	MH	at	1	year	and	surgical	outcomes	5	years	
11%	vs.	20%,	p=.10	
	
MH	vs.	no	MH	at	last	FU	
14.1	vs.	38%,	p<.001	
	 Froslie	2007	
	
	
Schinitzler	
2009	
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Figure	1.7	Efficacy	of	CD	therapies	in	inducing	early	MH	(4-10	wks)	,	10,11,145-155	
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Table	1.13	CD	Treatments	associated	with	mucosal	healing:	
	
Study	 Design	 Drug	
	
N	 Population	 Timing	 of	
endoscopic	
evaluation	
Endoscopic	
index	
Definition	 of	
MH	
%	 achieving	
MH	
Manosa	
2009	
(144)	
Single	
Centre		
IM	 Methotrexate	 25	
mg/wk/	 16	 wk	 then	
15mg/wk	
8	 CS	 dependent	
Ileo-colonic	
CD	 in	 clinical	
remission		
15	months	
(6-60	
months)	
No	 score	
used	
Disappearance	
of	 endoscopic	
lesions	
3/8	 (38%)	
total	
2/8	 (25%)	
partial	
Kozarek	
1989	
(145)	
Single	 Centre	
Open	label	
Methotrexate	
25	mg	wk	
14	 Long	 standing	
refractory	
Colonic	CD	
12	weeks	 No	score	 Endoscopic	
remission	 no	
description	
5/14=36%	
4/14=28%	
histological	
remission	
Mantzaris	
2009	
(146)	
Single	centre	
RCT	
open	 label	
study	
Azathioprine	
2-2.5mg/kg/day	 Vs	
budesonide	
6-9	mg/day	
77	 CS	 dependent	
ileocolitis	 or	
proximal	
colitis	 in	
clinical	
remission	
12	months	 CDEIS	 Disappearance	
of	 pathological	
findings	
22/30	73%		
11/19	 59%	
Ileum	
Vs.6/25	24%	
D’Haens	
1999		
Single	centre	
retrospective	
	
Azathioprine	
50	mg/day	
(1-2	wk)	to		
100	mg/day	
(1-2	wk)	to	2.5mg/kg/day	
20	 Refractory	
Crohn’s	 Colitis	
in	 clinical	
remission	with	
AZA	 without	
CS	
24.4+/-13.7	
months	
No	score	 Disappearance	
of	 all	
endoscopic	
lesions	
10/20	50%	
	
D’Haens	
1997	
(147)	
	
Single	centre	
retrospective	
	
	
Azathioprine	
50	 mg/day(1-2	 weeks)	
then	 100	 mg91-2	 weeks)	
then	2.1mg/kg/day	
	
15	
	
Severe	
refractory	 CD	
with	
postsurgical	
recurrence	 in	
clinical	
	
17.9+/-	 6	
months	
	
Rutgeerts	
score	
	
Complete	
disappearance	
of	 all	
pathological	
lesions	 in	 neo-
terminal	ileum	
	
6/15	40%	
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remission	 for	
6	months	with	
Aza	 without	
CS	
	
Sandborn	
et	al	
1995	
(148)	
Single	centre	
Open	label	
Azathioprine	IV	
(50mg/hr-	 36	 hrs)	 	 then	
50-150	mg	daily	orally	
6	 Moderately	 to	
severely	active	
Cd	 with	 CDAI	
>250	 and	
severe	
endoscopic	
lesions	 at	
baseline	
16	weeks	 No	score	 Normal	
appearing	
mucosa	 ,	
scarring	 pseudo	
polyps	
3/6	50%	
Modigilani	
1990	
(10)	
Multicentre	
open	label	
Prednisolone	1mg/kg/day	 142	 Active	 CD	
(CDAI>200)	
4-7	weeks	 CDEIS	 No	lesions	 17/142	12%	
38/142	27%	
Van	
Dullemen	
1995	
(149)	
Single	 centre	
open	 label	
study	
Infliximab	 single	 infusion	
of	10	or	20	mg	
9	 Active	 CD	
(CDAI	 >200)	
refractory	 to	
steroids	 all	
with	 active	
endoscopic	
disease	
4	weeks	 CDEIS	 Not	defined		
(complete	 or	
near	 complete	
healing)	
8/10	80%	
Rutgeerts	
2004	
(150)	
Multicentre	
open	RCT	
Double	
blinded	
study	
Infliximab	5	mg	IV	at	0,2,6	
and	 then	 5	 or	 10	
mg/kg/8wks	 Vs	 Infliximab	
5mg/kg/	 at	 0	 followed	 by	
placebo	 2,6	 and	 every	 8	
wk	
99	 Active	 CD	
(CDAI	 220-
400)		
81-
ulceratioins	 at	
baseline	
endoscopy	
10wk(n=74)	
54	weeks	
(n=58)	
CDEIS	 Complete	
absence	 of	
mucosal	
ulcerations	
observed	 at	
baseline	n=81	
13/45	29%	vs	
1/29	3%	
16/36	44%	vs	
4/22	(18%)	
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Colombel	
et	al	
2008	
SONIC	
(151)	
Multicentre	
randomised	
double	 blind	
study	
Azathioprine	
2.5mg/kg/day	 orally	 plus	
placebo	 IV	 vs	 Infliximab	
5mg/kg	 IV	 at	 0,2,6	 then	
every	 8	 weeks	 plus	
placebo	 orally	 Vs	
Infliximab	 plus	
azathioprine	
325	 Refractory	
moderate	 to	
severe	 CD	
(CDAI	 >220	
but	 <450)	
naïve	 to	 both	
immune-
modulators	
and	biologicals	
26	weeks	 No	score	 Complete	
absence	 of	
mucosal	
ulceration	 in	
colon	 and	
terminal	ileum	
18/109	15%	
Vs.	 28/93	
30%	Vs	
47/107	
43.9%	
	
	
D’Haens	et	
al	2008	
(152)	
Multicentre	
open	 label	
randomised	
Infliximab	 5	 mg/kg	
0,2,6weeks	 plus	 Aza	 2-
2.5mg/kg/day	 vs	
conventional	treatment	
133	 Active	 CD	
CDAI>200	
naïve	 to	
steroids,	
immune-
modulators	
and	biologicals	
2	 years	
(n=49)	
SES-CD	 No	ulcers	 19/26	 73.1%	
vs	 7/23	
(30.4%)	
	
	
	
Rutgeerts	
2009	
(153)	
Randomised	
double	 blind,	
placebo	
controlled	
study	
Adalimumab	 160/80	 mg	
SC	(0,2	weeks)	then	40	mg	
every	 2	 weeks	 VS	
Adalimumab160mg/80	mg	
SC	 (0,2	 weeks)	 then	
placebo	SC	
129	 Moderate	 to	
severe	 active	
Ileocolonic	 CD	
with	 baseline	
mucosal	
ulcerations	
12	weeks	
	
	
52	weeks	
	
SES	CD	 Absence	 of	
mucosal	
ulcerations	
ADA	
maintenance	
40	 mg	
eow???	
Week	12-	
17/62	27.4%		
Week	 52	
24.2%	Vs		
Induction	
only	placebo/	
13%	wk	12	&	
0%	wk	52	
	
Hebuterne	
2008	
(154)	
	
	
Multicentre	
Open	label	
	
Certolizumab	 pegol	 400	
mg	 SC	 0,2,4	 weeks	 and	
every	4	weeks	
	
	
89	
	
Active	 CD	
(CDAi	 220-
450)	 with	 2	
	
10	 weeks	
n=78	
	 	
Absence	 of	
ulcers	or		
ER=CDEIS	<6	
	
	
4/78	5%	
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segments	
showing	
ulcerative	
lesions	 with	
CDEIS	>8)	
43/78	55%	
Rutgeerts	
2004	
(155)	
Multicentre	
randomised	
double	 blind	
PCT	
Natalizumab	300	mg	IV	at	
0,4,8	vs	placebo	
53	 Active	 CD	
CDAI	220-450	
10	week	ds	 CDEIS	 No	ulcers	 8/37	22%	vs		
1/13	8%	
Borrelli	
2006	
(11)	
Single	centre	
Randomised	
controlled	
open	label	
Polymeric	 formula	 versus	
Steroids	
37	 	 10	weeks	 	 	 14/19	 EEN	
74%		
vs		
6/18	 33%	
Steroids	 ,	
P<0.05	
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4b.	Transmural	healing	
The	International	Organisation	of	IBD	recently	stated	“effective	treatment	of	CD	should	not	only	
focus	on	healing	mucosal	lesions	but	rather	also	on	the	entire	thickness	of	the	intestinal	wall”.	
MR	 Enterography	 can	 reliably	 measure	 Ileocolonic	 transmural	 disease	 activity	 accurately	
correlating	 with	 the	 endoscopic	 index	 of	 severity	 with	 added	 benefits	 of	 measuring	 disease	
activity	in	the	small	bowel	beyond	the	reach	of	endoscopy	(156).	A	further	novel	outcome	from	
this	study	will	be	the	measurement	of	transmural	disease	activity	before	and	after	EEN.		
Hypothesis	and	Aims	
Therapies	capable	of	inducing	and	maintaining	endoscopic	mucosal	healing	(MH)	in	CD	are	vital	
as	adult	data	confirm	rapid	early	and	sustained	MH	in	CD	is	associated	with	less	frequent	clinical	
relapses,	 fewer	 hospitalisations	 and	 reduced	 surgical	 resections.	 Use	 of	 Exclusive	 Enteral	
Nutrition	(EEN)	induction	over	corticosteroids	in	children	with	Crohn’s	disease	(CD)	is	associated	
with	 greater	 early	mucosal	 healing	 (MH)	 but	 long-term	 benefits	 are	 not	 well	 described.	 The	
overarching	goal	of	 this	 thesis	was	 to	 investigate	benefits	of	EEN	and	early	 thiopurine	use	on	
early	 mucosal	 recovery	 and	 the	 impact	 on	 future	 clinical	 course.	 	 Our	 hypothesis	 is	 that	
successful	early	control	of	 inflammation	 in	the	earliest	phase	of	CD	can	be	achieved	with	EEN	
and	will	reduce	the	frequency	of	future	relapse	and	thereby	prevent	complications	and	surgical	
resections.	Clinical	parameters,	biomarkers	and	mucosal	microbiome	characteristics	of	children	
with	 early	 mucosal	 recovery	 (responders)	 will	 be	 compared	 with	 non-responders	 to	 better	
elucidate	mechanisms	associated	with	mucosal	healing.		
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We	systematically	investigate	following	questions	in	this	thesis.	
Question	1:		
Does	 the	 choice	 of	 first	 induction	 therapy	 in	 combination	with	 early	 Immuno-modulators	
use	improve	long	term	outcomes	in	Paediatric	Crohn’s	Disease?		
Question	2:		
How	often	EEN	leads	to	complete	mucosal	and/or	transmural	healing?		
Does	EEN	 induced	early	endoscopic	remission	 impacts	short	 to	medium	term	outcomes	 in	
Paediatric	Crohn’s	disease?	
Question	3:		
Mucosal	healing	is	therapeutic	endpoint	in	Crohn’s	disease,	can	non-invasive	proxies	reliably	
predict	endoscopic	disease	activity?	
Question	4:		
Does	 the	degree	of	 early	mucosal	 healing	with	 Exclusive	 Enteral	Nutrition	 correlates	with	
long	term	outcomes	in	Paediatric	Crohn’s	disease?		
Question	5:		
Are	 there	 any	 distinct	mucosa	 associated	microbiome	 (MAM)	 changes	 in	 those	 achieving	
complete	mucosal	healing	vs.	active	endoscopic	disease	following	EEN.	
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Methodology:	
Study	1	
In	this	study,	we	retrospectively	analysed	our	prospective	collected	data	from	Brisbane	Paediatric	
IBD	 database	 of	 children	with	 CD	 diagnosed	 between	 2005-2014.	 Children	 completing	 induction	
therapy	either	with	CS	or	EEN	and	commencing	thiopurines	within	six	months	of	CD	diagnosis	and	
completing	a	minimum	follow	up	of	2	years	were	analysed.	
Study	2	
In	this	prospective	study,	newly	diagnosed	children	with	CD	(≤16	years)	between	November	2009	to	
December	2012	were	included.	All	new	diagnoses	of	CD	were	offered	EEN	as	the	preferred	first	line	
therapy,	those	electing	for	CS	as	a	sole	 induction	therapy	were	not	eligible	for	the	trial.	 	Children	
completing	 minimum	 of	 six	 weeks	 of	 EEN	 and	 a	 paired	 clinical,	 endoscopic	 assessment	 were	
included.		
For	 study	3,	 a	 convenience	sample	of	24	children,	who	had	 luminal	CD	quantifiable	on	complete	
Ileo-colonoscopy	 and	 paired	 Paediatric	 Crohn’s	 disease	 activity	 index	 (PCDAI),	 C	 reactive	 protein	
(CRP),	Faecal	calprotectin	(FC)	and	Endoscopy	at	diagnosis	and	after	8	weeks	of	induction	therapy	
were	 analysed.	 Study	 5	 is	 a	 pilot	 sub-study	 including	 treatment	 naïve	 children	 (n=8)	 with	
consecutive	 clinical,	 endoscopic	 data	 and	 mucosal	 biopsies	 before	 and	 immediately	 after	 EEN	
induction.	
Study	4	
This	is	an	extension	of	study	2,	including	all	children	diagnosed	between	2009-2014	and	completing	
a	minimum	of	six	weeks	EEN	with	a	paired	clinical,	endoscopic	assessment	and	a	minimum	follow	
up	of	1	year	
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Study	Cohort	for	Studies	1-5	(Figure	1.8)	
	
	
n=26	completing	EEN
Brisbane	Paediatric IBD	database	2014	
(183	CD)
• CD cohort , diagnosed prior to Nov 2009 =93
• New diagnosis CD, during Nov 2009-Nov 2012 = 42
• New diagnosis CD , Dec 2012-Dec 2014=48
Study 1: 89 completing EEN or CS with early Thiopurines
Two-year outcomes After Exclusive Enteral Nutrition Are Superior
to Corticosteroids in Pediatric Crohn's Disease Treated Early with thiopurines
First induction therapy (Nov 09-Oct 12 ,n=42)
• EEN=30
• CS =8
• Surgical resection=2
• Infliximab for complex perianal CD=2
Studies 2 : 26 completing EEN
• Exclusive enteral nutrition induces early clinical, mucosal and transmural
remission in paediatric crohn’s disease
Study 3: 20 EEN and 4 CS therapy
• Predicting Endoscopic Crohn's Disease Activity Before and After Induction
Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and
Fecal Calprotectin
Study 5 : 8 paired mucosal sample pre and post EEN
• The Relative Abundances of Dorea and Faecalibacterium spp. in the
Mucosa Associated Microbiome of Newly Diagnosed Children with
Crohn's Disease Are Differentially Affected by Exclusive Enteral Nutrition
(n=8)
First induction therapy(Nov 12-Dec 14,n=48)
• EEN=32
• CS=11
• Surgical resection=1
• Ant-TNF’s for complex perianal=4
Study 4 ( 54 completing EEN )
• Early mucosal healing with Exclusive Enteral Nutrition is associated with
improved outcomes in newly diagnosed children with luminal Crohn’s
disease
n=28	completing	EEN
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Chapter	2	
	
	
	Two-Year	Outcomes	After	Exclusive	Enteral	Nutrition	Induction	Are	Superior	to	Corticosteroids	in	
Pediatric	Crohn's	Disease	Treated	Early	with	Thiopurines.	Grover	Z,	Lewindon	P.	Dig	Dis	Sci.	2015	
Oct;	60(10):3069-74.		
	
The	purpose	of	this	chapter	is	to	investigate:	
1. The	 relative	 importance	 of	 choice	 of	 initial	 induction	 therapy	 and	 early	 use	 Immuno-
modulators	on	medium	term	outcomes	in	paediatric	Crohn’s	disease.	
2. More	specifically,	if	choice	of	EEN	over	corticosteroids	induction	therapy	in	the	setting	of	
dose	 optimised	 early	 thiopurines	 reduces	 need	 for	 rescue	 CS	 or	 IFX	 and/or	 surgical	
resections.		
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Abstract:	
Background:	 Impact	 of	 first-line	 induction	 therapy	 on	 medium-term	 outcomes	 in	 the	 setting	 of	
early	 thiopurine	 (TP)	 use	 in	 children	 with	 Crohn’s	 disease	 has	 not	 been	 evaluated,	 in	 particular	
whether	choice	of	exclusive	enteral	nutrition	(EEN)	over	corticosteroids	(CS)	for	induction	impacts	
clinical	outcomes	at	12	and	24	months.	
Aims	and	Methods:	In	this	retrospective	study,	89	children	from	our	database	with	new	diagnosis	
CD	 and	 follow-up	of	 at	 least	 2	 years	 following	 induction	with	 exclusive	 course	 of	 CS	 or	 EEN	 and	
early,	dose-optimized	TP	(within	6	months	from	diagnosis)	were	evaluated.	We	compared	steroid	
dependency	 (relapse	 within	 3	 months	 of	 tapering	 first	 course	 CS	 or	 inability	 to	 wean	 <10	 mg	
prednisolone),	 need	 for	 IFX,	 linear	 growth,	 and	 surgical	 resections	 over	 the	 first	 2	 years.	 Results	
Choice	of	EEN	over	CS	induction	was	associated	with	reduced	linear	growth	failure	(7	vs.	26	%,	p	=	
0.02),	CS	dependency	(7	vs.	43	%,	p	=	0.002),	and	improved	primary	sustained	response	to	IFX	(86	
vs.	68	%,	p	=	0.02).	Combined	CS/IFX-free	remission	and	surgical	resection	rates	were	similar.	
Conclusions:	 In	 the	setting	of	early	TP	commencement,	EEN	 induction	 is	superior	 to	CS	 induction	
for	reducing	growth	failure,	CS	dependency,	and	loss	of	response	to	IFX	over	the	first	2	years.	
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Introduction	
Crohns	disease	 is	a	chronic,	destructive	 intestinal	disorder	progressing	 in	 the	majority	of	patients	
from	 inflammatory	 behaviour	 to	 complicated,	 stenosing	 and/or	 penetrating	 behaviour.	 Several	
recent	 large	 paediatric	 cohort	 studies	 provide	 invaluable	 insight	 on	 natural	 progression	 of	
paediatric	onset	Crohn’s	Disease	and	confirm	1	in	3	children	will	have	complicated	CD	at	diagnosis,	
further	doubling	within	7-11	years	from	diagnosis.	(3-5,41).	The	cumulative	probability	of	intestinal	
resection	is	30%	at	10	years	and	50%	at	20	years	from	diagnosis.	(5)	This	is	an	improvement	from	
the	1970s	when	referral	based	cohorts	of	Paediatric	onset	CD	with	similar	follow	up	reported	much	
higher	 risks	 of	 surgical	 resection	 (67%-69%)	 (35-36).	 These	 reduced	 surgical	 rates	mirror	 current	
experience	and	presumably	a	 result	of	changing	practices.	There	 is	 reducing	 reliance	on	steroids,	
increased	 use	 of	 Immunomodulators	 and	 biologics	 and	 closer	 patient	 monitoring.	 The	 ultimate	
benefit	 of	 any	 non-curative	 treatment	 for	 CD	 is	 the	 ability	 to	 reduce	 frequency	 and	 severity	 of	
inflammatory	 relapses	 that	 contribute	 to	 long	 term	 cumulative	 bowel	 damage	 and	 these	 are	
increasingly	the	endpoints	against	which	each	treatment	must	be	measured.		
EEN	at	 induction	has	 recently	 superseded	steroids	 in	paediatric	practice	giving	a	more	prolonged	
corticosteroid	free	remission,	fewer	relapses	and	better	linear	growth	(168).		Early	commencement	
of	TP,	within	6	months	of	diagnosis,	has	become	widespread	practice	in	both	adult	and	paediatric	
CD	since	a	 seminal	RCT	 in	 treatment	naïve	children	with	CD	demonstrated	a	greater	 steroid	 free	
remission	 in	 those	 commenced	on	early	 thiopurines	 (97).	Recent	 retrospective	paediatric	 studies	
have	reported	much	lower	efficacy	of	TP	in	maintaining	remission	in	Paediatric	CD.	(53,169-171)	
Similarly,	two	current	adult	controlled	trials	have	concluded	that	early	introduction	of	TP	does	not	
improve	 outcomes	 including	 maintenance	 of	 steroid	 free	 remission,	 need	 for	 anti-TNF	 and	
intestinal	 surgery	 (172-173).	 The	 relative	 importance	 of	 choice	 of	 initial	 induction	 therapy	 on	
medium	term	outcomes	in	the	setting	of	early	TP	use	has	not	been	evaluated,	in	particular	whether	
83 
 
choice	of	EEN	induction	over	steroids	reduces	CD	relapses,	need	for	rescue	CS	or	 IFX	and	surgical	
resections.		
	
Material	and	Methods	
Patients	and	study	design	
The	 Brisbane	 Paediatric	 Inflammatory	 Bowel	 Disease	 database	 has	 been	 a	 major	 initiative	 for	
collecting	 IBD	 data	 both	 retrospectively	 and	 prospectively	 since	 2005,	 as	 part	 of	 an	 ethically-
approved	 longitudinal	 audit	of	 the	natural	history	and	genetics	of	CD	and	UC	at	Royal	Children’s	
Hospital	(RCH).			
Brisbane	Paediatric	 IBD	services	was	established	in	2005,	covering	Queensland	population	of	4.78	
million	 in	2014.	 	 IBD	database	only	captured	children	managed	at	Royal	Children’s	Hospital,	state	
tertiary	referral	children’s	hospital.	Children	with	IBD	diagnosed	and	managed	by	private	physicians	
across	Queensland	were	not	 included	in	the	database.	 	Basic	demographic	data,	 including	date	of	
diagnosis,	therapies,	endoscopy	findings	and	surgery	were	recorded	on	a	password	protected	excel	
data	sheet.		In	2014,	there	were	total	of	389	children	included	in	the	database	(183	CD,	141	UC,	65	
IBDU).			
From	our	IBD	database	of	183	children	with	CD,	we	identified	89	children	first	treated	solely	with	
EEN	or	CS	and	on	early,	maintenance	TP	 (<	6	months	 from	diagnosis)	 for	at	 least	six	months	and	
follow	up	of	2	years.	Reasons	for	exclusion	(n=94)	 included:	those	given	EEN	and	CS	concurrently	
(n=14);	 failure	to	commence	early	TP	(n=25);	 inadequate	follow	up/data	(n=31);	primary	anti-TNF	
induction	for	fistulising	perianal	disease	(n=10);	failure	to	continue	TP	or	ceased	due	to	intolerance	
(n=14).	 Phenotype	 data	 including	 patient	 characteristics:	 endoscopy,	 radiology,	 biochemistry,	
concurrent	 treatments	 and	 outcomes	 were	 retrieved	 from	 our	 database,	 medical	 charts	 and	
electronic	 endoscopy	 reporting	 system.	 The	 aims	 of	 our	 retrospective	 study	 were	 to	 compare	
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outcomes	over	the	first	two	years	following	exclusive	course	of	CS	or	EEN	on	early	maintenance	TP.	
The	primary	outcomes	of	 interest	were	 steroid	dependency,	CS/IFX	 free	 remission,	 linear	growth	
and	 surgical	 resections	 at	 12	 and	24	months	 following	diagnosis.	 Introduction	of	 TP	 and	 starting	
dose	was	at	the	discretion	of	the	treating	gastroenterologist,	aiming	for	AZA	dose	2–2.5	mg/kg/day	
or	 6-MP	 of	 1-1.5mg/kg/day,	 modified	 according	 to	 drug	 monitoring	 tor	 6-TG	 levels	 (>250	
pmol/8×108	red	blood	cells).	
	
Definitions		
Clinical	Phenotype	was	defined	using	Paris	classification	(158).	Height	Z	scores	-1.64	corresponding	
to	<5	 th	percentile	was	denoted	as	presence	of	growth	 failure	 (53).	BMI	Z	scores	were	calculated	
using	Centre	for	Disease	Control	(CDC)	growth	charts	and	BMI	Z	scores	<-1,	<-2,	<-3	defined	grade	
1,	grade	2	and	grade	3	thinness	respectively	based	on	international	expert	guidelines	(158).	Clinical	
remission	was	defined	as	PCDAI	≤10;	biochemical	remission,	CRP<5	mg/L	with	PCDAI	≤10	[161,175].	
Relapse	was	defined	as	PCDA>15	on	more	 than	one	occasion	1	week	apart	and	or	CRP	>	5	mg/L	
with	clinically	active	disease.	A	PCDAI>30	was	considered	moderate	to	severe	paediatric	CD	(161).		
Endoscopic	Scores	were	determined	retrospectively	by	authors	separately	based	on	electronically	
stored	endoscopic	 images	 and	 reports	 description	using	 the	 validated	 Simple	 Endoscopic	 Scoring	
system	for	Crohn’s	disease	(SES-CD)	(141).	 	Only	endoscopic	segments	completely	examined	were	
scored,	ulceration	of	ILCV	were	scored	as	right	colonic	disease	and	not	included	in	the	Ileal	score.	
Inability	to	intubate	ileum	due	to	stricture	was	scored	as	maximum	of	SES-CD	of	3	as	the	mucosal	
abnormalities	 could	 not	 be	 examined.	 	 	 SES-CD	was	 assigned	 based	 on	 consensus	 between	 two	
authors	 after	 reviewing	 images	 and	 endoscopy	 reports.	 Mild,	 Moderate	 and	 severe	 endoscopic	
disease	activity	was	defined	as	 SES-CD	4–10	mildly	 active;	 11–19	moderate	active	 and	19	 severe	
active	CD	(142).		
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EEN	as	a	sole	therapy	using	polymeric	feeds	either	oral	or	NG	tube	to	induce	remission	was	given	
for	 a	 minimum	 period	 of	 6	 weeks	 as	 described	 previously	 (175).	 Children	 were	 offered	 either	
Nutrison	(1	kcal/ml,	Nutricia	UK,	4	g	protein,	3.9	g	fat/100	ml)	through	nasogastric	tube	(NGT)	or	
resource	 protein	 (1.25	 kcal/ml,	 Nestle,	 9.4	 g	 protein,	 3.5	 g	 fat/	 100	 ml)	 orally	 based	 on	 their	
preference	 and	 dietetic	 consultation.	 Small	 amounts	 of	 clear	 fluids	 and	 jelly	 were	 allowed	
empirically	 and	 concurrently	 to	 improve	 palatability	 and	 those	 struggling	 with	 oral	 EEN	 were	
allowed	 to	 add	 small	 amounts	 of	 flavouring	 or	 change	 to	 NG	 route.	 Steroid	 dependency	 was	
defined	as	10	mg/day	prednisolone	or	clinical	 relapse	within	3	months	of	tapering	steroids	 (176).	
Early	TP	was	defined	as	introduction	within	6	months	of	diagnosis	(171).	Therapeutic	TP	levels	were	
defined	as	6TG	levels	>250	pmol/8×108	red	blood	cells	(178).	Failure	to	measure	and/or	levels	<	250	
pmol/8×108	red	blood	cells	were	considered	as	sub	therapeutic.	Sustained	primary	response	to	IFX	
was	defined	as	 lack	of	symptomatic	 inflammatory	relapse	(PCDAI>30	with	elevated	CRP	or	Faecal	
Calprotectin	 and/or	 endoscopically	 or	 radiologically	 confirmed	 relapse	 after	 successful	 initial	
response	 requiring	 IFX	 dose	 escalation	 or	 interval	 adjustment	 (179-181).	 Steroid	 and	 IFX	 free	
remission	was	defined	as	no	concurrent	need	for	either	CS	or	IFX	to	maintain	remission	in	addition	
to	TP.	
Statistical	methods	
All	statistical	calculations	were	performed	using	Graph	Pad	Prism	version	5.00	for	Windows,	Graph	
Pad	 Software,	 San	 Diego,	 CA,	 USA.	 Descriptive	 continuous	 data	 is	 reported	 as	 an	 inter-quartile	
range.	 Baseline	 disease	 characteristics	 including	 age,	 duration	 of	 symptoms,	 CD	 phenotype,	
behaviour,	 severity	and	growth	were	compared	between	EEN	and	Steroids	 induction	group	using	
both	 parametric	 unpaired	 T	 and	 nonparametric	 Mann	 Whitney	 U	 test.	 Categorical	 Clinical	
Outcomes	(Growth,	Steroid	dependency,	Clinical	remission,	Therapeutic	levels	of	TP,	Need	for	IFX,	
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and	intestinal	surgery)	were	compared	at	1	and	2	years	by	creating	2	by	2	contingency	table	using	
Fisher	exact	test.	P	value<0.05	was	used	for	significance.		
	
Results	
Baseline	demographic	and	phenotypic	characteristics		
89	children	with	CD	treated	with	either	EEN	(n=43)	or	Steroids	(n=46)	as	a	sole	induction	therapy	on	
early	 maintenance	 thiopurines	 (<6	mo.	 from	 diagnosis)	 and	 follow	 up	 for	 at	 least	 2	 years	 were	
included.	Baseline	disease	phenotype	and	clinical	characteristics	of	those	included	in	the	study	are	
given	in	Table	2.1.	CS	induction	group	were	younger	and	had	greater	isolated	colonic	disease,	while	
those	 receiving	EEN	had	more	pan-enteric	disease	 (Ileocolonic	disease)	and	a	greater	clinical	and	
endoscopic	disease	activity	at	diagnosis.	
	
First	and	Second	year	outcomes	on	early	maintenance	TP	(Table	2.2)	
During	 the	 first	 year	 after	 primary	 induction	 and	 early	 TP	 56%	 relapsed,	 39%	 requiring	 IFX,	 17%	
became	CS	dependent	and	13%	came	to	surgery.	Choice	of	EEN	over	CS	in	the	setting	of	early	dose	
optimised	TP	use	was	associated	with	 reduction	 in	 linear	growth	 failure	 (7%	vs.	26%,	p=0.02),	CS	
dependency	(7%	vs.	43%,	p=0.002)	and	sustained	primary	response	to	 IFX	 (86%	vs.	68%,	p=0.02).	
Combined	 CS	 or	 IFX	 free	 remission	 and	 intestinal	 resection	 during	 the	 first	 and	 second	 year	
following	diagnosis	were	no	different	in	those	initially	treated	with	CS	vs.	EEN	therapy.		
	
	
	
	
	
87 
 
	
	
Table	2.1.	Demographics,	Nutrition	and	Clinical	Phenotypes	of	study	cohort	at	diagnosis		
Choice	of		first	induction	therapy	 Steroid(n=46)	 EEN	(n=43)	 P	
Age:	Median(IQR)	 11.5(9.5-13)	 13(11.35-14)	 0.004	
Sex:	Male	(%)	 28(61%)	 29(68%)	 0.5	
Months	of	symptoms	before	diagnosis:	Median(IQR)	 5(2-60)	 5(3-9.5)	 0.6	
Age	Distribution	
							A1a	(0	-	<10	yrs)																																																						
							A1b	(10-17	yrs)							
	
15(32.5%)	
30	
	
4(9.3%)	
40	
	
0.008	
Disease	Distribution	
										Ileocolonic	L3	
										Ileal	L1	
										Colonic	L2	
	
23(50%)	
7	
15(32.5%)	
	
36(84%)	
6	
2	(4.5%)																																
	
0.001	
	
0.008	
Disease	Modifier		
				Upper	GI	location	(L4a+L4b)	(%	
									L4a	(Proximal	to	Treitz)	(%)	
									L4b	(Distal	to	Treitz)	(%)		
									L4a+L4b	
								Perianal	(%)	
	
27(59%)	
17	
5	
5	
9	
		
29(67%)	
20	
2	
7	
7	
	
	
0.5	
Disease	Behavior	at	diagnosis	
								Inflammatory	(B1)	(%)	
								Stricturing	(B2)	(%)	
								Fistulising/Stricturing	(B2+B3)	(%)	
	
39(85%)	
6	(13%)	
1	(4%)	
	
30(71%)	
12(27%)	
1(2%)	
	
	
0.11	
Height	Z	score		
							Growth	failure	(<1.64,	<5th	)	
							No	Growth	failure																																					
	
9(19.5%)	
36	
	
6(14%)	
38	
	
0.5	
BMI	Z	score	
						Normal	to	obese	
						Grade	1	thinness	Z	Score	<-1	(%)	
						Grade	2	thinness	Z	Score	<-2(%)	
						Grade	3	thinness	Z	Score	<-3	(%)																																						
	
22	
10(22%)	
8(17%)	
5(11%)	
	
22	
6(14%)	
12(28%)	
4(9%)	
	
0.64	
Clinical	Disease	Severity		(PCDAI)	
						Mild	PCDAI<30(%)	
						Moderate	to	Severe	PCDAI>30(%)	
	
18(39%)	
27(61%)	
	
6(14%)	
38(86%)	
	
0.007	
CRP	(C	reactive	Protein)	
							Normal	<	5mg/L	(%)	
							Abnormal	>5mg/L	(%)	
	
8(14%)	
38(86	%)	
	
2(5%)	
41(95%)	
0.09	
Endoscopic	Disease	Severity	(n=83)	
							Mild	(SES-CD	4-10)	(%)	
							Moderate-Severe	(SES-CD>	11)	(%)																																																
	
21(51%)	
20(49%)	
	
7(16%)	
35(84%)	
	
0.001	
0.001	
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Table	 2.2	 Outcomes	 at	 12	 &	 24	 months	 following	 CS	 vs.	 EEN	 induction	 and	 early	 use	 of	
maintenance	TP		
First	induction	therapy	 CS=46	 EEN=43	 P	
Value	
Early	use	of	Thiopurine	(TP)	
<	3	months	
3-6	months	
	
29(63%)	
17(37%)	
	
35(81%)	
8(19%)	
			
0.06	
TP	continued	
	≤12	months	
13-24	months	
	
40(87%)	
32(69.5%)	
	
38(88%)	
24(56%)	
	
1	
Therapeutic	6TG	(6	Thioguanine>250/pmol/8×108	RBC)	
≤12	months	(n=61)	
13-24	months(n=50)	
	
30(65%)	
27(84%)	
	
31(72%)	
23(96%)	
	
0.5	
BMI	(Grade	3	thinness=BMI	Z	score	<-3)		
≤12	months																																																						
13-24	months	
9(20%)	
6(13%)	
3(6.5%)	
4(9%)	
2(4.5%)	
2(4.5%)	
0.2	
	
Linear	growth	failure	(Height	Z	scores	-1.64)	
≤12	months	
13-24	months	
12(26%)	
8(17.5%)	
4(8.5%)	
3(7%)	
1(2%)	
2(5%)	
0.02	
0.02	
0.9	
Steroid	Dependency		
(Relapse	 ≤	 3mo	 from	 first	 course/unable	 to	 wean	
<10mg)	
≤	12	months	
13-24	months	
	
20(43%)	
13(28%)	
7(15%)	
	
3(7%)	
2(4.5%)	
1(2.5%)	
	
0.002	
	
Infliximab	use	
≤	12	months	
13-24	months		
28(61%)	
15(32.5%)	
13(28.5%)	
28(65%)	
20(46.5%)	
8	(19.5%)	
1	
0.19	
0.1	
Poorly	sustained	IFX	response	(	dose	intensification)	
≤	12	months	(n=11)	
13-24	months(N=9)	
15(32%)	
8(17%)	
7(15%)	
6(14%)	
3(7%)	
3(7%)	
0.02	
0.02	
0.07	
CS/IFX	free	remission	(PCDAI<10	with	no	CS/IFX)	
≤	12	months	
13-24	months	
	
18(39%)	
11(24%)	
	
22(51%)	
14(33%)	
	
0.3	
Surgical	resection	
Resection	(Non-Inflammatory	Phenotypes=20)	
Resection	(Inflammatory	phenotype=69)	
7(15%)	
4(9%)	
3(7%)	
10(23%)	
8(18%)	
2(5%)	
0.42	
0.2	
1	
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Tolerance	and	drug	levels	of	those	commenced	on	early	thiopurines	
	
Of	89	eligible	children,	78	continued	TP	for	at	least	12	months,	11(12%)	discontinued	TP	between	6-
12	months.	 Reason	 for	 discontinuation	were	 patient	 or	 physician	 discretion	 (n=7),	 bone	marrow	
toxicity	 (n=2),	 persistent	 nausea,	 unexplained	 fevers	 and	 oral	 ulceration	 (n=1)	 and	
pancreatitis/abnormal	 liver	 enzymes	 (n=1).	 TP	 were	 initiated	 within	 3	months	 from	 diagnosis	 in	
64/78	 (82%)	 and	 in	 14/78(18%)	 between	 3-6	months	 Optimal	 6TG	 levels	 (>250	 pmol/8×108	 red	
blood	 cells)	 were	 confirmed	 at	 least	 once	 in	 61/78(78%)	 during	 the	 first	 year	 after	 diagnosis.	 A	
further	56/78	(72%)	patients	continued	TP	beyond	12	months.	TP	was	ceased	during	second	year	
because	of	intolerance	(n=2)	and	physicians	discretion	(n=12).	During	the	second	year	50/56	(89%)	
maintained	 therapeutic	 levels	 of	 TP.	 Further	 sub	 analysis	 confirmed	 that	 Therapeutic	 6-TG	 levels	
and	timing	did	not	influence	CS/IFX	free	remission.	
	
Discussion	
This	is	the	first	Paediatric	Cohort	Study	evaluating	the	relative	importance	of	induction	therapy	with	
EEN	versus	CS	in	the	setting	of	early,	dose	optimised	TP	use	on	medium	term	outcomes	in	children	
with	 CD.	Our	 study	 demonstrates	 further	 evidence	 of	 EEN	 superiority	 over	 CS	 in	 reducing	 linear	
growth	 failure	 (7%	 vs.26%,	 p=0.002),	 steroid	 dependency	 (7%	 vs.	 43%,	 p=0.002)	 and	 improving	
sustained	response	to	IFX	(86%	vs.	67%,	p=0.02).		These	benefits	were	seen	despite	the	EEN	group	
having	a	more	severe	phenotype	with	more	extensive	disease	distribution	and	a	higher	clinical	and	
endoscopic	 disease	 activity	 at	 diagnosis.	 	 At	 one	 and	 two	 year	 endpoints,	 CS/IFX	 free	 remission	
rates	favoured	EEN	vs	CS	induction	(49%	vs.39%	at	1	year	and	33%	vs.	24%	at	2	years)	but	not	were	
statistically	different.	Our	results	also	 indicate	that	choice	of	 induction	therapy	did	not	alter	early	
surgical	outcomes	with	complicating	phenotype	already	established	 in	 some	patients	and	 further	
intestinal	resection	rates	in	 inflammatory	phenotypes	were	comparable	(6.6%	vs.	7.6%).	Although	
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progression	to	IFX	was	high	and	similar	in	both	induction	groups,	EEN	induction	significant	reduced	
need	for	further	CS	therapy	and	LOR	to	IFX	over	the	key	first	two	years.		
The	 timing,	 duration	 and	 levels	 of	 thiopurines	 did	 not	 have	 any	 influence	 CS/IFX	 free	 remission	
rates	 outcomes	 over	 the	 first	 2	 years	 (data	 not	 shown).	 Previous	 studies	 comparing	 long	 term	
outcomes	after	EEN	vs.	Steroids	have	also	demonstrated	reduced	relapse,	less	steroid	exposure	and	
better	 linear	 growth	 (92-94).	 Lambert	 et	 al	 (94)	 reported	 one	 year	 (61%	 vs.	 77%)	 and	 two-year	
relapse	rate	of	 (61%	vs.	89%)	comparing	EEN	with	Steroids	with	significantly	 less	use	of	 Immuno-
modulators	(26%	vs.	65%)	in	a	paediatric	cohort	where	early	TP	use	was	not	routine.	We	observed	
similar	 clinical	 relapse	 with	 (51.5%	 vs.	 61%,	 p=NS)	 and	 26%	 vs.	 63%,	 p=0.02)	 at	 1	 and	 2	 years	
following	EEN	vs.	CS	despite	a	higher	early	use	of	thiopurines	(100%	<	6	months,	72%	<	3	months	
after	diagnosis).	Despite	similar	clinical	relapse,	CS	dependency	was	more	frequently	encountered	
in	those	using	CS	at	initial	diagnosis,	although	this	may	be	a	potential	biased	outcome,	as	patients	
are	more	likely	to	consider	second	course	of	CS	at	relapse.	Similarly,	a	more	frequent	use	of	IFX	in	
the	 first	 year	 was	 noted	 after	 EEN	 vs.	 CS	 (46.5%vs.32.5%,	 p=NS),	 this	 is	 again	 a	 reflection	 of	
changing	treatment	paradigms.	
Using	a	definition	of	height	Z	scores	-1.64	as	presence	of	growth	failure,	we	confirm	much	greater	
proportion	 of	 children	 with	 persistent	 growth	 failure	 after	 CS	 induction	 vs.	 EEN	 (17.5%	 vs	 2%,	
p=0.02).	Several	studies	have	reported	better	linear	growth	on	EEN	vs.	Steroids	(88-90),	however	a	
recent	 large	 study	did	not	 confirm	benefits	on	height	outcomes	2	years	after	EEN	and	early	AZA	
(181).		It	should	be	noted	that,	change	in	height	velocity	Z	score	or	a	Z	score	<	-2	would	have	been	a	
more	accurate	measure	of	linear	growth	failure	(158),	we	also	did	not	account	for	pubertal	staging	
at	diagnosis,	as	poor	 linear	growth	Z	scores	 in	CS	group	could	be	potentially	explained	by	greater	
frequency	 of	 younger	 patient.	 Additionally,	 greater	 improvement	 in	 height	 Z	 score	 in	 our	 EEN	
cohort	could	be	related	to	the	synergistic	effect	of	EEN	and	early	IFX	use.	
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Using	early	thiopurines	in	this	selected	cohort	we	observed	one	and	two-year	CS/IFX	free	remission	
rates	 of	 (39%	 vs.	 51%,	 and	 24%	 vs.	 33%,	 p=NS)	 after	 CS	 vs.	 EEN.	 	 These	 disappointing	 results,	
despite	early	aggressive	TP	usage	are	comparable	 to	a	French	paediatric	 study	evaluating	 role	of	
early	thiopurines	after	CS	(n=31)	and	EEN	(n=42)	reporting	CS/IFX	free	remission	rates	of	39.8%	and	
31.2%	at	1	and	2	years	(170).	
Previous	 studies	 have	 confirmed	 benefits	 of	 concomitant	 enteral	 nutrition	with	 IFX	 in	 sustaining	
response	to	IFX	but	our	study	is	the	first	to	suggest	a	more	sustained	response	to	IFX	(86%	vs.	68%,	
p=0.02)	in	those	initially	treated	with	EEN	vs.	CS.	(180-181)	This	finding	should	be	explored	further	
in	a	prospective	study	but	it	is	plausible	EEN	compared	to	CS	induces	greater	endoscopic	remission	
thus	greater	reduction	in	inflammatory	disease	load	and	higher	trough	levels	of	IFX.	However,	these	
observations	need	further	validation	with	therapeutic	drug	monitoring.	
This	 study	 has	 several	 limitations	 including	 its	 retrospective	 nature,	 bias	 of	 changing	 treatment	
paradigms	 with	 time	 and	 lack	 of	 propensity	 score	 matching,	 a	 more	 accurate	 measure	 of	
intervention	in	observational	cohort	studies.	However,	medium	term	benefits	of	choosing	EEN	over	
CS	were	apparent	in	our	study	despite	more	Ileocolonic	disease	at	diagnosis	and	a	higher	baseline	
clinical	 and	 endoscopic	 disease	 scores	 in	 those	 treated	 with	 EEN.	 In	 conclusion,	 accepting	 the	
potential	of	changing	treatment	paradigms	and	limitations	of	our	design	our	data	suggest	medium	
term	benefits	of	choosing	EEN	over	CS	beyond	induction	therapy	with	significant	 improvement	 in	
linear	growth,	reduction	in	CS	dependency	and	a	more	sustained	response	to	IFX.			
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Publication:	Exclusive	enteral	nutrition	induces	early	clinical,	mucosal	and	transmural	remission	in	
paediatric	Crohn's	disease.	Grover	Z,	Muir	R,	Lewindon	P.	J	Gastroenterol.	2014	Apr;	49(4):638-45.		
	
	
The	purpose	of	this	chapter	is	to:	
1. Comprehensively	investigate	of	impact	of	EEN	induction	therapy	on	clinical,	biochemical,	
endoscopic	and	MRE	 (MR	Enterography)	parameters	 in	 children	with	newly	diagnosed	
moderate	to	severe	CD.			
2. Relate	early	endoscopic	response	to	EEN	with	subsequent	clinical	outcomes,	specifically	
endoscopic	confirmed	relapse,	CD	related	hospitalisation,	need	to	commence	biological	
agent	and	surgical	resection	at	1	year.		
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Abstract	
BACKGROUND	&	AIMS-	Exclusive	Enteral	nutrition	(EEN)	induces	clinical	and	mucosal	healing	(MH)	
in	Crohn’s	Disease	(CD)	with	MH	the	best	determinant	of	future	outcome.	We	investigated	efficacy	
of	EEN	for	inducing	early	clinical,	biochemical,	mucosal	and	transmural	remission	of	CD	and	related	
early	endoscopic	response	to	outcomes	at	1	year.		
METHODS:	 In	a	prospective,	open	 label	 study	34	children	 (Mean	13.1	years;	21	males)	with	new	
diagnosis	 CD	 were	 offered	 EEN,	 26	 completed	 a	 minimum	 6	 weeks	 EEN	 and	 underwent	 paired	
clinical,	biochemical	&	endoscopic	assessment	at	start	and	completion	using	PCDAI,	BMI,	CRP	and	
Simple	 Endoscopic	 Score	 for	 CD	 (SES-CD).	 A	 subset,	 16/26,	 had	 paired	MR	 Enterography	 scored.	
Early	good	endoscopic	response	(completes	MH,	(SES-CD=0)	or	near	complete	MH,	SES-CD	1-3)	was	
related	to	outcomes	at	1	year.		
RESULTS:	EEN	improved	mean	PCDAI	(37.88	to	7.01,	p<.001;	BMI	Z	scores	(-1.54	to	-0.54,	p<.01);	
Weight	Z	score	(-0.79	to-0.08,	p=0.03);CRP	(44.86	to	5.5,	p<.001);	Endoscopy	(SES-CD	14.28	to	3.88,	
p<.001)	 and	 MRE	 (5.14	 to	 2.79,	 p=.01).	 22/26	 (84%)	 achieved	 clinical	 remission;	 20	 (76%)	
biochemical	 remission.	 15	 (58%)	 had	 early	 good	 endoscopic	 response,	 (11	 complete	 MH	 (SES-
CD=0),	 4	 near	 complete	MH,	 SES-CD	 ,1-3)	 and	 3/14	 (21%)	 had	 transmural	 remission	 of	 Ileal	 CD	
(MRE-CD:	0-1).	Early	good	endoscopic	response	was	associated	with	reduced	endoscopic	confirmed	
relapse	 (53%	 vs.	 100%,	 p=0.02),	 anti	 TNF	 use	 (33%	 vs.88%,	 p=0.01)	 and	 hospitalisation	 (40%	 vs.	
88%)	at	1	year.			
CONCLUSIONS:	 EEN	 is	 effective	 for	 inducing	 early	 clinical,	 biochemical,	 mucosal	 and	 transmural	
remission.	Early	endoscopic	remission	improves	outcomes	at	1	year.	 	
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Introduction	
Crohn’s	Disease	(CD)	is	a	chronic,	debilitating	disorder	affecting	growth,	well-being,	education,	and	
employment	 and	 nearly	 25%	 of	 patients	 are	 diagnosed	 before	 16	 years	 of	 age	 (158).	 Paediatric	
onset	 Crohn’s	 disease	 is	 a	 more	 severe	 phenotype	 with	 the	 additional	 issues	 of	 growth	 failure,	
delayed	puberty,	poor	bone	density	and	the	consequences	of	a	chronic	disease	commencing	at	a	
vulnerable	 period	 of	 psychosocial	 development	 (42-51).	 Cohort	 studies	 comparing	 the	 clinical	
course	 of	 paediatric	 vs.	 adult	 onset	 CD	 confirms	 it’s	 more	 aggressive	 phenotype	 with	 extensive	
intestinal	involvement,	rapid	progression	and	increased	disease	activity	index,	year	by	year,	despite	
use	of	more	 immunosuppression	(3-5).	These	observations	demonstrate	the	need	for	both	better	
treatment	endpoints	and	interventions	in	the	paediatric	population.	Mucosal	healing	has	emerged	
as	 an	 important	 end	 point	which,	when	 achieved	 in	 the	 first	 year,	 leads	 to	 less	 frequent	 clinical	
relapses,	fewer	hospitalisations,	reduced	surgical	resections	and	lower	risk	of	fistulising	disease	(6-
7,152).	
Treatments	 for	 induction	 of	 remission	 in	 CD	 include	 corticosteroids,	 EEN	 (exclusive	 enteral	
nutrition)	 and	 biologic	 agents.	 For	 clinical-remission	 high	 quality	 studies	 and	 those	 in	 paediatric	
cohorts	comparing	steroids	and	EEN	show	them	to	be	equally	effective	in	up	to	80%	of	patients	(9).	
However;	clinical	remission	indicated	by	improved	symptom	control	alone	is	inadequate.	Not	only	
is	mucosal	disease	active	 in	 the	majority	of	asymptomatic	patients	 treated	with	steroids	 (10)	but	
treatment	 to	 this	 endpoint	 over	 the	 past	 20	 years	 has	 failed	 to	 avert	 the	 progressive	 and	
complicated	course	of	CD	(5),	particularly	in	children.	Our	hypothesis	was	that	EEN	induces	superior	
mucosal	 healing	 and	 achieving	 this	 early	 followed	 by	 standard	 practice	 of	 early	 introduction	 of	
thiopurine	(Azathioprine	and	6	Mercaptopurine	<3	months)	may	lead	to	sustained	clinical	remission	
and	improved	future	clinical	outcomes.		
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MATERIAL	AND	METHODS	
PATIENTS	AND	STUDY	DESIGN	
This	was	a	prospective,	single	centre,	open	label	study	including	newly	diagnosed	children	with	CD	
(≤16	years)	conducted	between	November	2009	to	December	2012	in	a	tertiary	referral	paediatric	
hospital.	Institutional	Ethics	approval	was	granted	and	written	consent	obtained	from	patients	and	
parents.	 This	 study	 was	 retrospectively	 registered	 with	 ANZ	 clinical	 trials	 registry	 -
ACTRN12612001032842	in	September	2012.		
The	 diagnosis	 of	 CD	 was	 based	 on	 established	 clinical,	 endoscopic,	 histological	 and	 radiological	
criteria.	All	new	diagnoses	of	CD	were	offered	EEN	as	the	preferred	first	line	therapy,	those	electing	
for	CS	as	a	sole	induction	therapy	were	not	eligible	for	the	trial.		Other	exclusions	criteria	included:	
stricturing	 disease	 with	 proximal	 bowel	 dilatation	 and	 obstructive	 symptoms;	 previous	 or	
concurrent	 use	 of	 steroids,	 thiopurines	 or	 biological	 agents	 for	 indication	 other	 than	 luminal	 CD	
(example	 autoimmune	 hepatitis	 or	 Juvenile	 idiopathic	 arthritis);	 inability	 to	 tolerate	 oral	 or	
Nasogastric	(NG)	tube	EEN	for	a	minimum	of	6	weeks.	
All	 enrolled	patients	underwent	 comprehensive	assessment	 including	PCDAI,	 growth	parameters,	
CRP,	Endoscopy	at	diagnosis	and	8	weeks.	Children	were	offered	either	Nutrison	(1Kcal/ml,	Nutricia	
UK,	 40g	 Protein,	 39	 g	 Fat	 /1000ml)	 through	 Nasogastric	 tube	 (NGT)	 or	 Resource	 protein	
(1.25Kcal/ml,	Nestle,	 18.8g	 Protein,	 7g	 Fat	 /200ml)	 orally	 based	on	 their	 preference	 and	dietetic	
consultation.	 The	 prescribed	 volumes	were	 based	 on	 Schofield’s	 equation	which	 predicts	 resting	
energy	expenditure	 (180).	 	Feeds	were	gradually	 increased	to	 target	volumes	 in	3	 to	5	days.	 	For	
those	 electing	 to	 receive	 EEN	 via	NGT,	 informed	 consent	was	 obtained	 for	NGT	 insertion	 during	
General	Anaesthetic	for	diagnostic	endoscopy,	 if	CD	was	confirmed.	Small	amounts	of	clear	fluids	
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and	 Jelly	were	 allowed	 empirically	 and	 concurrently	 to	 improve	 palatability	 and	 those	 struggling	
with	oral	EEN	were	allowed	to	add	small	amounts	of	flavouring	or	change	to	NG	route.	To	maximise	
compliance	 with	 EEN,	 clinical	 and	 dietetic	 staff	 provided	 support	 with	 regular	 phone	 calls	 and	
outpatient	visits.	After	completion	of	EEN	and	during	remission	phase	no	dietary	restrictions	were	
recommended.	
Primary	 end	 points	 of	 the	 study	 were	 to	 determine	 efficacy	 of	 EEN	 for	 inducing	 early	 clinical,	
biochemical,	mucosal	 and	 transmural	 remission	 at	 8	weeks.	 Secondary	 outcomes	were	 to	 relate	
early	 endoscopic	 response	 to	 subsequent	 clinical	 outcomes,	 specifically	 endoscopic	 confirmed	
relapse,	CD	related	hospitalisation,	need	to	commence	biological	agent	and	surgical	resection	at	1	
year.		
It	 is	our	practise	 to	 commence	Thiopurines	 (Azathioprine	or	6-Mercaptopurine)	during	or	 shortly	
after	EEN	induction	therapy	based	on	the	Markowitz	publication	confirming	lower	clinical	relapse	in	
children	 with	 early	 introduction	 of	 6-MP	 after	 steroid	 induction	 therapy	 (97).	 Time	 to	 initiate	
thiopurines	was	 at	 the	 discretion	 of	 the	 treating	 gastroenterologist.	 All	 children	were	 eventually	
commenced	on	Thiopurines	within	3	months	of	 their	 initial	diagnosis	aiming	 for	2-2.5mg/kg/day,	
modified	according	to	TPMT	status	and	drug	monitoring,	6-TG	levels	>250pmol/8×108	erythrocytes.		
Current	 Australian	 Pharmaceutical	 Benefits	 Scheme	 (PBS)	 criteria	 in	 children	 restrict	 use	 of	
infliximab	to	those	with;	complex	perianal	fistulising	disease	or	active	clinical	/endoscopic	disease	
after	 a	 minimum	 8	 weeks	 EEN	 or	 steroids	 and	 3	 months	 conventional	 Immunomodulator	
(Thiopurines	 or	 Methotrexate)	 use.	 	 Hence	 no	 patient	 with	 luminal	 CD	 was	 eligible	 for	 “early”	
biological	use.	
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DEFINITIONS		
Phenotype	
Classification	 was	 based	 on	 previously	 published	 modified	 Montreal/Paris	 classification	 (158);	
presence	of	growth	failure	was	defined	as	(Z	score	-1.64	corresponding	to	<5	th	percentile)	as	G1,	
and	G0	as	no	growth	failure	 (48).	 	BMI	Z	scores	were	calculated	using	Center	 for	Disease	Control	
(CDC)	growth	charts	and	BMI	Z	scores	<-1,	<-2,	<-3	defined	grade	1,	grade	2	and	grade	3	thinness	
respectively	based	on	proposed	international	expert	guidelines	(159).	
Disease	location	was	defined	using	abnormal	endoscopic	appearance;	abnormal	histopathology	in	
otherwise	 normal	 appearing	 mucosa	 was	 disregarded	 for	 the	 purpose	 of	 disease	 classification	
(158).	Extensive	 intestinal	 involvement	was	classified	as	 Ileocolonic	and	Upper	GI	(L3+L4)	disease.	
Small	Bowel	CD	out	of	reach	of	endoscopy	was	defined	using	standard	MR	Enterography	criteria;	
Bowel	wall	thickness	>3	mm,	contrast	transmural	enhancement,	skip	lesions,	Stricturing	/	fistulising	
disease	plus	other	 supportive	 features	 like	 fibro-fatty	proliferation,	mesenteric	 lymphadenopathy	
and	comb	sign	(159).		
Clinical	and	biochemical	disease	activity	
Clinical	 remission	 was	 defined	 as	 PCDAI<10;	 Biochemical	 remission,	 CRP<5	 mg/L	 with	
PCDAI<10(161,	 175,184).	 Relapse	 was	 defined	 as	 PCDAI>15	 on	more	 than	 one	 occasion	 1	 week	
apart	 and	or	CRP>5mg/L	with	 clinically	 active	disease.	A	PCDAI	>30	was	 considered	moderate	 to	
severe	Paediatric	CD.	(161)	
Mucosal	Disease	Activity	
Scores	were	determined	by	 the	endoscopist	 at	 time	of	 the	procedure	using	 the	validated	Simple	
Endoscopic	Score	 (SES)	 for	CD	(141):	SES-CD	4-10	mild	active	disease;	11-19	moderate	active	and	
>19	severe	active	CD.	 	As	per	the	guide,	the	sum	of	all	SES-CD	scores	were	added	for	each	of	the	
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five	segments	explored	during	colonoscopy,	and	a	maximum	score	of	3	was	given	for	non-passable	
stenosis	of	Ileum	where	examination	of	Ileum	was	not	possible.	
Complete	mucosal	healing	was	SES-CD	0;	near	complete	SES	1-3;	 Incomplete	>3	(142).	Early	good	
endoscopic	response	was	defined	as	complete	or	near	complete	mucosal	healing	at	8	week	follow	
up	 endoscopy.	 	 Those	 with	 partial	 or	 no	 response,	 SES	 >3	 were	 classified	 as	 poor	 endoscopic	
response.	
	
	
Transmural	Disease	Activity	
Previously	 validated	 MRI	 disease	 activity	 scores	 were	 applied	 to	 each	 MRE	 by	 an	 experienced	
Radiologist,	blinded	to	endoscopy	reports,	to	determine	transmural	disease	activity	of	small	bowel.	
Small	 bowel	 CD	 activity	 was	 defined:	 0-1	 no	 activity;	 2-6	 mild	 activity;	 >7	 moderate	 to	 severe	
activity	(161).	
	
Statistical	Methods	
All	statistical	calculations	were	performed	using	Graph	Pad	Prism	version	5.00	for	Windows,	Graph	
Pad	Software,	San	Diego	California	USA.	Descriptive	continuous	data	is	reported	as	an	Inter-Quartile	
range.	 Baseline	 disease	 characteristics	 including	 CD	 phenotype,	 behaviour,	 severity,	 time	 to	
diagnosis	 and	early	 Immuno-modulators	use	were	 compared	between	early	 good	and	early	poor	
endoscopic	responders	using	both	parametric	unpaired	T	and	nonparametric	Mann	Whitney	U	test.	
Primary	end	points	of	disease	activity	 scores	before	and	after	 intervention	were	calculated	using	
both	paired	T	and	non-parametric	Wilcoxon	 ranked	sum	test.	Secondary	outcomes	at	1	year	and	
99 
 
last	 follow	up	were	analysed	by	creating	2×2	contingency	 table	using	Fisher	exact	 test.	P	value	<	
0.05	was	used	for	significance.	
	
RESULTS	
Baseline	Demographic	and	Phenotypic	characteristics	(Table	3.1)	
Forty-two	 patients	 were	 diagnosed	 with	 CD	 during	 the	 study	 period,	 eight	 preferred	 steroid	
induction	therapy).	34	children	were	eligible	for	the	trial	and	8	excluded:	2	received	concurrent	anti	
TNF	 agent	 for	 fistulising	 peri-anal	 disease;	 2	 received	 concurrent	 steroids;	 1	 for	 Autoimmune	
hepatitis	and	arthritis;	1	for	arthritis	and	erythema	nodosum;	2	were	unable	to	complete	EEN	for	6	
weeks	because	of	abdominal	pain	and	diarrhoea	and	changed	to	steroid.		No	other	adverse	effects	
were	reported;	2	children	went	to	surgery	for	obstructive	stricturing	disease	soon	after	diagnosis.	
26	children	completed	a	minimum	6	weeks	EEN,	median	duration	EEN	9	weeks	(IQR,	6-14).	Median	
duration	of	symptoms	before	diagnosis	was	4	months	(IQR	3-11)	and	median	follow	up	was	20.54	
months	(14.16-24.53	IQR).			All	patients	had	paired	clinical,	biochemical	and	endoscopic	assessment	
at	baseline	and	after	8	weeks	EEN;	and	16/26	had	paired	MRE.	12/26	(46%)	completed	EEN	via	oral	
route	 alone,	 14/26(54%)	 received	 EEN	 via	NG	 tube	 because	 of	 palatability,	 inadequate	 intake	 or	
poor	 compliance.	 Follow	 up	 Colonoscopy	 with	 Ileal	 intubation	 was	 successful	 in	 all	 except	 one	
where	 Ileal	 stricture	precluded	 intubation.	Baseline	disease	phenotype	of	 the	26	eligible	 children	
was:	Median	age	13.1	years	(9.5-15.75	IQR),	19	Males;	Ileocolonic	disease	in	21	(80%),	Stricturing	8	
(31%,	 which	 includes	 1	 penetrating	 and	 4	 Perianal	 disease	 (15%).	 	 At	 diagnosis:	 clinical	 disease	
activity	 was	 moderate	 to	 severe,	 PCADI	 >30	 in	 23	 (88%);	 endoscopic	 disease	 activity	 was	 mod-
severe	SES-CD>10	 in	22	(84%);	MRE	was	active	 in	24/26	(92%)	children	at	diagnosis:	moderate	to	
severe	SB	activity	 in	4	 (15.4%);	BMI	Z	Scores	were	<-1	 in	18	 (70%,	grade	1	thinness)	and	<-2	 in	7	
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(27%,	grade	2-3	thinness).Growth	failure	(Z	score<1.64)	at	diagnosis	was	observed	in	4/26(15%).16	
(62%)	initiated	early	Thiopurines	(<8	weeks)	at	median	4	weeks	(IQR	3-8	weeks).	
Two	children	were	excluded	from	the	study	after	presenting	with	Stricturing	Ileo-caecal	disease	and	
obstructive	 symptoms	 associated	 with	 proximal	 dilatation	 on	 MR	 Enterography	 and	 went	 to	
surgery.	 Eight	 children	 with	 Stricturing/fistulising	 disease	 without	 obstructive	 symptoms	 were	
offered	EEN	prior	to	consideration	for	surgery	with	the	expectation	to	improve	nutrition	and	reduce	
inflammatory	load.	
	
Table	3.1.	Phenotype	and	Clinical	characteristics	of	study	children(n=26)	at	diagnosis	
Age	Median(IQR)	 13.10	(9.5-15.75)	
Sex	(Male/Female)	 19(73%)/7(27%)	
Duration	of	symptoms	before	diagnosis	 Median	4	months	(IQR	3-11)	
Distribution	
							Age	
										A1a	(0	-	<10)	
										A1b	(10-17)	
							Disease	
										Ileo-colonic	L3	
										Ileal	L1		
										Colonic	L2	
	
	
2(8%)	
24(92%)	
	
21(81%)	
4(15%)		
1(4%)	
Disease	Modifier	
				Upper	GI	(L4a+L4b)	
									L4a	(Proximal	to	Treitz)	
									L4b	(distal	to	Treitz)	
									L4a+L4b	(both)	
				Perianal	
Upper	GI		
14(53%)	
10(38%)	
1(4%)	
3(11%)	
4(15%)	
Disease	Behaviour	
								Inflammatory	(B1)	
								Stricturing	(B2)	
								Fistulising/Stricturing(B2+B3)	
	
18(70%)	
7(27%)	
1(3%)	
Growth	failure	
									Growth	failure	present	(G1)																																					
									No	Growth	failure	(G0)	
	
4(15.4%)	
22(84.6%)	
Clinical	Disease	Severity,	PCDAI	
								Mild	<30	
								Moderate	to	Severe	>30	
	
3(11.5%)	
23(88.5%)	
Endoscopic	Disease	Severity	 	
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Table	3.2.	Clinical,	Endoscopic	and	MRI	disease	activity	before	and	after	EEN	
Patient	Characteristics	 Before	EEN	 After	EEN	 P	Value	
Mean	Weight	Z	score	(n=26)	 -0.79	 -0.08	 0.03	
Mean	Height	Z	score(n=26)	 -0.19	 -0.005	 NS	
Mean	BMI	Z	Score(n=26)	 -1.40	 -0.54	 <0.01	
Mean	PCDAI(n=26)	 37.88	 7.01	 <0.001	
Mean	CRP(n=26)	 44.86	 5.5	 <0.001	
Mean	SES-CD(n=26)	 14.28	 3.88	 <0.001	
Mean	MRI	Score	of	small	bowel	(n=14/26)	 4.69	 2.63	 		0.01	
	
	
	
	
								Mild	(SES-CD	4-10)	
								Moderate	(SES-CD	11-19)	
								Severe	(SES-CD>19)	
4(15%)	
16(62%)	
6(23%)	
MRI	SB	Disease	Activity		
								No	Activity	(0-1)																																		
								Mild	(2-6)	
								Moderate	to	Severe	(>7)	
	
2(8%)	
20(77%)	
4(15%)	
Timing	to	Endoscopic	Re-evaluation	
Median	wks	from	start	of	EEN(IQR)												
Median	wks.	from	starting	Immunomodulators(IQR)	
	
8	(7.35-8.8)	
4(1-5.95)	
Follow	up	
Median	mo	from	diagnosis	(IQR)	
	
20.54	months	(14.16-24.53	IQR)	
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Figure	3.1:	Paired	Simple	Endoscopic	Score	 (SES-CD)	of	each	patient	before	and	after	 course	of	
EEN		
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Figure	3.2	Typical	Endoscopic	images	of	a	study	child	demonstrating	complete	MH	after	EEN.	
	 Ulcerated	Terminal	Ileum	 	 	 	 Normal	Ileum	
																										 	
Aphthous	Ulcers	Colon					 	 	 	 Healthy	Colon																																									
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Primary	End	Points	at	8	Weeks		
A	significant	overall	improvement	in	pre-treatment	disease	activity	was	observed	in	PCDAI,	Weight,	
BMI,	CRP,	SES-CD	and	Small	bowel	MRI	Disease	activity	scores	(Table	3.2).	After	completion	of	EEN	
22/26	 (84%)	 were	 in	 clinical	 remission;	 20/26	 (76%)	 in	 both	 biochemical	 and	 clinical	 remission;	
11/26	(42%)	children	had	complete	mucosal	healing	(SES=0);	4/26	(16%)	near	complete	healing	(SES	
1-3)	 to	 give	 an	 early	 good	 endoscopic	 response	 rate	 of	 58%;	 8/26	 (30%)	 improved	 but	 had	
incomplete	 healing	 SES>3;	 3/26	 (11%)	 had	 no	 response.	 (Figure	 3.1).	 On	 further	 sub-analysis,	 a	
higher	rate	of	good	endoscopic	response	was	seen	in	colonic	versus	Ileal	disease	segments,	but	it	
did	not	reach	significance	(61.5%	Vs	53.84%,	p>.05).		
Transmural	remission	
MRE	was	performed	both	at	diagnosis	and	at	 follow	up	 in	16/26(61%).	Median	time	to	follow	up	
MRE	after	termination	of	EEN	therapy	was	2	days,	with	a	wide	IQR	(1-28	days).	 	2/16	with	paired	
MRE	had	inactive	SB	disease	at	diagnosis.	Of	14/16	with	SB	disease	activity	at	diagnosis	and	a	follow	
up	MRE,	complete	transmural	remission	of	small	bowel	CD	activity	(score	0-1)	was	apparent	in	3/14	
(21%),	 improvement	 in	 transmural	activity	was	seen	 in	9/14	 (64%)	and	 there	was	no	 response	 in	
2/14(15%).		
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(Figure	3.3).	Transmural	SB	disease	activity	before	and	after	EEN	(n=16)	
	
	
Baseline	disease	severity,	phenotype	and	thiopurine	(TP)	use	 in	those	with	Good	(SES-CD<3)	Vs	
Poor	(SES-CD>3)	early	endoscopic	response		
PCDAI,	 BMI,	 CRP,	 SES-CD,	 early	 introduction	 of	 TP(<8weeks)	 and	 disease	 phenotype	 were	 not	
statistically	different	in	those	with	good	vs.	poor	early	endoscopic	response.	However,	there	was	a	
trend	towards	better	baseline	BMI	(-0.95	vs	-2.13,	p=0.06)	and	shorter	time	to	diagnosis	from	the	
onset	of	first	symptoms	(5.33	vs.10.52	weeks=0.07)	in	those	with	good	early	endoscopic	response.		
	
Baseline	disease	severity	and	phenotype	between	group	commencing	early	(<	8	weeks)	vs.	later	
TP		
PCDAI,	BMI,	CRP,	SES-CD	and	disease	phenotype	were	not	statistically	different	in	those	with	early	
(n=16)	 vs.	 subsequent	 use	of	 TP	 (n=10).	 Early	 good	 endoscopic	 response	 (SES,0-3)	was	 similar	 in	
group	with	early	use	of	TP	(9/16,56%)	vs.	 later	use	of	TP	(6/10,60%)	and	outcomes	at	12	months	
Mod-Severe
1
Mod- Severe
3
Mild	Activity	10
Mild	Activity	11
No	Activity	5
No	Activity	
2
MRE	Disease	Activity	before	EEN
Transmural	disease	remission	post	EEN
Mod-Severe	Activity	(>6) Mild	Activity	(2-6) No	Activity	(0-1
MRE	Disease Activity	after	EEN
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were	also	comparable.	(Table	3.2,3.3).	Three	children	discontinued	TP	 in	view	of	 intolerance/side	
effects	during	the	first	year	and	were	switched	to	Methotrexate.	
	
Table	3.3	
Baseline	variables	at	diagnosis	between	EEN	group	commencing	early	TP	(<	8	weeks)	vs.		TP	at	a	
later	stage	(>8	weeks).	
	 Early	TP	(n=16)	 Later	TP(n=10)	 Significance	
Mean	PCDAI	 39.06	 36	 0.20	
Mean	BMI	 -1.5	 -1.37	 0.8	
Mean	CRP	(mg/L)	 56.19	 26.10	 0.1	
Mean	SES-CD	 15.6	 12.3	 0.1	
Pan-enteric	disease	(Ileocolonic+UGI)	 11/16(68%)	 10/10(100%)	 0.12	
Complicating	disease	 4/16(25%)	 4/10(40%)	 0.6	
Concurrent	Partial	Enteral	Nutrition	 2/16	(12.5%)	 1/10(10%)	 1	
	
Table	3.4	
Outcomes	at	1	year	in	those	commencing	early	vs.	late	thiopurines	
Outcomes	at	1	year,	n=24	 Early	TP	(n=15)	 Subsequent	TP(n=9)	 P	value	
Endoscopic	Relapse	(n=17)	 10	 7	 0.6	
Hospitalisation	at	follow	up	(n=14)	 8	 6	 0.6	
Anti-TNF	use	(n=13)	 8	 5	 1	
Resection	(n=7)	 4	 3	 1	
	
	
107 
 
Secondary	End	Points	at	1	year	(n=24)	
Subsequent	 clinical	 outcomes,	 specifically	 endoscopic	 confirmed	 clinical	 relapse,	 hospitalisation	
directly	related	to	CD,	need	to	commence	anti-TNF	agent	and	surgical	resection	were	analysed	at	1	
year	 (n=24/26).	 Early	 good	endoscopic	 response	 led	 to	decreased;	 endoscopic	 confirmed	 relapse	
(8/15,53%	vs.	9/9,100%,	p=0.02),	hospitalisation	(6/15,40%	vs.	8/9,	88%,	p=0.03),	need	for	anti	TNF	
for	 luminal	disease	 (5/15,33%	vs.	8/9,88%,	p=0.01)	and	surgical	 resection	 (3/15,20%	vs.	4/9,44%,	
NS)	at	1	year.				
	
Outcomes	of	complicated	vs.	inflammatory	phenotype	at	diagnosis.	
Complicating	 (Stricturing	 and/or	 fistulising)	 vs.	 Inflammatory	 phenotype	 at	 diagnosis	 was	 more	
frequently	associated	with	moderate	to	severely	poor	BMI	Z	score	<	 -2.0	 in	5/8	vs.	3/16	(p<0.01)	
and	longer	duration	of	symptoms	before	diagnosis	(mean	12.15	vs.	5.47	months	p<0.02).	7/8	of	our	
cohort	 with	 non-obstructive	 stricturing	 at	 presentation	 required	 surgical	 resection	 despite	
improvement	in	mucosal	disease	severity	(Mean	SES	14.38	at	diagnosis	to	Mean	SES	5.50	post	EEN,	
p<0.05)	 and	 BMI	 recovery	 (Mean	 Z	 score	 -1.72	 at	 diagnosis	 to	 -0.76,	 p>0.05).	 Good	 endoscopic	
response	was	only	observed	in	3/8	complicating	disease	(SES-CD=3),	confirming	the	impression	EEN	
works	best	 for	patients	with	 inflammatory	phenotype.	Even	 in	Stricturing	patients,	EEN	corrected	
poor	nutrition	and	improved	clinical	status	in	preparation	for	successful	surgery.		
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Outcomes	of	CD	cohort	diagnosed	during	the	study	period		
42	children	were	diagnosed	with	CD	during	the	study	period,	of	which	26	completed	a	minimum	of	
six-week	 course	 of	 EEN	 and	 12	 completed	 weaning	 course	 of	 CS	 over	 8-10	 week’s	 (Figure	 3.4).	
Relapse	during	first	year	requiring	anti-TNF’s	was	similar	between	EEN	(13/26,50%)	and	CS	group	
(7/12,58%).	 9/38	 (24%)	 required	 intestinal	 resection	 (IR)	 within	 the	 first	 year.	 IR	 rates	 were	
(7/26,27%)	in	the	EEN	vs.	CS	group	(2/12,	17%,	p=0.6)	during	the	first	year.		
	
Figure	3.4	Main	outcomes	of	cohort	diagnosed	during	the	study	period		
	
	
	
	
	
	
CD	diagnosis	during	study	period,	N=42	
First		therapy	
• EEN=30
• CS =8
• Surgical resection=2
• Infliximab for complex perianal CD=2
CS (n=4)
• Auto-immune hepatitis (n=1)
• Erythema Nodosom (n=1)
• Did not tolerate EEN (n=2)
EEN (26 finished 6 weeks course
Outcomes
Outcome of EEN group at 1 year (n=26)
Therapies at 1 year
• TP monotherapy =13
• Anti-TNF’s
• Anti-TNF’s + TP=7
• Anti-TNF’s+ Methotrexate= 3
• Anti-TNF’s=3
Intestinal resection =7/26 (27%)
Outcome of CS group at 1 year (n=12)
Therapies at 1 year
• TP monotherapy = 5
• Anti-TNF’s
• Anti-TNF’s +TP=4
• Anti-TNF’s+ Methotrexate= 2
• Anti-TNF’s=1
Intestinal resection =2 (16%)
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Discussion	
This	 study	 is	 the	 first	 to	 comprehensively	 and	 prospectively	 address	 the	 early	 impact	 of	 EEN	 on	
clinical,	biochemical,	endoscopic	and	MRE	parameters	in	children	with	moderate	to	severe	CD.		EEN	
gives	excellent	early	clinical	response,	weight	recovery,	biochemical	remission	and	mucosal	healing.	
This	 study	 is	 also	 the	 first	 to	 evaluate	 the	 impact	 of	 EEN	 induced	 early	 mucosal	 healing	 on	
subsequent	medium	term	outcomes	in	children	receiving	maintenance	therapy	with	thiopurines.	
EEN	 is	 highly	 effective	 for	 the	 induction	 of	 disease	 remission	 exceeding	most	 currently	 reported	
treatment	endpoints,	providing	complete	mucosal	healing	in	over	40%	of	children	and	transmural	
remission	of	 small	 bowel	 CD	 in	 (3/14,	 21%).	 Previous	 trials	with	 EEN	used	 variable	definitions	of	
mucosal	healing	but	we	chose	a	more	rigorous,	simpler	endpoint,	that	of	complete	mucosal	healing	
(complete	disappearance	of	Ileocolonic	ulceration)	to	provide	compelling	evidence	of	efficacy.	We	
also	 demonstrated	 improved	 transmural	 disease	 activity	 in	 those	 with	 Ileal	 or	 Ileocolonic	 CD	
utilising	MR	Enterography	in	a	subset	of	children.		
Our	early	mucosal	healing	rates	are	comparable	to	other	trials	of	EEN.	 	A	single	Paediatric	RCT	 in	
newly	 diagnosed	 children	 with	 CD	 comparing	 EEN	 vs.	 steroids	 demonstrated	 EEN	 to	 give	
endoscopic	 remission	 (using	 CD-EIS)	 of	 74%	 at	 10	 weeks,	 comparable	 to	 our	 more	 rigorous	
definition	of	good	endoscopic	response	(SES-CD<3)	of	58%(10).	In	treatment	naïve	adults	with	CD,	
EEN	 gave	 complete	 endoscopic	 remission	 rate	 of	 44%	 at	 terminal	 ileum	 and	 39%	 in	 colon	 at	 4	
weeks	(12).		In	contrast,	our	study	showed	higher	but	non-significant	good	endoscopic	response	in	
colonic	vs.	 Ileal	disease	segments	 (61.5%	vs.53.8%,	p>0.05).	 	Both	studies	were	underpowered	to	
discriminate	 a	 difference	 but	 consistent	 with	 a	 recent	 study	 and	 systematic	 analysis	 which	
concluded	disease	phenotype	does	not	influence	EEN	induced	clinical	remission	rates	(65,75).		
These	well	 characterized	 outcomes	 specifically	 early	mucosal	 healing	 compare	 favorably	with	 all	
currently	 available	 induction	 therapies,	 including	 anti-TNF	 agents	 and	 particularly	 superior	 to	
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steroids.	Steroids	have	poor	ability	to	induce	mucosal	healing	with	active	endoscopic	disease	in	71%	
despite	clinical	remission,	with	only	12%	achieving	complete	mucosal	healing	(10).	An	Endoscopic	
sub	 study	 of	 ACCENT	 1	 using	 scheduled	 Infliximab	 therapy	 in	 a	 comparable	 adult	 cohort	 of	
treatment	naïve	CD	patients	reported	29%	complete	mucosal	healing	at	10	weeks	(163).	Our	study	
demonstrated	better	endoscopic	response	with	more	complete	mucosal	healing	and	greater	drop	
in	mean	SES-CD	(14.28	to	3.8,	p<0.001).		
We	did	not	identify	any	obvious	benefit	of	early	vs.	later	TP	use	with	EEN	induction	therapy.	Early	
endoscopic	 recovery	 and	 1	 year	 outcomes	 including	 endoscopic	 relapse,	 anti-TNF	 use,	
hospitalisation	and	intestinal	resection	were	comparable	between	early	vs.	 late	TP	use.	Our	study	
was	although	not	appropriately	powered	or	designed	to	address	short	and	medium	term	benefits	
of	early	vs.	 later	 IM	use.	Most	 children	commenced	TP	after	4	weeks	of	EEN	 to	optimise	patient	
vaccination	 status	 and	 the	 delayed	 peak	 efficacy	meant	 use	 or	 otherwise	 was	 unlikely	 to	 affect	
clinical,	 biochemical	 and	 endoscopic	 outcomes	 less	 than	 4	 weeks	 later.	 There	 are	 no	 published	
studies	looking	at	mucosal	healing	before	16	weeks	of	immunomodulator	treatment	(144-148).	
Our	 small	 EEN	 study	 cohort	 presented	with	 a	 high	 proportion	 of	 complicated	 phenotypes	 (8/26,	
31%)	 and	 this	 is	 reflected	with	 the	 high	 rate	 of	 adverse	 longer	 term	outcomes	 despite	 excellent	
early	 clinical	 response.	At	1	year,	17/24,	 (71%)	had	 relapsed;	13/24,	 (54%)	commenced	anti-TNF;	
14/24	(58%)	had	been	hospitalised	and	7/24	(29%)	had	surgical	resection.		A	non-significant	higher	
frequency	of	 complicated	disease	phenotype	at	diagnosis	was	observed	 in	 those	 included	 in	EEN	
study	 (8/26	 ,31%)	compared	to	32/183	 (17.5%,	P=0.11)	 in	our	Brisbane	 IBD	historical	cohort	 (not	
published).	This	could	be	partially	explained	by	availability	of	MR-Enterography	from	2009,	enabling	
improved	detection	of	complicating	phenotype	in	cohort	diagnosed	after	2009.		
	A	 recent	 French	 paediatric	 Cohort	 study	 reported	 complicating	 disease	 rates	 of	 28%	 at	
presentation	with	 a	 cumulative	 probability	 of	 surgical	 resection	 31%	 at	 10	 years	 and	 54%	 at	 20	
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years	from	diagnosis,	respectively	(41).	7/8	of	our	cohort	with	non-obstructive	structuring	disease	
at	presentation	required	later	surgical	resection,	despite	improvement	in	mucosal	disease	severity	
in	50%,	confirming	EEN	works	best	 for	patients	with	 inflammatory	phenotype.	Even	 in	Stricturing	
patients,	 EEN	 corrected	 poor	 nutrition	 and	 improved	 clinical	 status	 in	 preparation	 for	 successful	
surgery.		
We	 confirmed	 superior	 outcomes	 at	 1	 year	 in	 those	 with	 early	 good	 endoscopic	 response	 with	
reduced;	endoscopic	confirmed	clinical	relapses	(8/15,	53%	vs.	9/9,	100%,	p=0.02),	hospitalisation	
(6/15,40%	vs.	8/9,88%,	p=0.03);	and	need	for	anti-TNF	for	luminal	disease	(5/15,33%	vs.	8/9,88%,	
p=0.01).	 	 Our	 finding	 that	 early	 mucosal	 healing	 from	 EEN	 may	 be	 more	 important	 than	 early	
introduction	of	TP	for	improving	subsequent	clinical	outcomes	has	support.	In	a	placebo	controlled	
RCT	 with	 adalimumab	 in	 adults	 with	 moderate	 to	 severe	 CD	 the	 importance	 of	 early	 mucosal	
healing	was	demonstrated	with	a	positive	of	predictive	effect	of	early	(12	week)	mucosal	healing	on	
CDAI	at	52	weeks	(164).	 	Earlier	azathioprine	therapy	vs	 later,	“on	demand”	azathioprine	was	not	
associated	with	 better	 outcomes	 in	 adults	with	 disabling	 CD.	 	 Specifically;	 clinical	 remission	 rate	
(61%	vs	50%),	anti-TNF	use	(29%`	vs	26%)	and	surgery	(11%	vs	21%,	p=0.11)	(98).		
Our	cohort	of	newly	diagnosed	children	with	CD	has	high	frequency	of	anti-TNF	agent	use	(15/26,	
58%)	however,	this	reflects	the	changing	practice	of	paediatric	Crohn’s	with	new	treatment	targets	
including	deep	remission,	aiming	for	optimal	future	outcomes.	Nevertheless,	those	with	early	good	
mucosal	response	have	reduced	anti-TNF	use	at	1	year.	Our	study	also	highlights	poor	outcomes	in	
those	not	achieving	early	mucosal	healing	providing	a	strong	case	for	earlier	consideration	of	anti-
TNF	therapy.	
One	year	outcomes	including	relapse,	need	for	anti-TNF’s	and	intestinal	resection	rates	were	similar	
regardless	 of	 initial	 choice	 of	 EEN	 vs.	 CS,	 although	 our	 study	 was	 not	 powered	 to	 address	 this	
question.	 Numerically	 a	 greater	 IR	 rates	 was	 observed	 in	 group	 treated	 with	 EEN	 (7/26,	 27%	
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compared	to	CS	(2/12,	17%)	but	this	could	be	related	to	selection	bias	as	physicians	favoured	EEN	
over	 CS	 in	 children	 presenting	 with	 complicating	 disease	 phenotype	 at	 diagnosis.	 A	 rapid	
therapeutic	escalation	to	anti-TNF’s	was	noted	in	the	entire	cohort	with	over	half	of	them	(20/38,	
53%)	on	anti-TNF	within	 the	 first	 year	 (13/24,	 EEN	vs.	 7/12,	CS	group).	 This	 reflects	 again	newer	
treatment	paradigms	aiming	for	CS	free	endoscopic	remission.	
As	outlined	above,	there	are	number	of	 limitations	of	our	study	 including	size,	open	 label	design,	
and	 lack	of	 centralised	endoscopy	 reading	 and	unavailability	of	 paired	endoscopic	 assessment	of	
those	treated	with	CS.		
In	conclusion,	CD	in	children	is	recognised	as	a	more	aggressive	phenotype	than	in	adults	and	needs	
improved	 treatment	 endpoints.	 	 We	 demonstrate	 EEN	 to	 be	 highly	 effective	 for	 inducing	 early	
endoscopic	and	transmural	healing	in	treatment	naive	children	with	moderate	to	severe	CD.		Early	
mucosal	healing	with	EEN	and	thiopurines	does	not	prevent	most	children	with	Stricturing	disease	
coming	 to	 surgery,	 but	 reduces	 rates	 of	 endoscopic	 confirmed	 relapse,	 hospitalisation	 and	
introduction	of	anti-TNF	agents	at	1	year.		
	
	
Acknowledgments:	ANZ	Trustees,	Queensland	Medical	Research	institute	Brisbane.	
Conflict	of	interest:	The	authors	declare	that	they	have	no	conflict	of	interest.	
	
	
	
	
	
	
113 
 
Chapter	4	
	
	
Predicting	Endoscopic	Crohn's	Disease	Activity	Before	and	After	Induction	Therapy	in	Children:	A	
Comprehensive	Assessment	of	PCDAI,	 CRP,	and	Fecal	Calprotectin,	 	 Zubin	G1,	Peter	 L;	 	 Inflamm	
Bowel	Dis.	2015	Jun;21(6):1386-91	
	
	
	
The	purpose	of	this	chapter	is	to:	
1. Assess	correlation	of	non-invasive	proxies	including	Paediatric	Crohns	disease	activity	index	
(PCDAI),	 serum	CRP	(CRP)	and	Faecal	Calprotectin	 (FC)	with	a	validated	simple	endoscopic	
score	for	Crohns	disease	(SES-CD)	at	diagnosis.	
2. Review	 individual	 and	 combined	 performance	 of	 PCDAI,	 CRP	 and	 FC	 in	 predicting	
endoscopic	disease	activity	scores	after	induction	therapy	with	EEN	or	steroids.		
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Abstract	
Background:	 	 	Mucosal	Healing	 (MH)	 is	 a	 vital	 early	endpoint	 in	management	of	Crohn’s	disease	
(CD).	 MH	 depends	 on	 endoscopic	 assessment	 and	 there	 is	 increasing	 interest	 in	 non-invasive	
proxies,	 PCDAI,	 CRP	 and	 Faecal	 Calprotectin	 (FC).	 	 These	 proxies	 must	 be	 validated	 against	
endoscopic	disease	activity	(SES-CD)	at	diagnosis	and	after	induction	therapy	in	well	characterised	
cohorts	of	children	with	CD.	
Methods	and	Aims:	A	prospective	cohort	of	24	newly	diagnosed	children	(<16	years)	with	luminal	
CD	quantifiable	on	complete	 ileo-colonoscopy	had	paired	PCDAI,	CRP,	FC	and	SES-CD	at	diagnosis	
and	 after	 eight	weeks	 therapy	with	 EEN	 or	 steroids.	 The	 purpose	 of	 our	 study	was	 to	 correlate	
disease	 proxies	 (PCDAI,	 CRP,	 FC)	 with	 simple	 endoscopic	 score	 (SES-CD)	 at	 diagnosis	 and	 assess	
their	performance	in	predicting	endoscopic	disease	scores	after	primary	induction	therapy	with	EEN	
or	steroids.		
Results:	 At	 diagnosis:	 PCDAI	 had	 poor	 correlation	 (r=0.33);	 CRP	 (r=0.54)	 and	 FC	 (r=0.46)	 had	
moderate	correlation	with	SES-CD.		After	induction	therapy:	11/24	had	inactive	disease	(SES-CD	0-
2);	PCDAI	(r=0.34)	and	CRP	(0.28)	had	poor	correlation	with	SES-CD,	many	children	with	SES-CD≥3	
having	normalisation	of	both	PCDAI	and	CRP.		FC	had	good	correlation	(r=0.50)	but	many	with	SES-
CD	0-2	had	FC	>200	µgram/gm	stool.		FC<500	(Positive	likelihood	ratio,	PLR	3.2)	and	FC	drop	>50%	
(PLR	3.8)	had	greater	predictive	value	for	inactive	disease.		Composite	PCDAI	(<10),	CRP	(<5mg/dl)	
&	FC	<500	µgram	had	excellent	Negative	LR	(0.2)	predicting	inactive	disease.		
Conclusion:	 PCDAI	 is	 unreliable	 for	 endoscopic	 disease	 severity	 assessment.	 	 Only	 FC	 correlates	
with	endoscopic	activity	after	therapy	but	cut	off	<200	µgram	is	 too	high	for	defining	endoscopic	
recovery	in	children.		Composite	normalised	PCDAI,	CRP	and	FC	<500	µgram	should	be	considered	
the	non-invasive	endpoint	for	treatment	response	in	Paediatric	CD.	
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INTRODUCTION	
Deep	 remission	with	mucosal	healing	 (MH)	early	 in	 the	 course	of	 treatment	 is	 recognised	as	 the	
best	predictor	of	favourable	long	term	outcomes	in	adults	with	CD,	(1,6-8)	but	paediatric	evidence	
is	scarce.	 	Two	small	paediatric	studies	demonstrated	improved	relapse	rates	and	hospitalisations	
at	1	year	in	those	achieving	good	endoscopic	outcomes	after	induction	therapy	(93,	175).	The	gold	
standard	for	assessing	mucosal	 inflammation	is	endoscopy,	but	this	 is	 invasive	and	impractical	for	
regular	monitoring	which	requires	studies	to	use	surrogate	markers,	proxies	like	CDAI,	PCDAI,	CRP	
and	 Faecal	 Calprotectin	 (FC),	 to	 assess	 therapeutic	 response.	 This	 is	 of	 particular	 concern	 when	
non-invasive	 proxies	 like	 CDAI	 and	 PCDAI	 are	 used	 to	 determine	 treatment	 escalation	 and	 as	
endpoints	for	research	outcomes.			
Poor	concordance	between	clinical	disease	activity	index	(CDAI)	and	endoscopic	disease	activity	is	
well	 established	 in	 adults	with	 active	 CD	with	 up	 to	 70%	 of	 patients	 in	 clinical	 remission	 having	
significant	 mucosal	 lesions.	 (10,138)	 The	 Paediatric	 Crohn’s	 Disease	 activity	 Index	 (PCDAI)	 is	 a	
clinical	 tool	 like	 CDAI,	 that	 includes	 subjective	 variables	 and,	 unlike	 CDAI,	 PCDAI	 has	 not	 been	
validated	against	established	endoscopic	disease	activity	scores.	
Serum	CRP	and	Faecal	Calprotectin	 (FC)	 are	 in	widespread	use	as	proxies	 for	endoscopic	disease	
activity.		In	a	prospective	adult	endoscopic	study,	CRP	(r=0.53)	and	FC	(r=0.75)	had	good	correlation	
with	 simple	 endoscopic	 disease	 activity	 scores	 (SES-CD)	 (142).	 In	 a	 small	 paediatric	 study,	 good	
correlation	 of	 FC	 to	 SES-CD(r=0.76)	 was	 demonstrated	 in	 11	 children	 with	 CD	 and	 quantifiable	
Ileocolonic	lesions	on	endoscopy	(185).	A	larger	multicentre	prospective	study	in	children	with	CD	
demonstrated	CRP	and	FC	had	good	correlation	with	each	other	but	neither	had	good	correlation	
with	PCDAI.		Endoscopic	severity	was	not	assessed	in	this	study	(186)	Studies	using	FC	in	children	to	
measure	clinical	remission	demonstrate	many	children	do	not	normalise	FC	to	<200	μgm/gm	stool.		
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A	 paediatric	 Finnish	 study	 treating	 children	 with	 IBD	 to	 clinical	 remission	 with	 steroids	 and	 a	
Scottish	 study	 treating	 children	 with	 CD	 to	 clinical	 remission	 with	 EEN	 showed	 the	 majority	 of	
children	in	clinical	remission	had	elevated	FC.	(105,107)	
Paediatric	 studies	 evaluating	 performance	 of	 PCDAI,	 CRP	 and	 FC	 against	 a	 validated	 endoscopic	
disease	activity	tool	to	measure	therapeutic	response	are	warranted.		The	purpose	of	our	study	was	
to	 correlate	 these	 proxies	 with	 simple	 endoscopic	 score	 (SES-CD)	 at	 diagnosis	 and	 assess	 their	
performance	 in	predicting	endoscopic	disease	scores	after	primary	 induction	therapy	with	EEN	or	
steroids.		
	
METHODS	
Population	and	study	design	
This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	Clinical	 Trails	 Registry-	ACTRN12612001032842)	 of	 42	newly	diagnosed	 children	with	CD	
(<16	years)	offered	EEN	or	steroids	as	induction	therapy	and	commenced	on	early	thiopurines	(<3	
months)	 conducted	between	November	2009	 to	December	2013	 in	a	 tertiary	paediatric	hospital.	
(174)	 Institutional	 Ethics	 approval	 was	 granted	 and	written	 consent	 obtained	 from	 patients	 and	
parents.	 Convenience	 sample	 of	 24	 children	who	 had	 luminal	 CD	 quantifiable	 on	 complete	 Ileo-
colonoscopy	and	paired	PCDAI,	CRP,	FC	and	Endoscopy	at	diagnosis	and	after	8	weeks	of	induction	
therapy	was	 analysed.	 Eighteen	 children	were	 excluded	 (11	 =	 incomplete	 (n=1)	 or	 no	 follow	 up	
endoscopy	(n=10),	6	without	paired	FC,	1	with	isolated	proximal	small	intestinal	CD).		
Clinical	remission	was	defined	PCDAI≤10;	Biochemical	remission,	CRP<5mg/dl.	PCDAI	>30	moderate	
to	severe	Paediatric	CD.	(157)	FC	was	measured	by	a	quantitative	enzyme	immunoassay.	FC	<	200	
μg/gm	is	the	accepted	adult	cut	off	 for	defining	endoscopically	 inactive	disease	(186).	Endoscopic	
disease	activity	was	determined	by	the	endoscopist	at	time	of	procedure	using	the	validated	Simple	
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Endoscopic	Score	for	Crohn’s	Disease	(SES-CD)	(141).	Disease	activity	was	defined	as:	inactive	(0-2);	
mild	(3-6);	moderate	(7-15)	or	severe	(>15)	(188).	We	comprehensively	evaluated	the	performance	
of	paired	PCDAI,	CRP,	FC	and	SES-CD	for	assessing	endoscopic	disease	activity	at	diagnosis	and	post	
treatment	to	measure	therapeutic	response.	
STATISTICS	
All	statistical	calculations	were	performed	using	Graph	Pad	Prism	version	6.00	for	Windows,	Graph	
Pad	Software,	San	Diego	California	USA.	The	correlation	between	endoscopic	disease	activity	(SES-
CD)	 with	 clinical,	 serologic	 and	 faecal	 biomarkers	 was	 estimated	 using	 the	 non-parametric	
Spearman	rank	correlation	coefficient.		Paired	t	test	was	used	for	analysis	of	proxies	before	&	after	
induction	 therapies.	 Unpaired	 t	 test	 was	 utilised	 for	 calculating	 clinical,	 biochemical	 and	 FC	
between	 Ileal	and	 Ileocolonic	disease	phenotype.	Sensitivity,	Specificity	and	Likelihood	ratio	were	
compared	between	proxies	to	predict	endoscopic	disease	inactivity.	
	
RESULTS	
Paired	clinical	(PCDAI),	biochemical	(CRP),	faecal	(FC)	and	endoscopic	data	(SES-CD)	were	available	
in	 24	 children	 treated	with	either	 EEN	 (n=20)	or	 steroids	 (n=4)	 at	 diagnosis.	 Baseline	 results	 and	
disease	 phenotype	 are	 given	 in	Table	 4.1.	 Paired	 data	 on	 each	 parameter	 at	 diagnosis	 and	 post	
induction	therapy	are	given	in	Table	4.2.		
At	Diagnosis:	
The	performance	of	PCDAI,	CRP	and	FC	against	SES-CD	is	given	in	Figures	4.1-	4.3	Highlighted	is	the	
lack	of	correlation	(r=0.33,	p=NS)	for	PCDAI	against	SES-CD.	CRP	(r=0.54,	p	=	0.006)	and	FC	(r=0.46,	
p=0.02)	have	moderate	correlation	against	SES-CD.	
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TABLE	4.1.	Demographics	at	Diagnosis		
	
	
	
	
	
	
	
	
	
	
	
Included	 24	(15	Males)	
Excluded	 18	
6	Paired	FC	not	available		
12	Endoscopic	score	not	available	
							1	isolated	proximal	SB	CD	
							1	Incomplete	colonoscopy	
							10	No	follow	up	endoscopy	
Age	(IQR)	 13.5(9.5-15.2)	
Disease	Distribution	
										A1a	(0	-	<10)	
										A1b(10-17)	
										Ileo-colonic	L3	
										Ileal	L1		
										Colonic	L2	
	
1	
23(92%)	
18(75%)	
5(21%)		
1(4%)	
Disease	Modifier	
				Upper	GI		
									L4a	
									L4a+L4b	
				Perianal	
Upper	GI		
58%	
11(45%)	
3(13%)	
3(13%)	
Disease	Behaviour	
								Inflammatory	
								Stricturing	
	
20(83%)	
4(17%)	
Clinical	Disease	Severity	(PCDAI)	
								Mild	<30	
								Moderate	to	Severe	>30	
	
2(8%)	
22(92%)	
Endoscopic	Disease	Severity	
								Mild	(SES-CD	3-6)	
								Moderate	(SES-CD	7-15)	
								Severe	(SES-CD>16)	
	
1=4%	
12=50%	
11=46%	
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Table	4.2.		Paired	PCDAI,	CRP,	FC	and	SES-CD	at	Diagnosis	and	Post	induction	therapy		
	
	
DIAGNOSIS																																																																																AFTER	INDUCTION	THERAPY																																														
Patient	
(therapy)	
PCDAI	 CRP	 FC	 SES-CD	 PCDAI	 CRP	 FC	 SES-CD		
1	(EEN)	 32.5	 17	 1300	 4	 20	 5	 620	 0	
2	(EEN)	 40	 42	 1100	 15	 5	 1	 70	 0	
3	(EEN)	 35	 24	 470	 11	 10	 4	 950	 0	
4	(EEN)	 47.5	 19	 1300	 25	 5	 1	 280	 0	
5	(EEN)	 35	 20	 510	 8	 0	 1	 170	 0	
6	(EEN)	 35	 14	 1100	 15	 5	 2	 480	 0	
7	CS	 42.5	 54	 460	 22	 5	 2.7	 330	 0	
8	(EEN)	 17.5	 71	 1200	 18	 0	 1	 420	 0	
9	(EEN)	 32.5	 23	 1800	 21	 0	 1	 180	 0	
10	(EEN)	 45	 29	 580	 18	 30	 8	 170	 0	
11(EEN)	 32.5	 22	 1300	 13	 0	 2.7	 380	 2	
12.(EEN)	 47.5	 100	 240	 15	 10	 28	 450	 3	
13	CS	 37.5	 34	 240	 12	 5	 7	 1300	 3	
14	(EEN)	 42.5	 11	 550	 9	 5	 1	 1000	 3	
15(EEN)	 32.5	 43	 800	 12	 5	 1	 220	 4	
16(EEN)	 47.5	 13	 410	 12	 5	 1	 220	 4	
17(EEN)	 32.5	 10	 580	 12	 10	 5	 100	 6	
18(EEN)	 32.5	 59	 500	 23	 10	 30	 300	 7	
19	CS	 37.5	 17	 1800	 18	 15	 4.5	 580	 8	
20(EEN)	 37.5	 138	 2200	 32	 15	 4.5	 900	 8	
21(EEN)	 57.5	 19	 600	 18	 5	 6	 930	 9	
22(EEN)	 60	 78	 1400	 30	 30	 5	 1400	 12	
23(EEN)	 55	 72	 1900	 17	 10	 1	 1500	 13	
24	CS	 22.5	 15	 130	 11	 5	 3.4	 1240	 15	
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Table	4.3:	PCDAI,	CRP,	FC	SES-CD	values	at	diagnosis	&	after	Induction:	Inactive	vs.	Active	disease	
Mean	
(95%	CI)	
	
Inactive	Endoscopic	Disease	(SES	0-2)	
Diagnosis	 	 	 	 	 	 	 	 	 Post	 Induction	 	 	 	 	 P	
value	
Active	Endoscopic	Disease	(SES-CD	≥3)																
Diagnosis	 	 	 	 	 	 	 Post	 Induction	 	 	 	 	 	 	 	 	 P	
Value	
Mean	PCDAI	
95%	CI	
35.9	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 7.27																												
(0.0001)	
(30.4-41.3)								(0.84-13.7)																	
42	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 10																													
(0.0001)																																																																			
(35-48.5)										(5.7-14.2)	
Mean	CRP	
95%	CI	
30.45	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 2.67																													
(0.0005)	
(18.4-42.5)									(1.1-4.1)	
47	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 7.5																													
(0.002)	
(22.4-71.2)						(1.6-13.4)	
Mean	FC	
95%	CI	
1010	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 368																														
(0.003)	
(713-1308)								(199-536)	
873 	 	 	 	 	 	 	 	 	 	 	 	 780																																
(0.2)	
(448-1297)							(481-1079)	
Mean	SES-CD		
95%	CI	
15.45	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 0.18																															
(0.0001)	
(11.2-19.6)							(	-0.22-0.5)	
17	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 7.3																														
(0.003)		
(12.6-21.4)								(4.8-9.7)	
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Table	4.4.	Mean	FC	level	based	on	disease	location	after	induction	therapy	
Mean	(SD)	 Ileal		 Ileo-Colonic	 P	Value	
FC	active	Disease	(n=13)	 365(286)	 1018(390)	 0.006	
FC	Inactive	disease(n=11)	
455(288)	 158(81)	 0.05	
	
	
	
Table	4.5.	Positive	&	Negative	Likelihood	Ratio	of	proxies	against	endoscopic	scores	(SES-CD)	
	 Sensitivity	 Specificity	 Positive	LR	 Negative	LR	
Clinical	remission	=CR	(PCDAI≤10)	 47%	 60%	 1.1	 0.8	
Biochemical	remission=BR	(PCDAI≤10,CRP<5)	 64%	 80%	 3.2	 0.4	
Faecal	Calprotectin(FC)	<200		µgm/gm		 80%	 63%	 2.3	 0.3	
FC	<500	µgm/gm	 64%	 80%	 3.2	 0.4	
FC	>50%	drop	from	diagnosis	 69%	 82%	 3.8	 0.38	
BR	&	FC	,	FC	<500	µgm/gm	 82%	 85%	 5.3	 0.2	
	
Table	 4.6	 Pre	&	 Post	 EEN	 induction	 biomarker	 response	 to	 predict	 endoscopic	 remission	 (SES-
CD<3)		
	 Sensitivity	 Specificity	 Positive	LR	 Negative	LR	
FC	<500	µgm/gm	 61%	 71%	 2.1	 0.5	
FC	>50%	drop	from	diagnosis	 73%	 78%	 3.2	 0.35	
BR	&	FC	,	FC	<500	µgm/gm	 78%	 73%	 2.85	 0.3	
	
Table	4.7	Pre	and	Post	EEN	drop	in	Mean	FC	levels	in	group	with	or	without	endoscopic	remission	
	 Mean	FC	(SD)			
at	diagnosis	
Mean	FC(SD)	post	
Induction	therapy	
Mean	FC	drop,	P	Value	
EEN	group	with	MH	(SES-CD<3)	
n=10	
1066(424)	 372(264)	 694,	p=0.003	
EEN	group	without	MH		
n=10	
918(674)	 702(511)	 216,p=0.21	
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Figure	4.1-4.3,	Correlation	of	PCDAI,	CRP	and	FC	with	SES-CD	at	Diagnosis	
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Figure	4.4-4.6,	Correlation	of	PCDAI,	CRP	and	FC	with	SES-CD	post	induction	
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Figure	4.7.	Distribution	of	FC	after	induction	based	on	endoscopy	scores	
	
	
	
Post	Induction	Therapy:	
Overall	 therapeutic	response	after	therapy	 include:	clinical	remission	(PCDAI	<10)	 in	19/24	(79%),	
biochemical/clinical	 remission	 (PCDAI≤10	 and	 CRP	 <5mg/dL)	 in	 16/24	 (65%)	 and	 endoscopic	
remission	(inactive	disease	SES-CD	0-2)	in	11/24(46%).			
The	performances	of	PCDAI,	CRP	and	FC	against	SES-CD	are	given	in	Figures	4.4-4.6.		Highlighted	is	
the	 poor	 correlation	 of	 PCDAI	 (r=0.34,	 p=NS)	 and	 CRP	 (r=0.28,	 p=NS)	 with	 SES-CD.	 	 Of	 the	 13	
children	with	active	endoscopic	disease	post	induction,	10	(77%)	were	in	clinical	remission	(PCDAI	
≤10),	 5	 (38%)	 were	 in	 clinical	 and	 biochemical	 remission.	 FC	 (r=0.50,	 p=0.01)	 had	 a	 moderate	
correlation	with	SES-CD	and	only	1	child	(8%)	with	active	disease	had	a	normal	FC	(<200	µgram/gm	
of	 stool).	 However,	 7/11	 (63%)	 children	 with	 inactive	 endoscopic	 disease	 post	 induction	 had	
persistent	 FC	 >200	 µgram/gm.	 These	 patients	 with	 persisting	 FC>200	 with	 inactive	 endoscopic	
disease	had	no	evidence	of	proximal	small	bowel	disease	on	MRE	at	diagnosis	and	2/7	had	a	normal	
follow	 up	 MRE	 suggesting	 the	 elevated	 FC	 values	 from	 these	 children	 were	 not	 from	 residual	
undetected,	proximal	CD	
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In	children	with	active	endoscopic	disease	after	induction,	mean	FC	levels	did	not	drop	significantly	
(Table	3).	Greater	FC	values	were	observed	after	treatment	in	those	with	active	Ileocolonic	vs.	Ileal	
disease	 alone	 (Table	 4).	 Distribution	 of	 FC	 after	 treatment	 based	 on	 endoscopy	 outcomes	 are	
illustrated	in	figure	4.7.	
A	drop	in	FC	>	50%	from	diagnosis	to	post	induction	therapy	has	greater	utility	than	FC	<200µg	and	
FC	<500µg	for	inactive	endoscopic	disease	with	specificity	82%	and	PLR	3.8.		Combining	PCDAI	≤10,	
CRP<5mg/L	and	FC	<	500	µgram/gm	provides	much	greater	sensitivity,	 specificity,	PLR	of	5.3	and	
NLR	 0.2	 compared	 to	 other	 proxies	 (Table	 4.5).	 Further	 appraisal	 of	 FC	 in	 predicting	 endoscopic	
remission	post	EEN	induction	revealed	73%	sensitivity	and	78%	specificity	for	>	50%	drop	in	FC.	A	
significant	drop	 in	FC	was	only	apparent	 in	EEN	group	achieving	endoscopic	 remission	 (D	of	694,	
p=0.003)	,Table	4.6,4.7)	
DISCUSSION	
In	this	well	characterised,	prospective	study	of	treatment	naïve	children	with	moderate	to	severe	
Crohn’s	 disease	 we	 demonstrate	 that	 PCDAI	 is	 a	 poor	marker	 of	 endoscopic	 disease	 severity	 at	
diagnosis	and	a	poor	predictor	of	endoscopic	 treatment	 success.	We	confirm	 findings	 from	adult	
studies	 that	 demonstrate	 CRP	 and	 Faecal	 Calprotectin	 (FC)	 to	 be	 the	 current	 best	 non-invasive	
markers	of	endoscopic	disease	 severity	at	presentation.	We	also	demonstrate	FC	 to	be	 the	most	
reliable	 proxy	 for	 predicting	 good	 endoscopic	 outcomes	 after	 induction	 therapies	 and	 to	 inform	
follow	up.	 	We	confirm	 reports	 that	a	post	 induction	cut	off	 FC<200	µgram/gm	 is	 less	 reliable	 in	
children	 as	many	 children	with	 clinical,	 biochemical	 and	 endoscopic	 remission	will	 have	 FC	 >200	
µgram/gm.		We	report	the	novel	findings	that	FC	drop>50%	after	induction	therapy	provides	much	
greater	 reliability	 for	predicting	 inactive	disease	 than	FC<200	µgram/gm	and	 that	a	 composite	of	
PCDAI	≤10,	CRP	<	5mg/dl	 and	FC	<500	µgram/gm	 is	 an	excellent	proxy	 for	 accurately	 identifying	
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inactive	endoscopic	disease	following	EEN	or	Steroid	induction	in	children	with	CD	with	specificity	
of	85%	and	positive	like	hood	ratio	5.3.	
The	post	hoc	analysis	of	SONIC	trial	highlighted	the	inadequacy	of	CDAI	as	a	measure	of	study	entry	
criteria	 and	 therapeutic	 outcome	 with	 almost	 50%	 of	 patients	 treated	 with	 biologics	 in	 clinical	
remission	 had	 active	 endoscopic	 or	 biochemical	 evidence	 of	 residual	 disease	 activity	 (151,189).	
Clinical	 improvement	 is	 important	 for	 quality	 of	 life	 but	 is	 an	 unreliable	 marker	 of	 endoscopic	
disease	severity	and	should	not	be	used	to	assess	endoscopic	severity,	treatment	outcomes	or	the	
performance	 of	 newer	 non-invasive	 proxies.	We	 have	 now	 confirmed	 that	 the	 paediatric	 clinical	
tool,	 PCDAI	 should	 also	 no	 longer	 be	 used	 as	 a	 determinant	 of	 disease	 severity,	 nor	 informing	
treatment	escalation	 strategies	nor	 a	major	 endpoint	 to	determine	 treatment	 success,	 either	 for	
clinical	or	research	purposes.	
CRP	is	superior	to	PCDAI	and	CDAI	as	a	non-invasive	proxy	of	intestinal	inflammation	particularly	at	
diagnosis	 and	 for	 monitoring	 progress.	 Normalisation	 of	 the	 CRP	 is	 a	 common	 and	 important	
therapeutic	outcome.	 	However,	 in	our	 cohort,	 almost	60%	of	 children	with	normalised	CRP	and	
clinical	 remission	 still	 had	 active	 endoscopic	 lesions	 and	 so	 alone,	 a	 fall	 in	 CRP	 at	 8	 weeks	 is	
insufficient	reassurance	of	endoscopic	recovery.	
The	 correlation	 between	 endoscopic	 disease	 activity	 and	 FC	 has	 been	 well	 studied	 in	 adult	
populations	 and	 ranges	 from	 moderate	 to	 good,	 0.35-0.72(180,183,184).	 In	 a	 small	 paediatric	
study,	 good	 correlation	 of	 FC	 to	 SES-CD	 (r=0.76)	 was	 observed,	 however	 only	 11	 children	 had	
quantifiable	Ileocolonic	lesions	on	endoscopy	and	others	with	isolated	Ileal	disease	were	scored	on	
Ultrasound	alone	(190).	Another	multicentre	prospective	study	in	children	with	CD	confirmed	good	
correlation	between	CRP	and	FC	but	neither	correlated	with	PCDAI	and	 the	vital	 correlation	with	
endoscopic	 severity	 was	 not	 assessed	 (191).	 Studies	 using	 FC	 in	 children	 to	 measure	 clinical	
remission,	including	a	study	using	EEN	which	has	a	high	rate	of	endoscopic	remission,	demonstrate	
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many	children	do	not	normalise	FC	to	<200.	 	A	Finnish	study	treating	children	with	 IBD	to	clinical	
remission	with	steroids	and	a	Scottish	study	treating	children	with	CD	to	clinical	remission	with	EEN	
showed	 the	 majority	 of	 children	 in	 clinical	 remission	 had	 elevated	 FC.	 (105,107)	 We	 have	
demonstrated	FC	to	be	the	most	reliable	marker	of	disease	severity	post	induction	therapy	but	that	
adult	cut	off	values	of	FC<200	are	not	appropriate	for	the	paediatric	population.		All	7	patients	with	
persisting	FC>200	with	 inactive	endoscopic	disease	had	clinical	and	biochemical	remission	and	no	
evidence	on	MRE	at	diagnosis	of	proximal	small	bowel	disease.		Two	of	these	7	had	follow	up	MRE	
that	was	also	normal	suggesting	the	elevated	FC	values	from	these	children	were	not	from	residual	
undetected,	proximal	CD.	 	Correlation	of	biomarkers	with	MRE	was	not	discussed	in	this	paper	as	
there	were	insufficient	pairs	for	meaningful	analysis.			
While	FC	 cut	off	<200	 is	not	appropriate	 in	 the	paediatric	population,	an	absolute	 cut	off	of	500	
provides	greater	specificity.		Of	greater	interest	is	the	finding	that	a	dynamic	change	in	FC,	a	drop	
>50%	from	diagnosis	has	an	excellent	reliability	for	predicting	inactive	disease.		The	combination	of	
clinical	 and	 FC	 proxies	 to	 accurately	 predict	 endoscopic	 disease	 inactivity	 has	 been	 previously	
reported	 in	 adult	 studies	with	 combined	CDAI,	 CRP	 and	 Faecal	 biomarkers	 having	 sensitivity	 and	
specificity	of	79%	and	70%	(190).	Another	adult	study	combined	FC	and	HBI	to	give	sensitivity	86%	
and	 specificity	 of	 86%	&	 82%	 for	 inactive	mucosal	 disease	 (187).	Using	 PCDAI,	 CRP	 and	 FC	 <500	
μg/gm	we	confirmed	a	sensitivity	of	82%	and	Specificity	of	85%	with	PLR	5.3	and	NLR	0.2.		
One	of	the	major	drawbacks	of	our	study	is	convenience	sample	selection	and	lack	of	paired	MRE.	It	
is	 unclear	 if	 transmural	 and	 histological	 inflammation	 was	 persistent	 in	 children	 demonstrating	
elevated	 FC	 >	 200	 μg/gm,	 despite	 complete	 mucosal	 recovery.	 Despite	 limitations	 of	 a	 small	
convenience	sample	and	lack	of	centralised	endoscopic	scoring,	our	results	provide	practical	guide	
to	reliably	predict	endoscopic	healing	using	combination	of	clinical	and	objective	markers.	
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Conclusions	
Proxies	of	endoscopic	mucosal	healing	after	induction	therapies	are	increasingly	important	for	the	
management	 of	 patients	 with	 CD	 and	 for	 the	 assessment	 of	 new	 treatments.	 	 In	 a	 well	
characterised	 cohort	of	 children	with	CD	we	have	demonstrated	 that	PCDAI	 is	unreliable	 for	 this	
purpose,	 CRP	 has	moderate	 utility	 and	 FC	 has	 the	 best	 individual	 utility.	 	 FC	 drop	 >50%	 is	more	
appropriate	 for	use	 in	 children	and	a	 composite	of	PCDAI,	CRP,	 FC<500	μg	has	high	positive	and	
good	negative	likelihood	ratios	for	inactive	endoscopic	mucosal	disease	and	is	an	excellent	proxy	of	
mucosal	healing	and	endpoint	for	deep	remission.	
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Chapter	5	
	
	
	
Early	mucosal	healing	with	Exclusive	Enteral	Nutrition	 is	associated	with	 improved	outcomes	 in	
newly	diagnosed	children	with	luminal	Crohn’s	disease.	Grover	Z,	Burgess	C,	Muir	R,	Lewindon	P	,	
J	Crohns	Colitis.	2016	Oct;	10(10):1159-64	
	
	
The	purpose	of	this	Chapter	is	to		
1. Prospectively	evaluate	long	term	outcomes	on	maintenance	Immunomodulators	following	a	
course	of	exclusive	enteral	nutrition	in	newly	diagnosed	paediatric	Crohn’s	disease.	
2. Assess	 impact	 of	 EEN	 induced	 mucosal	 healing	 for	 predicting	 sustained	 remission	 on	
Immuno-modulators	without	need	for	rescue	corticosteroids	(CS),	IFX	or	intestinal	resection	
(IR).			
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Abstract:	
Background	
Exclusive	Enteral	Nutrition	(EEN)	induction	in	children	with	luminal	Crohn’s	disease	(CD)	gives	early	
mucosal	healing	(MH)	but	long	term	benefits	of	EEN	induced	MH	are	just	emerging.		
Aims	&	Methods:	 	We	 prospectively	 followed	 an	 Australian	 cohort	 of	 newly	 diagnosed	 children	
with	 predominantly	 luminal	 CD	 who	 completed	 at	 least	 six	 weeks	 EEN	 and	 with	 paired	 clinical	
(PCDAI),	biochemical	(CRP)	and	endoscopic	assessment	at	diagnosis	and	post	EEN.	All	commenced	
Immuno-modulators	 (IM’s)	early	 (<3	months	 from	diagnosis)	and	had	minimum	1	year	 follow	up.	
Our	primary	aim	was	to	 investigate	longitudinal	outcomes	of	EEN	treated	patients	based	on	early	
endoscopic	 recovery.	 The	main	 outcome	 of	 interest	 was	 sustained	 remission	 (SR)	 on	 IM’s	 alone	
without	need	for	Corticosteroids,	Infliximab	(IFX)	or	Surgery.	We	defined	complete	MH	as	SES-CD	0	
and	SES-CD≥1	ascribed	active	endoscopic	disease	(aED),	further	divided	into	near	complete	MH	(SES	
1–3),	mild	active	disease	(SES-CD	4-10)	and	moderate	to	severe	(SES-CD>10).		
Results:	54	eligible	children	(33	Males)	completing	EEN	induction	were	analysed.	Median	duration	
between	pre	&	post	EEN	assessments	was	60.5	days	(IQR,	56-69.5).	Post	EEN:	CR	(PCDAI<10)	was	
observed	 in	 45/54	 (83%),	 BR	 (PCDAI<10	 and	 CRP<5mg/dl)	 in	 39/54	 (72%).	 Complete	 MH	 was	
observed	 in	18/54	 (33%),	near	complete	 in	10/54(19%).	 	SR	was	superior	 in	 those	with	complete	
MH	vs.	aED;	13/18,	(72%)	vs.	10/36	(28%),	p=0.003	at	1	year,	8/16,	(50%)	vs.	3/24,	(8%),	p=0.008	at	
2	years	and	 (8/16,	 (50%)	vs.	1/19,	 (6%),	p=0.005)	at	3	years.	 	Near	complete	MH	did	not	 lead	 to	
superior	SR.	
Conclusions:	Only	complete	MH	post	EEN	induction	predicts	more	favourable	SR	up	to	3	years.	
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Introduction:		
Therapies	capable	of	inducing	and	maintaining	endoscopic	mucosal	healing	(MH)	in	CD	are	vital	as	
adult	 data	 confirm	 rapid	 early	 and	 sustained	MH	 in	 CD	 is	 associated	 with	 less	 frequent	 clinical	
relapses,	 fewer	 hospitalisations	 and	 reduced	 surgical	 resections	 (1,6-8,192).	 Paediatric	 studies	
prospectively	 comparing	 long	 term	outcomes	based	on	endoscopic	MH	are	 limited	but	 suggest	a	
positive	impact	of	early	MH	on	longer	term	outcomes	(178,193-195).		
Anti-TNF	agents	are	widely	used	for	induction	and	maintenance	of	remission	in	CD	and	a	range	of	
step	 up	 and	 step	 down	 strategies	 have	 emerged	 depending	 on	 availability	 and	 funding	 in	 each	
community.	 	 In	Australia,	government	funding	for	anti-TNF	agents	for	luminal	CD	is	predicated	on	
failure	to	respond	to	EEN	or	CS	and	at	least	3	months	of	standard	dosing	with	IM’s.		Infliximab	(IFX)	
had	been	the	sole	approved	anti-TNF	for	luminal	CD	in	children	until	September	2015.	In	our	unit	
over	the	past	5	years,	EEN	has	been	the	primary	induction	therapy	for	the	majority	of	children	and	
IFX	 has	 been	 employed	 as	 early	 as	 3	months,	 and	 soon	 after,	 for	 those	 failing	 EEN	 induction	 or	
relapsing	on	dose	optimised	IM’s.		IFX	free	sustained	remission	is	therefore	an	excellent,	additional	
proxy	of	long	term	remission	post	EEN	and	is	described	in	this	cohort.	We	evaluated	the	impact	of	
early,	EEN	induced	MH	for	predicting	sustained	remission	on	Immuno-modulators	without	need	for	
additional	therapy	including	corticosteroids	(CS),	IFX	or	intestinal	resection	(IR).			
	
Methods:	
This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	 Clinical	 Trails	 Registry-	 ACTRN12612001032842)	 of	 newly	 diagnosed	 children	 with	
predominantly	 luminal	 CD	 (<16	 years)	 treated	 with	 EEN	 and	 early	 thiopurines	 (<3	months	 from	
diagnosis).	 (174)	 Institutional	 Ethics	 approval	 was	 granted	 and	 written	 consent	 obtained	 from	
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patients	and	parents.	Children	completing	at	least	six	weeks	EEN	from	November	2009	–	November	
2014	 with	 a	 minimum	 of	 12	 months	 follow	 up	 and	 complete	 paired	 clinical,	 biochemical	 and	
endoscopic	assessment	before	and	after	EEN	were	included.	12	children	were	excluded	(9	without	
paired	 endoscopy,	 2	 with	 incomplete	 follow	 up	 endoscopy	 and	 1	 with	 isolated	 proximal	 small	
intestinal	 CD).	 Phenotype	 data	 including	 patient	 characteristics:	 endoscopy,	 radiology,	
biochemistry,	concurrent	treatments	and	outcomes	were	prospectively	collected.	Thiopurines	(TP)	
was	 initiated	 in	 all	 children	 aiming	 for	 Azathioprine	 2-2.5mg/kg/day	 or	 6-Mercaptopurine	 1-
1.5mg/kg/day,	modified	according	to	TPMT	status	and	targeting	6TG	levels	>250/pmol/8×108	RBC.	6	
TGN	levels	was	measurement	at	least	twice	in	the	first	year	of	the	diagnosis	and	at	least	annually	
thereafter	as	clinically	indicated.	
Clinical	 remission	 was	 defined	 as	 PCDAI≤10;	 biochemical	 remission,	 CRP<5	mg/l	 with	 PCDAI≤10.	
(148,173,183)	Endoscopic	response	was	determined	by	the	endoscopist	at	time	of	procedure	using	
the	validated	SES	for	CD;	complete	mucosal	healing	was	SES-CD	0	and	SES-CD≥1	active	endoscopic	
disease	(aED).	Active	Endoscopic	disease	(aED)	was	further	sub	classified	as;	near	complete	MH	(SES	
1–3),	mild	active	disease	(SES-CD	4-10)	and	moderate	to	severe	active	disease	(SES-CD>10).	 (140-
141)	
	
Sustained	 remission	 (SR)	was	 defined	 as	 supervised	 remission	 on	 IM’s	 alone	without	 any	 repeat	
course	of	EEN,	concomitant	partial	enteral	nutrition,	antibiotics	or	any	other	CD	therapies)	without	
documented	relapse.	Relapse	was	defined	as	elevated	PCDAI	>15	and	CRP	>5mg/dL	and/or	faecal	
Calprotectin	>250	µgm/gm	stool	and/or	endoscopically	or	radiologically	confirmed,	leading	to	IFX,	
CS	or	surgery.	Management	of	children	relapsing	during	and	after	EEN	 induction	on	maintenance	
IM’s	was	at	 the	discretion	of	 the	 treating	gastroenterologist.	Our	primary	aim	was	 to	 investigate	
longitudinal	 outcomes	 of	 EEN	 treated	 patients	 based	 on	 early	 endoscopic	 recovery.	 The	 main	
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outcome	of	 interest	was	sustained	remission	(SR)	on	IM’s	alone	without	need	for	Corticosteroids,	
Infliximab	 (IFX)	 or	 Surgery.	 Data	 on	 sustained	 CS/IFX/Surgical	 free	 remission	 was	 collected	 on	
children	completing	from	1	year	up	to	4	years	of	follow	up	and	the	impact	of	post	EEN	endoscopic	
score	 on	 SR	 was	 evaluated.	 Survival	 analysis	 was	 performed	 using	 Kaplan	 Meier	 plots,	 time	 to	
relapse	and	time	to	IFX	were	measured	separately	against	early	MH	and	endoscopic	responses	as	
an	additional	proxy	of	long	term	remission	
	
Statistics		
All	 statistical	 calculations	 were	 performed	 using	 IBM	 SPSS	 version	 22	 and	 Graph	 Pad	 Prism	
Software.	Descriptive	data	is	reported	as	an	Inter-Quartile	range.	Categorical	and	continuous	data	
were	analysed	using	 fisher	exact,	Chi	 square	and	unpaired	 t	 test.	Baseline	phenotype,	 laboratory	
and	 endoscopy	 variables	 pre	 and	 post	 EEN	 induction	 were	 compared	 between	 children	 with	
sustained	remission	vs.	relapse	and	those	with	early	MH	vs.	active	endoscopic	disease	(aED).	Kaplan	
Meir	survival	analysis	was	performed	to	evaluate	time	to	relapse	(mandating	IFX	or	CS	or	Surgery)	
and	 time	 to	 IFX	based	on	post	EEN	endoscopic	outcomes.	A	 cox	 regression	analysis	was	done	 to	
compare	hazard	risk	 in	those	with	clinical	remission	vs.	biological	remission	vs.	complete	mucosal	
healing	following	a	course	of	EEN.		
	
Results	
54	children	 (33	Males)	completing	EEN	 induction	with	paired	clinical,	biochemical	and	endoscopy	
data	 with	 median	 follow	 up	 of	 46	 months	 (95%CI	 36-46)	 were	 analysed.	 Follow	 up	 assessment	
including	 endoscopy	 were	 undertaken	 after	 induction	 course	 of	 EEN.	 While	 aiming	 for	 repeat	
Endoscopy	 after	 an	 8	 week	 EEN	 treatment	 course	 as	 outlined	 in	 our	 previous	 publication,	 we	
included	children	with	a	minimum	period	of	six	weeks	EEN	and	children	whose	follow	up	Endoscopy	
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was	delayed	 for	 several	 days	 to	 accommodate	practical	 issues.	 The	median	duration	of	 EEN	was	
8.57	weeks	(IQR	7.7-9.5weeks)	and	median	time	between	pre	and	post	EEN	assessment	8.6	weeks	
(IQR	 8-10	weeks).	 Time	 to	 follow	 up	 endoscopy	 after	 the	 course	 of	 EEN	 in	 those	with	 active	 vs.	
inactive	clinical	disease	were	similar	(55	vs.	61	days,	p=0.2).	
After	completion	of	EEN,	45	(83%)	were	in	clinical	remission;	39	(72%)	in	biochemical	remission;	18	
(33%)	children	had	complete	mucosal	healing	 (SES=0);	10	 (19%)	near	complete	healing	 (SES	1-3);	
26(48%)	had	incomplete	healing	with	mild	disease	activity	in	17	(31%)	and	9	(17%)	with	moderate	
disease	 activity.	 45/54	 (83%)	 Children	 relapsed	 over	 3	 years	 and	were	managed	with	 IFX	 (n=36,	
67%),	 Intestinal	 resection	 (n=6,11%),	 Intestinal	 resection	 and	 IFX	 (n=2)	 and	 CS	 (n=1).	 Repeat	
induction	course	of	EEN	or	Tacrolimus	was	not	utilised	in	any	of	our	cohort.	7/54	(13%)	of	children	
were	intolerant	to	thiopurines	and	were	switched	to	methotrexate.	
Comparison	 of	 clinical	 characteristics	 and	 outcomes	 for	 those	 with	 complete	 mucosal	 healing	
(SES-CD	0)	vs.	active	endoscopic	disease	(SES-CD≥1).	
Clinical	 characteristics	 at	 diagnosis	 and	 post	 EEN	 induction	 were	 comparable	 in	 children	 with	
complete	MH	compared	to	aED	except	those	with	complete	MH	had	from	a	greater	overall	drop	in	
mean	PCDAI	and	CRP	and	a	higher	proportion	of	children	with	CRP	normalisation	(<5mg/dL)	(Table	
5.1).	Greater	sustained	remission	was	observed	at	1,	2	and	3	years	in	those	achieving	complete	MH	
vs.	aED	post	EEN.	(Figure	5.1)	Kaplan	Meier	Survival	analysis	confirmed	both	a	greater	relapse	free	
survival	(supervised	remission	not	requiring	CS,	IFX	or	IR)	and	IFX	free	remission	in	those	with	early	
MH	vs.	aED.	(Figure	5.2,	5.3).			
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Predictors	of	Sustained	remission:	
Sustained	remission	at	1,	2	and	3	years	after	EEN	induction	and	early	IM’s	was	observed	in	23/54	
(42%)	,	11/40	(27.5%)	and	9/35	(26%).	Baseline	Clinical	and	Phenotypic	characteristics	were	similar	
between	groups	in	SR	vs.	Relapse	at	1	year,	apart	from	a	greater	mean	improvement	in	SES-CD	at	
post	 EEN	 endoscopy	 in	 those	 with	 SR	 and	 a	 longer	 follow	 up	 of	 the	 sustained	 remission	 group	
(Table	 5.2).	 	 We	 also	 evaluated	 the	 discriminative	 value	 of	 post	 EEN	 induction	 clinical	 vs.	
biochemical	remission	vs.	endoscopic	healing	in	predicting	sustained	remission	using	cox	regression	
analysis.		Only	MH	not	clinical	nor	biochemical	remission	predicted	a	superior	sustained	remission.	
(Table	5.3).	Quality	of	post	EEN	MH	(SES-CD)	was	also	measured	against	risk	of	subsequent	relapse.	
Only	complete	MH	SES-CD=0	reliably	predicted	a	greater	relapse	free	survival	at	1,	2	and	3	years	
compared	to	those	with	near	complete	(NCH)	vs.	Mild	active	disease	vs.	Moderate	active	disease	
(Figure	5.4).		
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Table	5.1.		
Comparison	of	Demographic	and	Clinical	Characteristics	pre	&	post	EEN	between	children	with	
complete	MH	vs.	active	Endoscopic	disease	
	 Complete	 MH	
(n=18)	
aED	(n=36)	 P	
Mean	Age	 12.2	 12.67	 0.92	
Females	(%)	 6(33%)	 15(41.5%)	 0.76	
Mean	PCDAI		
At	Diagnosis(SD)	
Post	Induction(SD)	
	
36	(10.3)	
3.6(5.2)	
	
39.5(10.1)	
7.7(7.1)	
	
0.30	
p=0.01	
Mean	CRP	(mg/dl)	
Diagnosis	Mean,	(SD)	
		Number	with	CRP>5mg/L	(94%)	
Post	induction	CRP,	(SD)	
		Number	with	CRP	<5	mg/L	(94%)	
	
31.5(20)	
17/18(94.5%)	
2(1.1)	
16/17		
	
50.6(48.7)	
34/36(94.5%)	
9.4(15.2)	
22/34	
	
0.12	
1	
p=0.03	
p=0.04	
SES-CD	
At	Diagnosis	
	
13.5	
	
	
14.4	
	
0.41	
	
Disease	Phenotype	at	presentation	
Ileal	(n=8,17%)	
Ileocolonic	(n=40,74%)	
Colonic	(n=6,11%)	
	
3	
13	
2		
	
5	
27	
4	
	
1	
Disease	Modifier	at	presentation	
UGI	disease	(n=32,59%)	
Perianal	Disease	(n=11,20%)	
Complicating	disease,	B2/B3	(n=7,13%)	
	
11	
3	
2	
	
21	
8	
5	
1	
Mean	 days	 from	 EEN	 to	 FU	
endoscopy(SD)	
60	days	(10.3)	 61.5	days	(11.9)	 0.89	
Mean	time	from	diagnosis	to	IM	use		
(n=49,	AZA	,	5,6MP)	
4.3weeks	(1.9)	 5.4	weeks	(3.4)	 0.27	
Mean	Follow	up	from	Diagnosis	 46	months	(11.5)	 37.5	months	(18.7)	 0.05	
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Table	 5.2.	 Comparison	 of	 Demographic	 and	 Clinical	 Characteristics	 pre	 and	 post	 EEN	 between	
children	with	sustained	remission	vs.	relapse	in	the	first	year	
		 Sustained	remission	(n=23)	 Relapse	(n=31)	 P	
Mean	Age(SD)	 11.9(2)	 12.8(1.8)	 0.08	
Females,	(38%)	 11		 10	 0.27	
Mean	PCDAI	(SD)	
At	Diagnosis(SD)	
Post	Induction(SD)		
	
37(8)	
4.9(5.9)	
	
39(11.5)	
7.6(7.2)	
	
0.4	
0.1	
Mean	CRP	(mg/dl),(SD)	
At	Diagnosis(SD)	
Post	induction(SD)	
CRP	<	5mg/dL	(78%)	
	
42.3(46)	
4.42(6.3)	
20/23	
	
43.3(38)	
9.8(15.4)	
22/31	
	
0.81	
0.18	
0.2	
Mean	SES-CD	
At	Diagnosis(SD)	
Post	Induction(SD)	
	
13.9	(6.2)	
3.4(5.7)	
	
14.5(5.3)	
6.61(5.3)	
	
0.24	
0.03	
Disease	Phenotype	
Ileal	(15%)	
Ileocolonic	(74%)	
Colonic	(11%)	
	
5	
18	
2	
	
3	
22	
4	
	
1	
Disease	Modifier	
UGI	disease	(59%)	
Perianal	Disease	(20.6%)	
Complicating	disease	(B2/B3)	
	
14(26%)	
3	(5.6%)	
3	
	
18(33%)	
8	(15%)	
4	
	
1	
0.23	
1	
Mean	time	from	diagnosis	to	TP	use	 4.1weeks(2.2)	 5.16	weeks(3.1)	 0.09	
Mean	Follow	up	from	diagnosis(SD)	 48(13)	 37(18)	 0.03	
	
	
Table	5.3		
Cox	regression	analysis	comparing	post	EEN	clinical	and	biological	remission	vs.	mucosal	healing	
in	predicting	relapse		
	 Odds	ratio		 Significance	 95%	 CI	 for	 Odds	
ratio	
Mucosal	Healing	 0.48	 0.04	 0.23-0.98	
Biochemical	
remission	
0.47	 0.08	 0.2-1.1	
Clinical	remission	 0.71	 0.53	 0.24-2.06	
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Outcome	of	the	children	excluded	from	the	study	
12	 children	 were	 excluded	 due	 to	 lack	 of	 or	 incomplete	 post	 induction	 endoscopy.	 Sustained	
remission	at	1,	2	and	3	years	after	EEN	induction	and	early	IM’s	for	those	excluded	from	the	study	
and	without	 endoscopic	 response	 for	 sub-classification	were	6/12(50%),	 3/8	 (37%)	 and	2/7(28%)	
respectively.	
Medication	exposures	at	last	follow	up	
At	median	follow	up	of	46	months	(95%CI	36-46),	22/54,	(41%)	were	on	combination	therapy	(anti-
TNF	 with	 IM’s),	 16	 (30%)	 on	 anti-TNF’s	 alone	 and	 15/54	 (29%)	 on	 monotherapy	 with	 immune-
modulators.		
	
Discussion:	
This	 is	the	largest	prospective	longitudinal	cohort	study	confirming	improved	long	term	outcomes	
in	newly	diagnosed	children	with	luminal	CD	achieving	early	complete	mucosal	healing	on	EEN.	We	
have	also	again	demonstrated	that	control	of	symptoms	or	improvement	of	serum	biomarkers	with	
clinical	remission	alone	are	inferior	compared	to	complete	mucosal	healing	after	EEN	induction	in	
predicting	sustained	remission	(SR).	SR	was	greatest	in	those	achieving	complete	disappearance	of	
ulcers.	 	 Near	 complete	MH	 did	 not	 give	 significantly	 improved	 SR	 over	 more	 active	 endoscopic	
disease.	
Relapse	 was	 progressively	 more	 frequent	 in	 those	 with	 aED	 vs.	 complete	 MH;	 Relapse	 was	
progressively	 more	 frequent	 in	 those	 with	 aED	 vs.	 complete	 MH	 ;	 26/36	 (72%)	 vs.	 5/18(28%),	
p=0.003	at	1	year,	21/24(92%)	vs.	8/16,	(50%),	p=0.008	at	2	years	and	18/19(94%)	vs.	(8/16,	(50%)	,	
p=0.005)	at	3	years.	
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Our	finding	of	early	complete	mucosal	healing	is	vital	for	optimising	subsequent	clinical	outcomes	
has	 support	 from	 recent	 studies.	 A	 placebo	 controlled	 RCT	 with	 adalimumab	 in	 adults	 with	
moderate-severe	CD	demonstrated	the	positive	impact	of	early	(12	week)	complete	MH	(SES-CD=0)	
on	Week-52	outcomes.		In	this	study,	a	“1-point	increase	in	Week-12	SES-CD	score	was	associated	
with	 a	 5.0-point	 increase	 in	 Week-52	 CDAI	 score	 (p<0.05)”.	 Conversely	 higher	 Week-12	 SES-CD	
scores	were	associated	with	reduced	Odds	(OR=0.6,	p<0.05)	of	Week-52	remission	(164).	Another	
recent	paediatric	anti-TNF	cohort	study	with	planned	follow	up	endoscopy	between	9-12	months	
also	reported	positive	predictive	value	of	complete	MH	with	79%	clinical	remission	rates	at	2	years	
in	those	with	achieving	complete	MH	vs.	67%	with	partial	MH	(SES-CD	drop>50%)	(195).	Complete	
disappearance	of	ulcers	(CDEIS=0)	or	a	tighter	definition	of	endoscopic	healing	(SES-CD	£2)	can	lead	
to	 superior	 outcomes,	 this	 concurs	with	 our	 findings	 as	 only	 those	with	 complete	MH	had	 good	
outcomes	(245-246)	
	
Our	 early	 mucosal	 healing	 rates	 following	 EEN	 therapy	 are	 comparable	 (33%)	 to	 our	 previous	
reports	of	44%.	(175)	Our	study	 is	also	the	first	to	prospectively	examine	the	 impact	of	early	EEN	
induced	 mucosal	 healing	 on	 important	 real-life	 long	 term	 clinical	 outcomes	 i.e	 need	 for	
Infliximab/CS	 or	 surgical	 resection	 in	 a	 well	 characterised	 cohort	 with	 a	 consistent	 practice	 of	
diagnosing	and	management	of	CD	relapse.		In	a	previous	retrospective	study	comparing	EEN	vs.	CS	
induced	endoscopic	remission,	those	with	EEN	induced	early	endoscopic	remission	were	less	likely	
to	relapse	within	1	year	(40%)	compared	to	CS	(70%).	(93)	
Our	 study	was	not	designed	 to	address	 the	 impact	of	early	 IM’s	use	on	early	mucosal	healing	or	
subsequent	 clinical	 outcomes.	 Most	 children	 commenced	 IM’s	 around	 4	 weeks	 as	 has	 been	
common	 paediatric	 practice	 and	 the	 delayed	 peak	 efficacy	 of	 Thiopurines	 meant	 early	 use	 was	
unlikely	to	affect	early	endoscopic	outcomes.		However	recent	adult	controlled	trials	demonstrated	
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early	introduction	of	thiopurines	did	not	improve	outcomes	including	maintenance	of	steroid	free	
remission,	need	for	anti-TNF	and	intestinal	surgery.	(172-173).	Our	data	supports	this	finding	as	the	
mean	time	to	initiate	IM’s	were	similar	in	those	with	early	MH	vs.	active	endoscopic	disease	and	in	
those	with	sustained	remission	vs.	relapse	confirming	that	early	use	or	otherwise	of	thiopurines	is	
not	as	important	as	early	Mucosal	healing.		
Greater	number	of	children	with	complete	MH	vs.	aED	demonstrated	post	induction	normalisation	
of	 CRP	 (94%	 vs.	 65%,	 p=0.04,	 however	 CRP	 value	 at	 diagnosis	 was	 higher	 in	 those	 with	 active	
endoscopic	 disease	 vs.	 CMH	 (mean	 50.6	 vs.31.5	 mg/dl,	 p=NS)	 probably	 indicating	 greater	
inflammatory	disease	load.		
We	acknowledge	that	our	longitudinal	cohort	study	has	limitations	as	an	uncontrolled	study,	small	
sample	size	and	potential	for	bias.	However	potential	for	bias	was	low	as	introduction	of	IFX	to	this	
cohort	was	predefined	by	government	funding	criteria.	More	 importantly	escalation	of	treatment	
was	not	solely	based	on	presence	of	symptoms	but	also	at	least	one	abnormal	objective	biomarker	
of	inflammation	including	CRP,	Faecal	Calprotectin	or	repeat	endoscopic	or	radiological	evidence	of	
relapse.		
In	our	 current	 study,	we	did	not	examine	 serological	 immune	 response,	 genetic	 and	microbiome	
signatures	 to	 predict	 disease	 course	 and	 /or	 therapeutic	 response	 as	 suggested	 by	 recent	 data.	
Using	 systems	 dynamic	 analysis	 approach,	 Dubinsky	 et	 al	 confirmed	 small	 bowel	 involvement,	
perianal	 disease	 and	 increased	 serological	 immune	 response	 to	 be	 strongly	 associated	 with	
complicating	 paediatric	 CD	 (196).	 Recently,	 Haberman	 et	 al	 also	 documented	 that	 microbial	
signatures	from	Ileal	tissue	provided	a	modest	predictive	value	with	higher	AP0A1	gene	expression	
and	 Veillonella	 to	 Blautia	 ratio	 associated	 with	 a	 better	 sustained	 steroid	 free	 remission	 (197).	
These	 observations	 suggest	 further	 comprehensive	 studies	 are	 warranted	 combining	 detailed	
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clinical,	 endoscopic,	 serological,	 genetic	 and	 microbiological	 signatures	 to	 predict	 disease	
outcomes.	 In	 conclusion,	 we	 demonstrate	 that	 early	 complete	 MH	 post	 EEN	 induction	 predicts	
sustained	 remission	over	 and	beyond	3	 years	 on	maintenance	 Immunomodulators	 and	 that	 only	
complete	MH	(SES-CD=0)	provides	improved	outcomes.		Our	data	also	indicates	that	early	mucosal	
healing	may	be	more	 important	 than	baseline	disease	 severity	or	 timing	of	 IM’s	 introduction	 for	
predicting	sustained	anti-TNF/Surgical/	free	remission	up	to	3	years	and	beyond.			
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Figure	5.1.	Outcomes	of	those	with	early	mucosal	healing	vs.	Active	endoscopic	Disease	(aED)		
	
	
	
	
	
	
	
	 	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
3 years FU = 16  
Sustained remission = 8/16 (50%) 
New relapse = 0 
 
3 years FU = 19  
Sustained remission = 1/19 (6%) 
New relapse = 0 
 
N = 54  
1 year FU 
Sustained remission= 13/18 (72%) 
Relapse during the 1st year=5/18 
• Infliximab (IFX) = 4 
• Intestinal Resection (IR) =1 
aED = 36/54 
2 years FU = 16  
Sustained remission = 8/16 (50%) 
New relapses = 3, (IFX =3)  
 
1 year FU 
Sustained remission = 10/36(28%) 
Relapse during 1st year = 26/36 
• IFX=22 
• IR=2, IR/IFX = 2 
• CS=1 
2 years FU = 24 
Sustained Remission=3/24 (12.5%) 
New relapses =7, (IFX=5, IR+IFX=5) 
 
(2 < 2 year FU) (12 < 2 year FU) 
(5 < 2 year FU) 
MH = 18/54 
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Figure	5.2		
Months	to	relapse:	Post	EEN	complete	mucosal	healing(n=18)	vs.	active	endoscopic	disease(n=36)	
	
Figure	5.3	
Months	to	Infliximab:	Post	EEN	complete	MH(n=18)	vs.	active	endoscopic	disease	(aED),n=36	
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Figure	5.4.	
Months	relapse	vs	SES-CD	post	EEN	Induction		
(n=18	(CMH),	n	=10	(Mildly	active),	n=17	(Moderate	active)	&n=9,	Severe	active	disease	)	
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Chapter	6	
	
	
Alterations	in	the	mucosa	associated	microbiome	of	newly	diagnosed	children	with	Crohn’s	Disease	
following	 a	 period	 of	 exclusive	 enteral	 nutrition	 Z.	 Grover,	 A.	 Kang,	 G.L.	 Radford	 Smith,	 N.M.	
Fukuma,	Lisa	A.	Simms,	M.	Morrison	and	P.J.	Lewindon	
	
	
The	purpose	of	this	chapter:	
1. Characterise	 the	 Mucosal	 associated	 Microbiome	 of	 treatment-naïve	 children	 diagnosed	
with	CD	before	and	after	EEN;		
2. Relate	changes	in	these	MAM	profiles	following	EEN	with	correspondent	endoscopic	disease	
activity	scores	(SES-CD).		
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Abstract:	
Introduction:	 Mucosal	 healing	 (MH)	 is	 a	 vital	 endpoint	 in	 CD	 and	 can	 be	 achieved	 by	 exclusive	
enteral	 nutrition	 (EEN).	 Faecal	 microbiome	 studies	 report	 EEN	 coincides	 with	 reduced	 bacterial	
diversity,	 however	 the	mucosa-associated	microbiome	 (MAM)	 is	 distinct	 and	 poorly	 reflected	 in	
faeces.	Aims	&	Methods:	We	 characterize	 the	MAM	of	 pinch	biopsies	 collected	 at	 diagnosis	 and	
after	completion	of	EEN	(Median	7.9	weeks,	95%	CI=7.5-8.2	weeks)	from	8	treatment	naïve	children	
diagnosed	with	CD;	and	relate	changes	 in	profiles	with	correspondent	endoscopic	disease	activity	
scores	 (SES-CD).	 16S	 rRNA	 gene	 amplicon	 libraries	 of	 MAM	 communities	 were	 produced	 and	
sequenced	using	Illumina	MiSeq	platforms	and	analysed	using	QIIME	and	related	packages.	Results:	
Clinical	 and	 endoscopic	 scores	 for	 all	 children	 improved	 after	 EEN	 with	 complete	 (4/8)	 or	 near	
complete	 (4/8)	MH.	 Gross	 alterations	 in	MAM	profiles	 after	 EEN	were	 similar	 to	 those	 found	 in	
previous	faecal	studies.	Alpha	diversity	was	reduced	(mean	Chao1	values	of	276	and	220	pre-	and	
post-EEN,	respectively;	95%	CI	26-85,	p=0.003).	There	was	an	increase	in	relative	abundance	of	taxa	
assigned	to	Lachnospiraceae	and	parallel	decrease	in	Ruminococcaceae	taxa;	principally	accounted	
for	by	increase	in	Dorea	spp.,	and	decrease	in	Faecalibacterium	spp.		A	trend	of	increase	in	Dorea	
species	was	evident	 in	those	with	complete	vs.	 incomplete	MH	(p=0.05).	Conclusion:	EEN	induces	
complete	or	near	complete	MH	and	alters	the	MAM,	reducing	diversity	and	changing	key	lineages	
of	 Firmicutes.	 EEN	 changes	 the	MAM	 nutritional	 and	 physiological	milieu	 resulting	 in	 an	 altered	
microbiome	of	reduced	diversity	that	is	not,	of	itself,	“dysbiotic”.		
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Introduction	and	Aims:	
Crohn’s	 disease	 (CD)	 incidence	 and	 prevalence	 are	 rising,	with	 approximately	 25%	 of	 new	 onset	
patients	 diagnosed	 during	 childhood	 and	 with	 a	 more	 severe	 disease	 burden	 (2-4).	 For	 these	
patients,	exclusive	enteral	nutrition	(EEN)	is	now	widely	accepted	as	an	effective	induction	therapy,	
with	 a	 clinical	 remission	 rate	 equivalent	 to	 steroids	 but	 more	 importantly,	 superior	 mucosal	
remission	 rates	 of	 40-70%	 (11-12,	 175).	 Despite	 the	 success	 of	 EEN,	 little	 is	 known	 about	 the	
mechanisms	 of	 these	 interventions	 promoting	 mucosal	 healing,	 or	 why	 some	 patients	 are	 non-
responders.	 In	 that	 context,	 our	 understanding	 how	 the	 gut	 microbiota	 is	 affected	 by	 EEN	 is	
relatively	 deficient.	 Recent	 studies	 exploring	 the	 stool	 microbiota	 during	 EEN	 in	 paediatric	 CD	
demonstrate	 reductions	 in	microbial	 diversity	 along	with	 improvement	 in	 clinical	 disease	 activity	
scores.	 These	 alterations	 include	 the	 depletion	 of	 specific	 bacteria	 such	 as	 Faecalibacterium	
prausnitzii,	which	is	widely	considered	to	be	beneficial	for	its	anti-inflammatory	properties	(14-16),	
and	 contrast	 with	 studies	 of	 adult	 CD	 patients	 (198-199).	 The	 mucosa-associated	 microbiome	
(MAM)	is	now	accepted	to	be	distinct	from	the	faecal	microbiome	(17-18)	and	there	are	currently	
no	published	studies	correlating	post-EEN	induction	endoscopic	disease	activity	scores	and	parallel	
changes	in	MAM.	A	single	case	report	described	the	ileum	microbiome	changes	pre-	and	post-EEN	
in	a	newly	diagnosed	child	with	CD,	compared	to	a	single	healthy	control	(197).	The	pre-EEN	MAM	
in	 the	 child	with	 CD	 showed	 reduced	microbial	 diversity,	 increased	 levels	 of	 Proteobacteria	 and	
lower	 levels	 of	 Bacteroidetes	 species	 compared	 to	 the	 healthy	 control.	 These	 changes	 corrected	
post-EEN	with	reduction	 in	Proteobacteria	and	 increase	 in	Bacteroidetes	and	Firmicutes	phyla,	 to	
become	more	 similar	 to	 healthy	 controls.	 These	 authors	 concluded	 that	 EEN	 restores	 the	MAM	
diversity,	but	this	is	in	contrast	with	two	recent,	larger	studies	noted	above.		
In	summation,	while	EEN	promotes	MH	in	most	patients,	there	are	conflicting	results	arising	from	
the	 limited	 studies	 of	 the	 changes	 in	 stool	 microbiota	 and	 MAM	 during	 EEN,	 and	 a	 lack	 of	
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microbiome	 studies	 paired	 with	 endoscopic	 data.	 Here,	 we	 present	 the	 results	 of	 a	 prospective	
cross-sectional	 study	 to	 characterise	 the	 MAM	 of	 treatment-naïve	 children	 diagnosed	 with	 CD	
before	and	after	 EEN;	 and	 relate	 changes	 in	 these	MAM	profiles	with	 correspondent	endoscopic	
disease	activity	scores	(SES-CD).		
Methods:	
This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	Clinical	Trials	Registry—ACTRN12612001032842)	of	newly	diagnosed	children	with	CD	(<16	
year)	 offered	 EEN	 or	 steroids	 as	 induction	 therapy	 and	 commenced	 on	 early	 thiopurines.	 Those	
electing	 to	use	EEN	 induction	 therapy,	were	offered	either	Nutrison	 (1	Kcal/ml,	Nutricia	UK,	40	g	
Protein,	 39	 g	 Fat	 /1000ml)	 through	 Nasogastric	 tube	 (NGT)	 or	 Resource	 protein	 (1.25	 Kcal/ml,	
Nestle,	94	g	Protein,	35	g	Fat	/1000	ml)	orally	based	on	preference	gradually	 increasing	to	target	
volumes	in	3	to	5	days.	Small	amounts	of	clear	fluids	and	Jelly	were	allowed	to	improve	palatability	
for	those	struggling	with	oral	EEN.		
	
Children	undergoing	investigations	for	suspicion	of	CD	with	no	recent	history	of	antibiotic	use	were	
offered	 to	 participate	 in	 this	 pilot	 study.	 Institutional	 Ethics	 approval	 was	 granted	 and	 written	
consent	obtained	from	patients	and	parents.	Mucosal	biopsies	were	collected	from	ileum,	Caecum	
and	 Sigmoid	 from	 all	 participating	 children	 at	 diagnosis.	 However,	 only	 treatment	 naïve	 children	
with	consecutive	clinical,	endoscopic	data	and	mucosal	biopsies	before	and	immediately	after	EEN	
induction	were	included	in	the	study.	
	
Clinical	 and	 biochemistry	 data	 including	 PCDAI	 and	 CRP	 were	 collected	 prospectively	 and	
endoscopic	 disease	 severity	 was	 determined	 by	 the	 endoscopist	 at	 time	 of	 procedure	 using	 the	
validated	simple	endoscopy	score	for	CD	(SES-CD);	complete	mucosal	healing	was	SES-CD=0.	At	the	
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time	 of	 endoscopies,	 pinch	 tissue	 biopsies	 from	 the	 ileum,	 caecum	 and	 sigmoid	 colon	 were	
collected	and	snap	frozen	on	dry	ice,	and	then	stored	at	-80oC	until	use.		
	
DNA	extraction	
Microbial	DNA	was	 extracted	 from	all	 the	samples	using	 the	 repeated	bead	beating	method	and	
column	 purification	 (199).	 Briefly,	 each	 pinch	 tissue	 biopsy	 was	 transferred	 into	 2-ml	 screw	 cap	
tubes	containing	0.4	g	of	zirconia/silica	beads	(0.1	mm	and	1.0	mm,	Daintree	Scientific,	St.Helens,	
Tasmania,	Australia)	 and	600	µL	of	 Lysis	Buffer	 (500	mM	NaCl,	 50	mM	Tris-HCl	 (pH	8.0),	 50	mM	
EDTA	and	4%	(w/v)	sodium	dodecyl	sulfate).	The	sample	was	homogenized	at	5000	rpm	for	60	s	for	
three	15	s	 intervals	using	 the	Precellys®24	 (Bertin	 Instruments,	Montigny-le-Bretonneux,	France).	
Total	 genomic	DNA	was	 extracted	 from	 the	 lysate	 and	purified	 using	 a	Maxwell®	 16	 Tissue	DNA	
Purification	 Kit	 (Promega,	 Madison,	 WI)	 compatible	 with	 the	 Maxwell®	 16	 MDx	 Research	
Instrument	(Promega,	Madison,	WI).	
	
Microbial	16S	rRNA	gene	sequencing	and	data	analysis	
A	 total	 of	 112	mucosal	 biopsies	 from	20	 participating	 children	 (n=16	 CD,	 2=UC,	 2=Control)	were	
analysed	using	16S	rRNA	gene	sequencing.	The	V6-V8	hypervariable	regions	of	the	16S	rRNA	gene	
were	PCR	amplified	from	100	ng	of	purified	DNA,	using	Bacteria-domain	specific	primers	fused	with	
the	Illumina	primer	overhang	adapter	(forward	overhang	adapter	-	917F,	5’-	TCG	TCG	GCA	GCG	TCA	
GAT	GTG	TAT	AAG	AGA	CAG	GAA	TTG	RCG	GGG	RCC	-3’	and,	the	reverse	overhang	adapter	-	1392R,	
5’-	 GTC	 TCG	 TGG	 GCT	 CGG	 AGA	 TGT	 GTA	 TAA	 GAG	 ACA	 GAC	 GGG	 CGG	 TGW	 GTR	 C	 -3’.	 The	
amplified	 products	were	 cleaned	using	Agencourt	 AMPure	 XP	 beads	 (Beckman	Coulter,	Danvers,	
MA)	 according	 to	manufacturer’s	 instructions.	 Dual-index	 barcodes	were	 added	 to	 the	 amplicon	
target	using	the	Nextera	XT	Index	Kit	(Illumina,	San	Diego,	CA).	 	The	specific	band	of	interest	(624	
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bp)	 was	 excised	 and	 purified	 using	 the	Wizard®	 SV	 Gel	 and	 PCR	 Clean-Up	 System	 (Promega,	
Madison,	 WI)	 and	 subsequently	 with	 Agencourt	 AMPure	 XP	 beads	 (Beckman	 Coulter,	 Danvers,	
MA)	according	 to	 manufacturer’s	 instructions.	 Samples	 were	 quantified	 using	 the	QuantiFluor®	
dsDNA	 Sample	 Kit	 on	 the	Quantus™	 Fluorometer	 (Promega,	 Madison,	 WI).	 All	 samples	 were	
normalized	to	4	nM	final	concentration	and	then	pooled	into	a	single	microcentrifuge	tube.	Paired-
end	 sequencing	 was	 performed	 using	 the	 Illumina	 MiSeq	 platform	 (Illumina,	 San	 Diego,	 CA),	
supported	 and	 operated	 by	 the	 Australian	 Centre	 for	 Ecogenomics	 (University	 of	 Queensland,	
Brisbane,	Australia).		
	
The	sequence	data	were	analysed	using	Quantitative	Insight	Into	Microbial	Ecology	(QIIME)	version	
1.9.1	(200).	Sequences	that	were	not	classified	as	Bacteria	or	Archaea,	or	were	found	to	be	in	low	
abundance	 (<0.001%),	with	 a	Phed	 score	of	 lower	 than	20,	or	 samples	producing	 less	 than	1000	
sequences	 meeting	 these	 criteria	 were	 removed	 and	 not	 analysed	 further.	 The	 remaining	
sequences	were	 clustered	 into	 operational	 taxonomic	 units	 (OTUs)	 by	 PyNAST	 (201)	with	 a	 97%	
sequence	 identity	 threshold	 against	 the	 Green	 genes	 core	 set	 database	 version	 13.8	 (202).	 The	
generated	 biom	 table	 was	 normalised	 by	 CSS-normalization.	 Alpha	 (within-sample)	 and	 beta	
(between-sample)	 diversity	 metrics	 were	 calculated	 using	 QIIME.	 Chao1	 (203)	 was	 used	 as	 an	
estimator	 for	 richness	 of	 the	 community.	 Distance	 between	 samples	 was	 represented	 by	 the	
weighted	UniFrac	 distance	metric	(204)	 and	 visualized	 using	 Principal	 Coordinate	Analysis	 (PCoA)	
plotting.	
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Statistics	
All	statistical	calculations	were	performed	using	Graph	Pad	Prism	version	5.00	(Graph	Pad	Software,	
La	 Jolla,	 CA).	 Paired	 t-tests	 were	 performed	 to	 compare	 Chao1	 and	 specific	 genus-level	 groups	
before	 and	 after	 EEN	 therapy.	 Spearman	 Rho’s	 correlation	 analysis	 was	 used	 to	 examine	 and	
identify	correlations	between	specific	OTUs	and	SES-CD	scores.	
	
Results	
8	 children	 (5	 females)	 completed	 exclusive	 course	 of	 EEN	 (Median	 7.9	 weeks,	 95%	 CI=7.5-8.2	
weeks)	 and	had	a	 complete	 clinical,	 endoscopic	 and	 sequential	MAM	dataset,	which	 included	68	
biopsies	 (Ileum=23,	 Caecum=19	 and	 Sigmoid	 colon=26).	 	 	 Of	 8,	 3	 completed	 EEN	 via	 oral	 route	
alone	(Resource	Protein,	1.25	Kcal/ml,	Nestle,	94	g	Protein,	35	g	Fat	/1000	ml),	5/8	received	EEN	via	
NG	tube	because	of	palatability,	inadequate	intake	or	poor	compliance.	
Clinical	and	endoscopic	measures	 for	all	8/8	patients	 improved	after	8	weeks	EEN	with	complete	
(4/8)	 or	 near	 complete	 (4/8)	 MH	 (Table	 1).	 Only	 sequence	 data	 with	 at	 least	 1000	
sequences/sample	were	included	for	analysis,	and	rarefaction	curve	of	number	of	observed	OTUs	is	
shown	in	Figure	6.1.		
As	expected,	both	the	PCDAI	score	and	CRP	levels	were	also	substantially	decreased	in	8/8	patients,	
further	 confirming	 improvements	 in	 patient	 symptoms	 and	 gut	 inflammation.	 Based	 on	 these	
results,	we	conclude	that	all	8	patients	not	only	responded	positively	to	EEN	induction	therapy,	but	
the	MAM	profiles	would	be	an	accurate	 reflection	of	how	 this	 intervention	affects	 this	microbial	
community.	
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Figure	6.1.	Rarefaction	curve	demonstrating	number	of	observed	OTUs		
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Table	6.1.	Phenotype	and	Clinical	Characteristics	of	the	study	cohort,	n=8,	pre	and	post	EEN	
	
Pt	
ID	
Age	 Montreal	
Classification	
Biopsy		Site	
Ileum=I	 ,	
Caecum=C	
Sigmoid	=S	
Pre-EEN				
Post	-EEN																						
PCDAI	
	
Pre-EEN					
Post-	EEN	
													CRP	
	
				Pre-EEN						
Post		EEN	
										SES-CD	
	
Pre-EEN	 	 	 	 	 	 	 	 	 	 Post	
EEN	
01	 11	 Ileal	 I=2		
C=1		
S=1		
I=2	
C=1	
S=1	
32.5	 20	 17	 5	 4	 0	
05	 13.5	 Ileocolonic	
	+	UGI	
I	=1	
C=1	
S=2	
I=1	
C=1	
S=1	
40	 5	 42	 1	 15	 0	
07	 13.6	 Ileocolonic	 I	=1	
C=2		
S=2	
I=2	
C=2	
S=2	
35	 10	 24	 4	 11	 0	
18	 14	 Ileocolonic	
+	UGI	
I	=1	
C=1	
S=2	
I=1	
C=1	
S=1	
35	 0	 111	 2	 15	 0	
02	 14.5	 Ileocolonic	 I	=1	
C=1	
S=1	
I=1	
S=4	
45	 30	 29	 8	 30	 3	
04	 13.2	 Ileocolonic	 I	=2	
C=2		
S=2	
I	=2	
C=2		
S=2	
47.5	 10	 100	 10	 15	 3	
11	 11.5	 Ileocolonic	 +	
UGI	
I	=2	
C=1	
S=1	
I=1	
C=1	
S=1	
37.5	 5	 34	 7	 12	 3	
22	 14.5	 Colonic	 +	
UGI	
I	=2	
C=1	
S=1	
I=1	
C=1	
S=1	
17.5	 10	 71	 1	 18	 3	
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The	alpha	(within	sample)	diversity	of	MAM	is	reduced	by	EEN	
The	 mean	 rarefaction	 curves	 for	 samples	 collected	 pre-	 and	 post-EEN	 are	 shown	 in	 Figure	 1.	
Although	not	statistically	significant,	there	is	a	consistent	and	distinct	difference	in	OTU	frequencies	
between	 sampling	periods,	with	 the	pre-EEN	samples	possessing	a	greater	number	of	OTUs	with	
increasing	sequence	depth	(i.e.	number	of	reads).	Such	findings	suggest	that	the	period	of	EEN	does	
result	 in	 a	 reduction	 of	 alpha	 (within	 sample)	 MAM	 diversity	 in	 these	 children,	 and	 this	 was	
confirmed	 by	 analysis	 of	 the	 Chao1	 scores	 for	 individual	 samples,	 which	 showed	 a	 reduction	
following	EEN	(p=0.02)	(Table	6.2).	Interestingly,	our	sub-analysis	of	the	change	in	Chao1	diversity	
scores	 for	 patients	 showing	 complete	 endoscopic	 MH	 (SES-CD=0)	 compared	 to	 incomplete	 MH	
revealed	 a	 significant	 reduction	 in	 MAM	 diversity	 only	 in	 those	 with	 complete	 mucosal	
healing,(p=0.003)	(Table	6.2).		
	
Table	6.2.	Microbial	Diversity	(Chao1)	in	those	with	Complete	MH	vs.	Incomplete	MH	before	and	
after	EEN	
	
Group	 							All	(n=8)	 Mucosal	Healing	(n=4)	 Incomplete	healing	(n=4)	
	
Mean	Chao1	
Before	
EEN	
273.5	
After	EEN	
226	
Before	
EEN	
276	
After	EEN	
220	
Before	EEN	
270.9	
After	EEN	
233	
95%	CI		(p	value)	 6.6	-	88	(p=0.02)	 26	-	85	(p=0.003)	 -51	-	127	(p=0.37)	
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	The	MAM	communities	are	dominated	by	the	same,	limited	number	of	Bacterial	phyla	pre-	and	
post-EEN			
The	relative	abundance	of	the	major	Bacterial	phyla	across	all	MAM	samples	from	CD	patients,	and	
a	healthy	control	 subject,	are	 shown	 in	Figure	2.	There	appeared	 to	be	no	strong	 influence	 from	
anatomical	 site	 on	 these	 profiles,	 at	 the	 Phylum	 level	 of	 classification,	 with	 the	 Firmicutes	 and	
Bacteroidetes	 phyla	 being	 the	 most	 dominant	 in	 all	 these	 samples.	 However,	 the	 relative	
abundance	 of	 the	 Bacteroidetes	 was	 increased	 in	 most	 samples	 from	 the	 CD	 patients	 and	
furthermore,	 the	 relative	 abundance	of	 the	Proteobacteria	phyla	 is	 also	 remarkable	 in	most,	 but	
not	all	samples	from	CD	patients.	The	relative	abundance	of	the	Actinobacteria	remained	consistent	
across	all	sample	types,	with	only	an	infrequent	but	remarkable	occurrence	of	OTUs	assigned	to	the	
Verrucomicrobia	and	Fusobacteria	phyla.			
	
The	MAM	communities	 of	 pCD	patients	 can	be	differentiated	by	 their	 initial	 SES-CD	 score	 and	
respond	similarly	to	the	combined	effects	of	EEN	and	mucosal	healing			
The	 Principal	 Component	 Analysis	 of	 the	 beta	 diversity	 (variability	 of	 the	 microbial	 community	
between	samples)	both	at	diagnosis	and	after	the	EEN	intervention	are	shown	in	Figure	3.	For	each	
patient	visit,	the	MAM	profiles	recovered	from	the	different	biopsy	sites	were	most	similar	to	each	
other,	and	no	site-specific	differences	were	evident	either	within	or	between	patients,	or	patient	
visits.	 Interestingly,	 the	MAM	profiles	 for	 the	patient	with	the	two	 lowest	 initial	SES-CD	scores	 (4	
and	11)	were	distinctly	different	from	the	other	6	patients	(SES-CD	scores	of	15-30),	resulting	in	the	
MAM	profiles	from	this	pilot	study	being	separated	into	distinct	“groups”.	The	MAM	profiles	for	all	
the	 patients	 also	 show	 some	 alterations	 resulting	 from	 the	 combined	 effects	 of	 the	 EEN	
intervention	and	mucosal	healing	with	most	of	the	patients	showing	a	consistent	shift	in	their	MAM	
profiles	(as	annotated	by	the	arrows	shown	in	Figure	3).	In	summation,	and	although	the	number	of	
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patients	in	this	pilot	study	are	not	large,	the	initial	MAM	profiles	of	the	patients	at	time	of	diagnosis	
do	 appear	 to	 be	 different	 relative	 to	 their	 SES-CD	 score,	 but	 the	 combined	 effects	 of	 EEN	 and	
mucosal	healing	appear	to	produce	a	similar	alteration	in	their	MAM	profiles.								
	
	
Figure	6.2.	Taxa	–Phylum	plots	of	microbiome	from	mucosal	biopsies	including	all	index	cases	and	
control	
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Figure	 6.3.	 PCoA	 plot	 showing	 bacterial	 community	 distances	 between	 samples	 based	 on	 site	 of	
biopsy	
	
		
	
	
	
	
	
	
Pt 02, 05, 04,18,11,22 
Diagnosis =SES-CD~ (15-30) 
Pt 01 Diagnosis SES-CD score 4  
Pt 07 Diagnosis SES ~ 11 
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Specific	MAM	changes	after	EEN	intervention		
The	MAM	profiles	 following	 EEN	 demonstrated	 significant	 increase	 in	 the	 relative	 abundance	 of	
OTUs	assigned	to	Genus	Dorea	 (p=0.006)	and	decrease	 in	relative	abundance	of	Faecalibacterium	
spp.	(p=0.003)	(Figure	6.4).	Groups	were	subdivided	into	those	with	complete	MH	and	incomplete	
MH	to	further	characterise	specific	microbial	signatures	associated	with	complete	MH.	
Greater	increase	in	Dorea	species	was	evident	in	those	with	complete	MH	although	not	statistically	
significant	 (p=0.05),	while	 relative	abundance	of	Faecalibacterium	 significantly	 reduced	after	 EEN	
intervention.	(Table	6.3)	
	
	
Figure	6.4.	Relative	abundance	of	Dorea	and	Faecalibacterium	before	(V1)	and	after	(V2)	induction	
course	of	EEN	
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Table	6.3	Mean	change	in	relative	abundance	of	Dorea	and	Faecalibacterium	Spp.	Before	(V1)	and	
after	EEN	(V2)	in	those	with	complete	vs.	incomplete	MH		
	
Change	in	relative	abundance		 Mucosal	Healing	 Incomplete	Mucosal	Healing	
Dorea	Spp.		
Mean	 Change	 from	 V1	 to	 V2	 (p	
value)	
-0.04	(p=0.05)	 -0.02(p=0.09)	
Faecalibacterium	Spp.	
Mean	 Change	 from	 V1	 to	 V2	 (p	
Value)	
0.05(p=0.04)	 0.03(p=0.02)	
	
	
Discussion	
The	 changes	 in	 the	 MAM	 in	 response	 to	 EEN	 therapy,	 and	 their	 relationships	 with	 endoscopic	
disease	 activity	 are	 crucial	 for	 understanding	 EEN	 mechanism	 of	 action.	 In	 this	 novel	 study	 of	
modest	sample	size	we	explored	changes	in	MAM	following	EEN	in	children	with	CD.	Employing	16S	
rRNA	 gene	 sequencing,	 we	 confirmed	 an	 overall	 reduction	 in	 MAM	 diversity	 following	 EEN.	
Previous	 studies	 indicated	 reduction	 in	 stool	 microbial	 diversity	 post	 EEN	 to	 be	 a	 crucial	 step	
associated	with	 clinical	 remission	 but	 our	 study	 is	 the	 first	 to	 document	 significant	 reduction	 in	
mucosal	microbial	diversity	to	be	associated	with	complete	mucosal	healing	(p=0.003).			
	A	significant	increase	in	the	relative	abundance	of	Lachnospiraceae	family,	particularly	Dorea	genus	
and	 reduction	 in	 the	 relative	 abundance	 of	 Faecalibacterium	 community	 were	 observed.	 These	
findings	 are	 given	 additional	 relevance	 by	 a	 recent	 paediatric	 study	 exploring	 longitudinal	 stool	
microbiome	 changes	 in	 CD	 that	 demonstrated	 lower	 levels	 of	 Lachnospiraceae	 to	 be	 associated	
with	absence	of	mucosal	healing	(non-responders)	to	Immunomodulators	and	biologics	(206).	
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Whether	 increased	 abundance	 of	Dorea	 in	 patients	 following	 EEN	 is	 a	 reflection	 of	 its	 sustained	
growth	during	period	of	nutritional	starvation	or	a	consequence	of	reducing	inflammation	requires	
further	 studies.	 In	 a	 recent	 study	 exploring	MAM	 in	 20	 adults	 undergoing	 Ileocolonic	 resection,	
Mondot	et	al.	observed	a	fourfold	increase	of	Lachnospiraceae	taxa	following	Ileocolonic	resection	
(ICR),	more	specifically	increased	proportion	of	Dorea	longicatena	and	Bacteroides	plebeius	in	those	
maintaining	 endoscopic	 remission	 post-ICR	 (207).	 It	 is	 also	 possible	 that	 key	 microbiome	 shifts	
following	EEN	are	caused	by	alteration	in	the	nutritional	ecology	of	the	large	bowel,	which	favours	
host	 driven	 nutrient	 sources,	 albeit	 at	 lesser	 amounts	 than	 encountered	 with	 liberalised	 diet.		
Enhanced	growth	of	Dorea	during	periods	of	nutritional	starvation	could	be	related	to	its	inherent	
ability	to	thrive	on	host	derived	nutrients	(mucins	and	proteoglycans).	
Faecalibacterium	spp.	are	now	widely	recognized	for	their	“anti-inflammatory”	properties	and	their	
persistence	 and	 recovery	 in	 the	 gut	 is	 associated	 with	 improved	 health	 outcomes	 in	 adult	 CD	
patients	 via	 prolonged	 remission.	 (198,199)	 In	 contrast,	 several	 studies	 have	 challenged	 the	
presumptive	protective	role	of	Faecalibacterium	prausnitzi,	with	greater	abundance	 in	those	with	
active	 CD	 at	 diagnosis	 compared	 to	 healthy	 controls	 (2087-209)	 and	 a	 significant	 reduction	 of	
Faecalibacterium	spp.	post	EEN	in	those	with	greater	remission	(14).		
As	such,	reduction	in	mucosal	abundance	of	Faecalibacterium	spp.	following	EEN	in	our	study	are	in	
agreement	with	previous	 studies.	 (14)	 	Our	data	again	 suggests	 that	Faecalibacterium	 spp.	while	
considered	beneficial,	may	not	be	required	for	mucosal	healing	as	part	of	the	mechanisms	driven	
by	 EEN	 induction	 therapy.	 (208)	 In	 that	 context,	 their	 role	 may	 be	 compensated	 for	 by	 other	
members	of	the	community,	as	suggested	by	the	 increased	abundance	of	Dorea-affiliated	species	
on	the	gut	mucosa,	which	is	also	now	identified	as	a	key	bacterium	affecting	prolonged	remission	
(207).		
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Whether	 reduction	 in	 bacterial	 diversity	 following	 EEN	 is	 a	 cause	 or	 consequence	 of	 mucosal	
healing	 needs	 further	 elucidation.	 It	 is	 plausible	 that	 a	 significant	 reduction	 in	 bacterial	 diversity	
during	 period	 of	 EEN,	 particularly	 in	 those	 with	 complete	 mucosal	 healing	 reflects	 a	 new	
equilibrium	state	between	the	MAM,	the	environment	and	the	host.	
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Chapter	7	
	
	
Conclusion	and	future	directions:	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
163 
 
In	this	chapter,	key	themes	are	explored	and	thesis	findings	related	to	recently	published	research.	
Additionally,	the	limitations	of	the	findings	are	discussed	to	provide	perspective	for	future	research.	
Several	key	areas	related	to	Exclusive	Enteral	Nutrition	(EEN)	use	in	Paediatric	CD	are	evaluated.		
Chapter	1	Introduced	the	epidemiology	and	key	differences	between	Paediatric	vs.	Adult	Onset	CD.	
A	detailed	 literature	 review	was	undertaken,	exploring	efficacy	of	EEN	 therapy	with	emphasis	on	
importance	of	attaining	early	mucosal	healing,	identifying	gaps	in	the	literature	and	refining	study	
aims.		As	significant	advances	have	been	made	in	this	field	of	Paediatric	CD	over	the	last	four	years,	
new	emerging	evidence	in	the	field	of	CD	has	been	summarised.		
		
Inflammatory	bowel	disease	is	emerging	as	a	global	disease	and	early	life	exposures	play	a	major	
role	in	causation	and	perpetuation	of	CD	
	
Epidemiological	 trends	 suggest	 IBD	 is	 an	emerging	global	disease	with	 rising	prevalence	 in	newly	
industrialised	 nations.	 A	 recent	 systematic	 review	 suggests	 the	 incidence	 of	 IBD	 in	 newly	
industrialised	 nations	 such	 as	 Asia,	 Africa	 and	 South	 America	 is	 increasing	 while	 the	 prevalence	
remains	static	in	Europe	and	North	America	(211).	Rates	of	IBD	in	immigrant	populations	have	also	
increased	 dramatically,	 as	 reported	 by	 a	 recent	 Canadian	 health	 administration	 study	 (212).	
Another	concerning	 trend	 is	 increase	 in	early	age	of	 IBD	onset	with	an	estimated	annual	percent	
increase	by	7.2%.	These	observations	have	been	noted	in	both	Scottish	and	Canadian	cohorts	again	
implicating	a	greater	role	of	early	life	exposures	and	environmental	factors	in	the	pathogenesis	of	
IBD	(213).	
The	preventative	role	of	early	life	positive	exposures	to	the	development	of	IBD	were	explored	in	a	
recent	 case	 control	 study	 of	 incident	 cases	 of	 IBD	 and	 matched	 controls	 from	 the	 Asia	 Pacific	
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region.	 Ng	 et	 al.	 reported	 a	marked	 protective	 effect	 of	 breast	 feeding	 for	 12	months	 (adjusted	
Odds	 ratio	 0.10)	 and	 a	 greater	 risk	 of	 developing	 IBD	with	westernised	diet	 (increased	 juice	 and	
cereal	 intake)	 (214).	 A	 Canadian	 population	 based	 birth	 cohort	 study	 also	 reported	 a	 strong	
protective	effect	of	rural	residency	during	early	childhood	years,	with	a	lower	incident	rate	ratio	of	
0.58	(0-10	years)	and	0.72	(10-17	years)	(215).	A	strong	association	was	also	seen	between	early	life	
exposures	 and	 a	 complicated	 clinical	 course	 of	 Crohn’s	 disease	 in	 a	 recent	 large	 paediatric	
longitudinal	cohort	study.	Breast	feeding	was	protective	and	maternal	smoking	was	associated	with	
risk	 of	 complicated	 clinical	 course	 (216).	 These	 epidemiological	 trends	 strongly	 support	 the	
contribution	of	 lifestyle	 related	 factors	 to	 the	risk	of	developing	and	the	clinical	course	of	 IBD,	 in	
particular	of	Crohn’s	disease	(which	is	what	your	thesis	is	on).		
	
Dietary	 factors	 are	 closely	 linked	 with	 intestinal	 epithelial	 and	 immune	 biology	 and	 may	
contribute	to	pathophysiology	of	IBD	
	
Although	 diet	 is	 the	 most	 frequently	 reported	 life	 style	 risk	 factor	 associated	 with	 IBD	 flare	 by	
patients,	 there	 are	 limited	 prospective	 studies	 examining	 the	 role	 of	 diet	 in	 contributing	 to	 or	
perpetuating	inflammation	in	IBD	(26).	Prospective	lifestyle	and	dietary	risk	cohort	studies	suggests	
a	preventative	role	of	 fibre	 intake	from	fruits,	vegetables	and	an	adverse	association	with	animal	
proteins	 and	 trans-unsaturated	 fats	 (24-25).	 More	 recently,	 studies	 have	 linked	 specific	 dietary	
factors	 with	 intestinal	 inflammation.	 Animal	 and	 in-vitro	 human	 intestinal	 ecosystem	 studies	
provide	first	hand	evidence	of	epithelial	barrier	dysfunction,	aberrant	mucosal	 immune	responses	
and	 unhealthy	 microbiota	 from	 secondary	 to	 emulsifiers	 and	 saturated	 fats	 exposures	 (28,29).	
These	 findings	 have	 greatly	 contributed	 to	 our	 understanding	 of	 role	 of	 diet	 in	 inflammation,	
establishing	association	between	dietary	factors	and	development	and	course	of	IBD.	
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A	recent	comprehensive	review	evaluated	role	of	diet	in	pathogenesis,	prevention	and	treatment	of	
IBD.	 The	 authors	 link	 evidence	 of	 dietary	 factors	 such	 as	 high	 sugar,	 high	 fat,	 low	 fibre	 diet	 on	
mucus	layer,	intestinal	barrier	function,	bacterial	clearance	and	regulatory-T	cells	in	animal	models	
and	cell	lines	(217).	
Linking	 dietary	 factors	 with	 causation	 and	 perpetuation	 of	 IBD	 is	 highly	 intricate,	 as	 it	 involves	
studying	a	 complex	 interplay	between	diet,	host,	 genetics	and	microbiome.	Using	animal	models	
and	cells	lines	to	understand	IBD	pathophysiology	has	its	limitations	as	results	from	animal	studies	
cannot	always	be	extrapolated	to	human	intestinal	biology.	
Some	of	these	limitations	can	be	overcome	by	recent	advances	in	stem	cell	technology	permitting	
culture	of	human	intestinal	organoid	(HIO)	or	“mini-guts”.	 	HIO	have	been	utilised	in	many	recent	
studies	 as	 they	 can	 retain	 genetic	 and	 biologic	 characteristics	 of	 human	 intestine.	 There	 are	
limitations	 of	 HIO;	 they	 are	 monolayer	 of	 epithelial	 and	 mesenchymal	 cells	 and	 lack	 the	 vital	
context	of	immune	cells	and	the	neuronal	enteric	system	(218).	Incorporating	immune	and	enteric	
nervous	 system	 will	 pave	 way	 for	 studying	 interaction	 between	 host,	 dietary	 factors	 and	
microbiome	in	HIO	in	future.	(219).	
	
Predictors	of	disabling	CD	in	children		
A	 disabling	 CD	 can	 be	 defined	 as	 one	 that	 is	 associated	 with	 frequent	 relapse,	 development	 of	
penetrating	and/or	structuring	or	perianal	disease	and	need	for	surgery.	Data	from	EPIMAD	registry	
suggest	that	clinical	predictors	at	diagnosis	are	insufficient	in	predicting	disabling	CD	in	children	but	
presence	 of	 Height	 Z	 score	 <	 2	 SD	 and	 complicated	 phenotype	 at	 diagnosis	 are	 poor	 outcome	
predictors	(220).	There	are	two	recent	 large	studies	examining	factors	associated	with	a	disabling	
course	of	CD.	
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A	 prospective	 multicentre	 paediatric	 study	 recently	 examined	 clinical,	 serological,	 genetic	 and	
microbiome	 factors	 associated	 with	 complicated	 CD,	 defined	 as	 change	 from	 inflammatory	
phenotype	 to	 structuring	 and	 fistulising	 CD.	 At	 a	 median	 follow	 up	 of	 3	 years,	 78/913(8.5%)	
developed	 complicated	 disease.	 African	 American	 race,	 ASCA	 IgA	 and	 C	 Bir	 1	 serology	 was	
associated	with	nearly	three	times	higher	risk	of	penetrating	disease	(HR	3.0).	Stricturing	phenotype	
was	associated	with	ASCA	 IgA,	C	Bir	1	serology	and	 Ileum	extra	cellular	matrix	genetic	signatures	
(221).		
In	 another	 recent	 large	 study	 of	 1442	 children	 with	 CD,	 clinical	 factors	 associated	 with	 risk	 of	
intestinal	resection	were	examined.	Authors	reported	a	25%	actuarial	risk	of	intestinal	resection	at	
10	 years	 and	 complicating	 phenotype	 at	 diagnosis	 as	 the	 only	 clinical	 predictor	 for	 surgical	
resection	(222).	
Results	 from	 population	 based	 cohort	 studies	 remind	 us	 that	 treatment	 algorithms	 based	 on	
symptom	 severity	 alone	 are	 insufficient	 and	 a	 greater	 emphasis	 should	 be	 given	 to	 addressing	
factors	strongly	associated	with	disabling	disease	course.		
	
Chapter	 2,	 investigated	 the	 value	 of	 choosing	 EEN	 vs.	 CS	 induction	 therapy	 at	 diagnosis	 in	 the	
setting	 of	 routine	 early,	 dose	 optimised	 TP	 use	 on	 clinical	 outcomes	 over	 the	 first	 2	 years.	 	We	
confirmed	benefits	of	 EEN	with	 superiority	over	CS	 in	 reducing	 linear	 growth	 failure	 (7%	vs.26%,	
p=0.002),	steroid	dependency	(7%	vs.	43%,	p=0.002)	and	improving	sustained	response	to	IFX	(86%	
vs.	 67%,	 p=0.02).	 Choosing	 EEN	 over	 CS	 did	 not	 alter	 early	 surgical	 outcomes	 with	 comparable	
intestinal	 resection	 rates	 (6.6%	 vs.	 7.6%)	 in	 those	 with	 inflammatory	 phenotypes	 at	 diagnosis.	
These	 results	 support	 the	 initial	 choice	 of	 EEN	 over	 CS	 induction	 therapy	 in	 shaping	 future	
outcomes	of	Paediatric	CD	during	the	first	two	years	of	diagnosis.		
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There	 are	 several	 limitations	 to	 our	 study,	 including	 its	 retrospective	 design,	 bias	 of	 changing	
treatment	 paradigms	 with	 time	 (increase	 in	 use	 of	 anti-TNF’s)	 and	 lack	 of	 propensity	 score	
matching,	 a	 more	 accurate	 measure	 of	 intervention	 in	 observational	 cohort	 studies.	 However,	
benefits	of	choosing	EEN	over	CS	as	a	first	 induction	agent	were	apparent	 in	our	study,	despite	a	
higher	baseline	clinical	and	endoscopic	disease	scores	in	those	treated	with	EEN.		
There	 is	growing	evidence	confirming	superiority	of	EEN	over	CS	as	an	 induction	 therapy	beyond	
the	 first	 year.	 A	 recent	 publication	 from	 the	Halifax	 group,	 using	 propensity	matching	 compared	
outcomes	over	2,4	and	6	years,	in	those	commencing	EEN	(n=76)	vs	CS	(n=35).	Covariates,	including	
sex,	age,	duration,	behaviour	and	perianal	disease	were	matches	between	cohorts	treated	with	EEN	
vs.	CS.	They	demonstrated	superior	short	term	clinical	remission	(87%	vs.	58%,	p=0.01)	and	a	trend	
towards	a	 lower	anti-TNF’s	use	at	2	years	 (24%	vs.	40%).	Despite	a	higher	proportion	with	 linear	
growth	 failure	at	diagnosis	 in	 the	EEN	vs.	CS	group	(17%	vs.	3%),	a	better	 linear	growth	recovery	
was	reported	at	1	year	in	the	EEN	compared	to	CS	group.	Also	reported	was	a	long-term	reduction	
in	need	for	CS	in	those	initially	treated	with	EEN,	although	this	is	likely	biased	by	a	decision	to	use	
EEN	again	at	relapse	instead	of	CS	driven	by	patient/family	preference	(223).	
The	best	evidence	to	support	choice	of	EEN	over	CS	as	a	first	line	therapy	comes	from	a	recent	large	
prospective	GROWTH	 cohort	 study,	 outcomes	 over	 2	 years	were	 compared	 between	 EEN	 vs.	 CS	
induction	therapy.	Higher	short	term	clinical	remission	rates	in	those	with	mild-moderate	CD	and	a	
trend	towards	better	linear	growth	recovery	was	seen	in	those	treated	with	EEN	over	CS	(224).	
Disease	 relapse,	 complication	 rates	 (GROWTH	CD)	were	similar	 to	previous	 reports,	 regardless	of	
first	use	of	EEN	or	CS	(224).	
A	 recent	 systematic	 review	 by	 Swaminathan	 et	 al	 compared	 EEN	 vs.	 CS	 induction	 therapy	 for	
Paediatric	CD.	They	included	451	children	reporting	EEN	to	be	as	effective	as	CS	for	inducing	clinical	
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remission	in	new	or	relapsed	CD	and	also	demonstrated	significant	superior	Endoscopic	remission	
rates	for	EEN	vs	CS	(OR	4.5,	95%	CI	1.6-12)	(225).	
Relapse	rates	remain	very	high	when	patients	return	to	normal	diet,	implicating	a	role	for	antigenic	
or	 pro-inflammatory	 factors	 in	 the	 normal	 diet.	 There	 are	 several	 observations	 that	 support	 this	
hypothesis.	Firstly,	 the	clinical	efficacy	of	EN	 in	CD	can	be	related	to	volume	of	EN	use	or	rather,	
amount	of	normal	diet	consumption.	Superior	clinical	remission	rates	are	reported	in	those	taking	
80-100%	total	caloric	intake	through	polymeric	diet,	compared	to	50%	(226-227).			
These	 studies	 provide	 first	 hand	 evidence	 that	 effect	 of	 EEN	 on	 CD	 activity	 may	 be	 related	 to	
exclusion	 of	 normal	 table	 foods.	 This	 has	 led	 to	 searches	 for	more	 palatable	 normal	 food	 based	
therapeutic	 diets	 in	 CD	 which	 can	 both	 induce	 and	 maintain	 remission.	 There	 are	 many	 recent	
publications	 focussing	 on	 this	 area.	 A	 summary	 of	 recent	 dietary	 intervention	 studies	 report	
improvement	 in	 CD	 related	 symptoms,	 and	 in	 some	 cases	 biomarkers,	 but	 they	 lack	 endoscopic	
defined	outcomes	(Table	3)228-235	
The	 Crohn’s	 disease	 Exclusion	 diet	 (CDED)	 is	 one	 such	 dietary	 approach	 that	 involves	 excluding	
dietary	 factors	 previously	 associated	 with	 disruption	 of	 mucus	 layer	 (gluten,	 dairy,	 animal	 fat,	
processed	diet,	maltodextrin,	 xanthum	gum	and	emulsifiers),	epithelial	 integrity	and	dysbiosis.	 In	
this	dietary	intervention	study,	children	(n=34)	and	young	adults	(n=13)	were	allowed	to	have	50%	
polymeric	formula	along	with	the	elimination	diet.		PCDAI	and	CRP	remission	was	reported	in	70%	
by	six	weeks	(228).	 	 	A	subsequent	study	from	the	same	group	reported	efficacy	of	CDED	in	more	
refractory	 cohort	 of	 patients	with	 loss	 of	 response	 to	 Infliximab	 despite	 dose	 escalation	 (17/21,	
70%)	 and	 combination	 therapy	 (18/21,	 80%)	 with	 immune-modulators	 and	 previous	 intestinal	
resection	 (7/21,	 30%).	 Clinical	 remission	 was	 reported	 in	 13/21	 (65%)	 and	 CRP	 normalisation	 in	
9/21	 (40%).	 This	 report	 is	 the	 first	 to	 demonstrate	 the	 impact	 of	 dietary	 therapy	 in	 a	medically	
refractory	group	with	CD	and	that	CDED	alone	without	polymeric	formula	may	be	effective	in	some	
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patients	(229).		
A	diet	similar	in	composition	to	EEN	(CD-TREAT)	–	induces	similar	changes	in	microbiome		
A	solid	food	based	diet	was	designed	by	Scottish	research	group	to	replicate	the	composition	and	
nutrients	of	EEN	with	a	hypothesis	that	macronutrient	and	micronutrient	composition	(fiber,	fatty	
acids	and	lactose	and	gluten	free)	may	be	critical	for	EEN’s	efficacy	in	CD.	In	this	Pilot	study,	healthy	
participants	were	randomised	to	receive	EEN	or	CD-Treat	diet	and	faecal	samples	were	analysed	for	
gut	microbial	metabolic	changes.	 	A	similar	reduction	in	faecal	butyric	and	caproic,	 increase	in	pH	
and	 sulphide	 were	 seen	 in	 those	 randomised	 to	 receive	 CD-Treat	 and	 EEN	 diet.	 Further	 results	
including	clinical	&	biomarker	remission	rates	(CRP	and	Faecal	calprotectin)	in	Children	and	adults	
with	CD	on	EEN	vs.	CD-TREAT	are	awaited	(230).	
Directed	elimination	diet	–personalised	dietary	solution	to	CD	
A	personalised	approach,	with	a	dietary	prescription	based	on	serum	reactivity	to	IgG4	based	food	
antigens	 has	 been	 assessed.	 Twenty-nine	 adults	 completed	 IgG4	 targeted	 exclusion	 diet	 with	
symptomatic	 improvement	 in	 90	%(26/29)	 and	mean	 drop	 in	 ESR	 (231).	 Authors	 from	 the	 same	
group	performed	a	sham	controlled	trial	using	IgG4	as	an	adjunct	diet	in	76	adults	with	CD.	Patients	
either	excluded	4	foods	with	high	IgG4	titre	(true	diet)	vs.	4	foods	with	low	titre	(sham	diet)	for	four	
weeks	with	some	improvement	in	CDAI	and	quality	of	life	reported.	Milk,	beef,	pork	and	egg	were	
the	commonest	foods	excluded	(232)	
A	recent	study	explored	the	utility	of	IgG4	based	diet	as	a	maintenance	remission	strategy,	after	a	
course	 of	 EEN	 in	 Chinese	 adults	with	 CD.	 Enhanced	 immune	 responses	 to	 rice,	 tomato,	 egg	 and	
maize	was	specifically	seen	 in	CD	patients	with	higher	remission	rates	 in	controls	with	no	dietary	
exclusion	(25%)	vs.	(12.5%)	in	those	targeted	to	receive	the	IgG4	based	exclusion	diet	(233).	
170 
 
Specific	Carbohydrate	diet	
Specific	carbohydrate	diet	 is	 another	 elimination	 diet	 excluding	 simple	 carbohydrates,	 starch,	
grains.	 	 In	 a	 small	 prospective	 study	of	9	 children,	 clinical	 and	mucosal	 improvement	on	Capsule	
Endoscopy	was	seen	at	12	and	52	weeks	(234.Another	Paediatric	study	including	20	children	with	
CD,	clinical	 improvement	was	observed	but	a	more	recent	study	from	same	group	reports	 lack	of	
mucosal	healing,	a	key	determinant	of	long	term	outcomes	(235-236).	
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Table	7.1	Therapeutic	diets	in	Inflammatory	Bowel	Disease	
	
	
	
	
	
	
	
	
	
IBD	type	/DIET MAIN	COMPONENTS RESULTS Author
Crohn’s	Disease
CD-TREAT
Cross	over	RCT	adults
Ordinary	food	based	diet	
similar	composition	to EEN	
vs.	EEN
Increase	stool	pH	,	increase	sulphide
and	harder	stool	consistency and	
bacterial	community	shifts	similar	
between	CD-TREAT	and	EEN
Svolos,	Abstract	ECCO	2016(230)
Crohn’s	disease
CDED+	Partial EN
in	children/adults
CDED+	Partial	EN	
After	failure	of	anti-TNF
Exclude
Gluten	,Dairy
Animal	Fat	,Processed	meat
Emulsifiers	, Canned food
Remission	
Clinical 33/47(70%)	,	
CRP	remission=21/20	(70%
Remission	wk 6	=HBI	<	5,	13/21	
(62%)
Sigall-Boneh R,	Inflamm Bowel	
Dis.2014	(228)
Sigall-Boneh R	JCC 2017	(229)
IBD
SCD	in	children
Exclude
Processed	sugar	
Canned	vegetables	
All	grains	
Potatoes,	yams,	starchy	
foods	,Chickpeas,	bean	
sprouts,	and	soybeans	
Canned/processed	meats	
,All	milk,	high-lactose	
cheeses,	commercial	yogurt	
Clinical improvement	7	CD
26	(20	CD,	6UC)	–symptoms	
improvement
1/7	(Ileo-colonic mucosal	healing)
Cohen S,JOGN	2014	(234)
Obih ,Nutrition	2016	(235)
Wahbeh G	,JPGN,2017(236)
Crohn’s	disease
EEN	followed	by	Food	
antigen	based	diet	
exclusion	for	disease
remission
A	significantly	enhanced	
immune	response	to	rice,	
tomato,	egg	white/egg	yolk	
and	maize	was	observed	in	
CD	patients
CD	relapsed	in	12.5%	of	the	
exclusion	group	vs.	25%	of	the	
control.
Wang G	,	
Clinics	and	research	in	hepatology	
and	gastroenterology	Nov	2017	
(233)
Low	FODMAP	diet	in	IBD Fermentable sugars Improves	functional	bowel	
symptoms in	patient	with	IBD
Prince ,	Inflamm Bowel	2016	(237)
172 
 
Efficacy	of	EEN	in	situations	where	biologics	may	not	be	considered	useful	or	are	contraindicated	
The	role	of	exclusive	enteral	diet	as	a	primary	therapy	in	active	CD	was	first	described	four	decades	
ago	with	studies	reporting	enteric	fistula	closure,	clinical	remission	and	reduced	surgical	resection	
in	medically	refractory	adults	with	CD	(75-76).	Several	recent	reports	suggest	a	positive	role	of	EEN	
in	complicated	Crohn’s	disease,	where	biologics	may	be	contraindicated	or	not	considered	useful.	
Role	of	EEN	in	inflammatory	CD	related	stricture	was	reported	in	an	open	study	of	65	adults.	48/65	
completed	12	weeks	EEN	 therapy	with	65%	clinical	 remission	and	54%	radiologic	 remission	 rates	
(238).	
In	another	adult	 study	 including	41	adults	with	entero-cutaneous	 fistula/internal	penetrating	and	
structuring	 CD,	 75%	 of	 patients	 experienced	 fistula	 closure	 and	 60%	 of	 those	 with	 stricturing	
phenotype	observed	clinical	remission	(239).	
A	 recent	 English	 study	 also	 reported	 the	 role	 of	 EEN	 to	 optimise	 surgical	 outcomes	 for	 adult	
patients	 with	 complicated	 CD	 led	 to	 25%	 avoiding	 surgery	 (13/51)	 and	 a	 nine-fold	 reduction	 in	
serious	post-operative	complications	in	those	completing	a	four-week	course	of	pre-operative	EEN	
(240).	
Conclusion:	There	is	growing	interest	in	therapeutic	diets	for	management	of	CD.		While	these	diets	
are	attractive	with	 likely	better	adherence	than	EEN,	good	endoscopic	outcomes	are	missing.	We	
need	well	designed	large	dietary	clinical	trials	with	blinded	central	endoscopic	reading	to	confirm	if	
elimination	diets	can	 induce	mucosal	healing.	Once	confirmed,	dietary	and	medical	 therapies	can	
be	combined	to	achieve	best	outcomes	in	CD.	
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Chapter	 3	 describes	 early	 clinical,	 biochemical,	 mucosal	 and	 transmural	 remission	 in	 newly	
diagnosed	children	with	CD	following	a	course	of	exclusive	enteral	nutrition	in	the	setting	of	early	
thiopurine	(TP)	use	and	relates	early	endoscopic	recovery	to	outcomes	at	1	year.	15/24	(58%)	had	
early	good	endoscopic	response	(11	complete,	4	near	complete	MH)	and	3/14	(21	%)	had	complete	
transmural	remission	of	Ileal	CD	(MRE-CD:	0–1).	Early	good	endoscopic	response	(SES-CD	0-3)	was	
associated	 with	 improved	 outcomes	 at	 1	 year.	 Good	 vs.	 poor	 early	 endoscopic	 response	 was	
associated	with	reduction	in	endoscopic	confirmed	relapse	(53%	vs.	100	%,	p	=	0.02),	anti-TNF	use	
(33%	vs.	88	%,	p	=	0.01)	and	hospitalisation	(40	vs.	88	%)	at	1	year.	This	study	is	first	to	evaluate	the	
impact	of	 EEN	 induced	early	mucosal	healing	on	 subsequent	medium	 term	outcomes	 in	 children	
receiving	maintenance	therapy	with	thiopurines.	
.			
Previous	trials	with	EEN	used	variable	definitions	of	mucosal	healing,	but	we	chose	a	more	rigorous,	
simpler	binary	endpoint,	that	of	complete	mucosal	healing	(complete	disappearance	of	Ileocolonic	
ulceration)	to	provide	compelling	evidence	of	efficacy.	Borrelli	et	al.	reported	endoscopic	remission	
rates	of	74%	at	10	weeks	compared	to	40%	(11/24,	complete	MH,	SES-CD=0)	and	(15/24,58%	good	
endoscopic	 response	 (SES-CD	 0-3).11	 We	 arbitrarily	 choose	 a	 definition	 of	 SES	 0-3	 as	 good	
endoscopic	response,	this	cut	off	was	chosen	as	practically	even	apthous	ulcers	in	any	segment	of	
bowel	mean	a	minimum	SES-CD	score	of	3.	Lack	of	centralised	endoscopic	reading	 in	our	study	is	
another	limitation,	as	this	mitigates	the	risk	of	local	investigator	bias	(241).	
Despite	 limitations	 of	 design	 and	 size,	 our	 data	 suggest	 that	 early	 MH	 is	 more	 important	 than	
baseline	endoscopic	disease	severity	as	better	1	year	outcomes	were	seen	in	those	with	early	good	
endoscopic	 response,	 it	 also	 raises	 number	 of	 questions	 such	 as	 what	 is	 the	 minimum	 level	 of	
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endoscopic	healing	required	to	achieve	better	outcomes	beyond	the	first	year?	Does	completeness	
of	healing	leads	to	a	more	durable	remission	rates	
A	 subset	 of	 patients	 underwent	MR	enterography	 at	 diagnosis	 and	 after	 EEN	 (16/26,60%),	 of	 14	
with	active	 ileal	Crohn’s	disease	at	diagnosis,	3/14	 (21%)	achieved	transmural	healing(TMH).	 	We	
did	not	sub-analyse	our	EEN	induced	TMH	due	to	small	numbers.	However,	only	a	small	proportion	
of	 children	 achieved	 combined	 transmural	 (TMH)	 and	mucosal	 healing	 2/14(15%),	 similar	 to	 low	
rates	reported	by	the	Image	kids	study	(21/151,	14%)	(242).	
The	 Image	 kids	 study	 also	 reported	 high	 rates	 of	 TM	 healing,	 despite	 active	mucosal	 disease	 in	
83/151(55%).	 This	 observation	 is	 in	 contrast	 to	 our	 observation,	 as	 we	 observed	 a	much	 higher	
proportion	 of	 children	 with	 TM	 disease	 activity	 8/14(57%)	 on	 MRE,	 despite	 good	 endoscopic	
response	(SES-CD=0-3).	
This	could	be	explained	by	the	follow	up	MRE	after	EEN	being	performed	too	early,	within	a	median	
period	8.5	weeks	(IQR,	7-12	weeks)	of	diagnosis.	 It	 is	plausible	that	 lack	of	TM	healing	in	our	EEN	
cohort,	despite	endoscopic	remission,	may	represent	 lack	of	deeper	healing	that	requires	greater	
time.		This	was	also	the	conclusion	from	a	study	showing	50%	of	patients	with	normal	ileum	on	Ileo-
colonoscopy	after	therapy,	have	evidence	of	active	disease	in	terminal	or	distal	ileum	on	MRE	(243).	
Finally,	 the	 objective	 of	 the	 Image-Kids	 study	was	 not	 to	 assess	MRE	 response	 to	 a	 therapeutic	
intervention	and	so	disease	duration,	time	to	repeat	MRE	was	heterogeneous	(242).			
To	conclude,	emerging	data	suggest	 that	achieving	TM	healing	 is	associated	with	 favourable	 long	
term	outcomes,	but	it	is	a	more	stringent	target	and	takes	longer	time	compared	to	MH	(243).	
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Chapter	 4,	 demonstrated	 the	 individual	 reliability	 of	 symptom	 based	 scores	 (Paediatric	 Crohn’s	
disease	 activity,	 PCDAI),	 biochemistry	 (CRP)	 and	 stool	 biomarker	 (Faecal	 Calprotectin,	 FC)	 in	
predicting	 endoscopic	 disease	 activity	 (SES-CD)	 in	 new	 diagnosis	 Crohn’s	 after	 induction	 therapy	
with	 EEN	or	 steroids.	We	explored	 the	 contention	 that	 control	 of	 symptoms	does	not	 equate	 to	
effective	control	of	mucosal	 inflammation.	We	demonstrated	that	CRP	and	FC	were	more	reliable	
than	symptom	scores	but	not	sufficiently	accurate	for	predicting	mucosal	disease	recovery	to	serve	
as	 sole	 primary	 endpoints	 for	 treatment	 of	 Crohn’s	 disease.	 We	 confirmed	 that	 the	 patient	
reported	 symptom	 score	 (PCDAI)	 is	 the	 least	 reliable,	 blood	 test	 (CRP)	 had	moderate	 utility	 and	
stool	biomarkers	(FC)	had	the	best	individual	utility	in	predicting	degree	of	mucosal	inflammation.		
A	 recent	 Canadian	 prospective	 cohort	 study	 reproduced	 this	 study	 finding	 and	 confirmed	 poor	
correlation	of	clinical	symptoms	(wPCDAI	)	with	endoscopic	disease	activity	in	children	with	newly	
diagnosed	CD	(244).	
Despite	the	limitations	of	small	size,	we	confirmed	that	of	13/24(54%)	children	with	active	ulcers	on	
follow	up	endoscopy;	80%	reported	minimal	or	no	symptoms,	40%	had	no	symptoms	with	normal	
bloods	 but	 only	 10%	 had	 normal	 faecal	 calprotectin	 (FC).	 FC	 had	 the	 best	 individual	 correlation	
(r=0.50)	but	many	with	complete	or	near	complete	mucosal	healing	had	FC	>200	µgram/gm	stool.	A	
Composite	score	combining	all	three	proxies	(PCDAI	(<10),	CRP	(<5mg/dl)	&	FC	<500	µgram)	had	an	
excellent	Negative	Likelihood	ratio	(0.2)	predicting	complete	or	near	complete	mucosal	healing.		
The	 value	 of	 surrogate	 biomarkers	 in	 predicting	 mucosal	 and	 transmural	 healing	 was	 further	
examined	 in	 a	 recent	 large	 prospective	 paediatric	 study.	 Poor	 concordance	 of	 mucosal	 and	
transmural	 disease	 was	 again	 demonstrated	 with	 11-43%	 of	 those	 with	 active	 mucosa	 and/or	
transmural	disease	reported	to	be	 in	clinical	 remission.	A	FC	cut-off	 level	of	300mg/gm	predicted	
MH	 (80%	 sensitivity	 and	 80%	 specificity)	 and	 a	 lower	 cut-off	 100mg/gm	 predicted	 combined	
mucosal	and	transmural	healing	(242).	
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A	reduction	in	FC	following	a	course	of	EEN	has	been	reported	by	multiple	studies.	A	greater	than	
50%	 drop	 in	 FC	 from	 baseline	 was	 associated	 with	 a	 73%	 sensitivity	 and	 78%	 specificity	 for	
predicting	endoscopic	remission	(SES-CD	0-3)	following	EEN	induction	therapy	in	our	cohort.	
in	a	subgroup	analysis	of	the	EEN	only	group	(n=20),	a	significant	drop	in	FC	(Mean	FC	pre	&	post	
EEN	D694,	p=0.003)	was	only	seen	in	those	achieving	endoscopic	remission.	
Two	major	limitations	of	this	study	are	bias	introduced	by	convenience	sample	selection	and	non-
availability	 of	 transmural	 healing	 data	 due	 to	 lack	 of	 paired	 MRE.	 It	 is	 therefore	 unclear	 if	
transmural	and	histological	inflammation	was	persistent	in	children	with	elevated	FC	>	200	μg/gm,	
despite	 complete	 endoscopic	 mucosal	 recovery.	 Despite	 these	 limitations,	 our	 results	 suggest	 a	
composite	 score	 using	 combination	 of	 clinical	 and	 objective	 markers	 can	 predict	 endoscopic	
healing.		
		
Chapter	 5,	 reported	 longitudinal	 outcomes	 of	 54	 newly	 diagnosed	 children	 with	 predominantly	
luminal	CD	(<16	years)	completing	EEN	induction	and	early	thiopurine	(<3	months	from	diagnosis).	
Early	 Complete	 MH	 was	 observed	 in	 18/54	 (33%),	 near	 complete	 in	 10/54(19%).	 	 Control	 of	
symptoms	 or	 improvement	 of	 serum	 biomarkers	 with	 clinical	 remission	 alone	 was	 inferior	 in	
predicting	 endoscopic	 remission.	 The	 complete	 early	 disappearance	 of	 ulcers	 (mucosal	 healing)	
after	EEN	was	associated	with	greater	sustained	remission	(SR).		
Relapse	 was	 progressively	 more	 frequent	 in	 those	 with	 active	 endoscopic	 disease	 (aED)	 vs.	
complete	MH;	26/36	(72%)	vs.	5/18(28%),	p=0.003	at	1	year,	21/24(92%)	vs.	8/16,	(50%),	p=0.008	
at	 2	 years	 and	 18/19(94%)	 vs.	 (8/16,	 (50%),	 p=0.005	 at	 3	 years.	 This	 study	 is	 also	 the	 first	 to	
prospectively	examine	the	impact	of	early	EEN	induced	mucosal	healing	on	important	real-life	long	
term	clinical	outcomes	i.e	need	for	Infliximab/CS	or	surgical	resection	in	a	well	characterised	cohort	
with	a	consistent	practice	of	diagnosing	and	management	of	CD	relapse.			
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We	also	demonstrated	that	EEN	induced	early	MH	rates	are	not	influenced	by	clinical,	endoscopic	
severity	 or	 location	 of	 disease	 at	 diagnosis,	 this	 is	 an	 important	 finding	 when	 physicians	 are	
contemplating	choice	of	EEN	vs.	CS	in	a	newly	diagnosed	child	with	CD.	
	
Figure	7.1	
	
	
	
Our	 study	 demonstrated	 that	 completeness	 of	 mucosal	 healing	 is	 vital	 in	 achieving	 durable	
remission	beyond	the	first	year.		Our	findings	are	supported	by	a	recent	adult	observational	study	
suggesting	that	a	strict	definition	of	mucosal	healing	as	(CDEIS=0)	may	be	associated	with	lower	risk	
of	relapse	and	surgical	resection	(245).	
In	another	adult	study	a	definition	of	SES≤2	was	associated	with	sustained	clinical	remission	(246).	
Our	 results	 highlight	 that	 a	 strict	 definition	 of	 mucosal	 healing	 (SES-CD=0)	 is	 hard	 end	 point	 to	
achieve.	This	was	also	demonstrated	by	a	recent	open	label	study	in	adults	with	moderate	to	severe	
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CD	 (CALM	 study),	 comparing	 a	 tight	 control	 arm	 using	 biomarkers	 vs.	 a	 conventional	 clinical	
management	 arm.	 Complete	 endoscopic	 remission	 rates	 were	 18%	 (CDEIS=0)	 compared	 to	 46%	
endoscopic	 remission	 (CDEIS	 <4)	 in	 the	 group	with	 tight	 control.	 A	 16%	 greater	 improvement	 in	
endoscopic	remission	rates	in	the	tight	control	group	(46%	vs.	30%	in	Conventional	arm)	required	a	
three	times	greater	use	of	every	week	adalimumab	(45%	EW	Adalimumab	vs.	15%	EW	Adalimumab)	
(247).	
Although	not	an	intended	outcome	of	our	study,	a	treatment	to	target	approach	was	followed	with	
the	 EEN	 cohort.	 In	 children	 experiencing	 a	 first	 relapse	 after	 EEN	 therapy,	 despite	 therapeutic	
dosing	of	conventional	immune-modulators,	treatment	was	escalated	to	biologics	either	based	on	
biomarkers	alone	or	in	combination	with	biomarkers+/-	endoscopy.		
We	did	not	escalate	treatment	in	asymptomatic	children	with	abnormal	biomarkers	or	endoscopy	
at	 the	 end	 of	 EEN	 induction	 therapy,	 all	 these	 relapsed	 over	 the	 following	 year	 leading	 to	 later	
treatment	 escalation.	 We	 observed	 a	 relatively	 high	 anti-TNF	 commencement	 rate	 in	 our	 EEN	
cohort	reaching	71%	within	a	median	follow	up	of	4	years	 (41%	combination	therapy	Anti-TNF’s+	
IM’S,	30%	Anti-TNF	monotherapy;	29%	immune-modulator	monotherapy).			
	
It’s	 time	to	embrace	a	 treat	 to	 target	approach	but	 it	 remains	unclear	 if	 therapeutic	adjustments	
based	 on	 biomarkers	 are	 superior	 to	 repeated	 endoscopy	 examination	 in	 achieving	 mucosal	
healing.	On	one	hand,	 FC	and	CRP	are	excellent	non-invasive	biomarkers	but	up	 to	20%	patients	
with	a	normal	CRP<5mg/L	and	FC<250	μg/	gm	of	stools	at	48	weeks	failed	to	achieve	MH	(CDEIS<4)	
in	 the	 CALM	 study	 (248).	 The	 other	 important	 issue	 is	 that	 escalation	 of	 therapies	 based	 on	
biomarker	alone	may	result	in	overtreatment	of	substantial	proportion	of	patients.		
Repeat	endoscopic	evaluation	 to	make	 treatment	adjustments	aiming	 for	MH	 is	 less	well	 studied	
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but	 emerging	 data	 suggest	 that	 this	 approach	 may	 be	 feasible	 and	 is	 associated	 with	 superior	
outcomes	 if	 escalation	 of	 therapy	 is	 performed	 in	 those	 failing	 to	 achieve	 MH	 (249).	 Recently	
published	 expert	 paediatric	 guidelines	 suggest	 that	 repeat	 endoscopic	 examination	 for	 MH	 is	
helpful	 but	 it	 does	 carry	 a	 risk	 associated	 with	 multiple	 general	 anaesthetics	 and	 health	 care	
burden.	Future	trials	need	to	evaluate	whether	treating	to	an	endoscopic	endpoint	is	better	than	a	
biomarker	based	approach	(250).	
Chapter	 6	 reports	 longitudinal	mucosal	 associated	microbiome	 changes	 (MAM)	 at	 diagnosis	 and	
after	completion	of	EEN	(Median	7.9	weeks,	95%	CI=7.5-8.2	weeks)	from	8	treatment	naïve	children	
diagnosed	with	 CD.	 Employing	 16S	 rRNA	 gene	 sequencing,	we	 confirmed	 an	 overall	 reduction	 in	
MAM	diversity	following	EEN.	Previous	studies	indicated	reduction	in	stool	microbial	diversity	post	
EEN	 to	be	a	 crucial	 step	associated	with	 clinical	 remission	but	our	 study	 is	 the	 first	 to	document	
significant	reduction	in	mucosal	microbial	diversity	to	be	associated	with	complete	mucosal	healing	
(p=0.003).			
A	significant	increase	in	the	relative	abundance	of	Lachnospiraceae	family,	particularly	Dorea	genus	
and	reduction	in	the	relative	abundance	of	Faecalibacterium	community	were	observed	after	EEN	
therapy.	 These	 findings	 are	 interesting	 as	 a	 recent	 paediatric	 study	 exploring	 longitudinal	 stool	
microbiome	 changes	 in	 CD	 demonstrated	 lower	 levels	 of	 Lachnospiraceae	 to	 be	 associated	with	
absence	 of	 mucosal	 healing	 (non-responders)	 to	 Immunomodulators	 and	 biologics.	 Whether	
increased	 abundance	 of	 Dorea	 in	 patients	 following	 EEN	 is	 a	 reflection	 of	 its	 sustained	 growth	
during	period	of	nutritional	starvation	or	a	consequence	of	reducing	inflammation	requires	further	
studies.	
Faecalibacterium	spp.	are	now	widely	recognized	for	their	“anti-inflammatory”	properties	and	their	
persistence	in	the	gut	is	associated	with	improved	health	outcomes	in	adult	CD	patients,	our	results	
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suggest	 significant	 reduction	 in	 Faecalibacterium	 spp.	 following	 EEN	 presumably	 indicating	 that	
their	abundance	may	not	be	required	for	mucosal	healing	as	part	of	the	mechanisms	driven	by	EEN	
induction	therapy.	
There	are	several	limitations	of	our	study,	including	small	size	and	lack	of	functional	metabolomics	
analysis.	Alterations	of	the	gut	microbial	metabolic	functional	activity	on	EEN	have	been	reported	in	
recent	studies.	Reductions	have	been	observed	in	faecal	butyric	acid,	genetic	expression	of	biotin	
and	 thiamine	 biosynthetic	 pathways.	 In	 contrast	 an	 increase	 in	 stool	 pH,	 stool	 sulphides	 and	
spermidine/putrescine	 biosynthesis	 are	 documented	 (14,15).	 Dunn	 et	 al	 recently	 reported	 an	
increase	 in	 the	 functional	metagenomics	pathways	 involved	 in	 the	degradation	of	 environmental	
pollutants	 and	 xenobiotics	 and	 reduction	 in	 NOD-like	 receptor	 signalling	 in	 those	 with	 a	 poor	
clinical	response	to	EEN	(134)	
There	 are	 only	 limited	 data	 on	metabolomic	 changes	 during	 dietary	 interventions.	 	 In	 treatment	
naïve	children	with	CD,	stool	metabolic	alterations	similar	 to	 those	seen	 in	children	on	EEN	were	
observed	 on	 a	 CD-TREAT	 diet,	 an	 ordinary	 diet	 with	 a	 nutritional	 composition	 identical	 to	 EEN	
(Svolos	V	et	al.	ECCO,	March	2016).		As	we	look	to	using	more	normal,	less	restrictive	diets	than	EEN	
in	CD,	these	observations	are	encouraging	but	preliminary.	However,	a	more	objective	endpoint	of	
response	 such	as	mucosal	or	endoscopic	healing	are	 required	 to	establish	 therapeutic	efficacy	of	
dietary	 interventions.	 To	 better	 characterise	 underlying	 functional	 metabolomics	 mechanisms	
associated	with	mucosal	remission,	endoscopic	assessment	and	biopsies	should	be	obtained	before	
and	after	dietary	interventions	and	on	normal	diet.			
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Conclusion:	
Exclusive	 Enteral	 Nutrition	 (EEN)	 in	 children	 with	 Crohn’s	 disease	 (CD)	 is	 associated	 with	 early	
complete	mucosal	 healing	 (MH)	 in	up	 to	one-third	of	 children.	Completeness	of	mucosal	 healing	
following	EEN	induction	is	strongly	associated	with	improved	long-term	outcomes.	In	the	two	thirds	
of	 children	 failing	 to	 achieve	 complete	 MH	 the	 majority	 will	 suffer	 moderate	 to	 severe	 clinical	
relapse	 within	 2	 years,	 requiring	 anti-TNF,	 surgery	 or	 both	 despite	 dose	 optimised	 Immuno-
modulators.		
This	thesis	highlights	an	urgent	need	to	revise	current	treatment	paradigms	for	escalating	therapies	
targeting	mucosal	remission.		
Our	 data	 reinforces	 the	 finding	 of	 poor	 correlation	 of	 endoscopic	 measured	 inflammation	 with	
symptom	based	scores	 (PCDAI);	serum	CRP	and	stool	calprotectin	are	more	reliable.	A	composite	
score	of	normalised	PCDAI,	CRP	and	stool	calprotectin	cut-off	<500	µgram	was	the	most	reliable	for	
predicting	 endoscopic	 remission	 during	 EEN	 induction	 therapy.	 	 a	 practical	 prediction	 tool	 for	
endoscopic	 response,	 however	 further	 validation	 in	 large	 multicentre	 studies	 is	 required	 to	
establish	theirutility.		Using	combination	of	biomarkers	targets	to	make	treatment	adjustments	can	
lead	to	better	outcomes	as	demonstrated	by	the	recent	CALM	study.	Aiming	for	CRP<5	mg/L	and	FC	
<250	micogram/gm	strongly	correlated	with	endoscopic	remission	(246).	
Conflicting	results	from	the	changes	in	stool	microbiota	vs.	mucosal	microbiota	during	EEN,	and	lack	
of	 knowledge	 of	 microbiome	 signatures	 associated	 with	 endoscopic	 mucosal	 healing	 were	
examined	 in	a	 limited	cohort	of	 children	with	CD.	Our	 results	 indicate	 that	 reduction	 in	bacterial	
diversity	 following	 EEN	 is	 strongly	 associated	 with	 mucosal	 healing.	 Whether	 this	 is	 cause	 or	
consequence	of	mucosal	healing	needs	further	evaluation.		
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Faecalibacterium	spp.	are	now	widely	recognized	for	their	“anti-inflammatory”	properties	and	their	
persistence	 and	 recovery	 in	 the	 gut	 is	 associated	 with	 improved	 health	 outcomes	 in	 adult	 CD	
patients	via	prolonged	remission.	Our	results	are	in	agreement	with	two	previous	stool	microbiome	
studies	 reporting	 reduction	 in	 F.	 prausnitzii	subgroups	 studies	 on	 EEN	 (Jia	 et	 al.	 FEMS	
Microbiol.2010,	 Gerasimidis	 et	 al.	 Inflamm	 Bowel.	 Dis	 2014)	 suggesting	 Faecalibacterium	 spp.	
presence,	while	 beneficial,	may	 not	 be	 required	 for	mucosal	 healing	 as	 part	 of	 the	mechanisms	
driven	by	EEN	induction	therapy.		
We	observed	significant	increases	in	the	relative	abundance	of	Lachnospiraceae	family,	particularly	
Dorea	 genus.	While	 enhanced	 growth	 of	Dorea	 during	 periods	 of	 nutritional	 starvation	 could	 be	
related	 to	 its	 inherent	 ability	 to	 thrive	on	host	derived	nutrients	 (mucins	 and	proteoglycans)	but	
these	 findings	 may	 be	 relevant,	 as	 two	 recent	 paediatric	 studies	 exploring	 longitudinal	 stool	
microbiome	changes	in	CD	also	identify	of	Lachnospiraceae	Spp.	as	key	bacterium	associated	with	
prolonged	 remission	 (Gevers	 et	 al.	 Cell	 Host	Microbiome	 2014,	 Dunn	 et	 al.	 Inflamm	 Bowel.	 Dis	
2016).	
Nonetheless,	we	did	not	examine	the	impact	of	EEN	on	functional	activity	of	gut	microbiome	and	
future	studies	are	warranted	to	better	elucidate	both	structure-function	activity	of	the	microbiota	
in	 those	 achieving	 MH	 vs.	 active	 endoscopic	 disease.	 Lack	 of	 resources	 precluded	 our	 planned	
comprehensive	 analysis	 of	 cytokines,	mucosal	 CD25+FoxP3+	 expression	 in	 predicting	 therapeutic	
response	to	EEN.	
Future	studies	should	also	perform	 longitudinal	analysis	of	MAM	signatures	while	on	normal	diet	
associated	with	sustained	remission	vs.	those	relapsing.	Critical	information	from	MAM	signatures	
and	 metabolic	 pathways	 of	 endoscopic	 responders	 vs.	 non-responders	 will	 enhance	 our	
understanding	 of	 “pro-inflammatory	 vs.	 anti-Inflammatory	 microbiota”	 providing	 grounds	 to	
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improve	dietary	interventions	by	promoting	the	growth	of	anti-Inflammatory	gut	microbiota.			
It	 is	 time	 to	 also	 harness	 newer	 technology,	 using	 human	 intestinal	 organoid	 (HIO)	 for	 studying	
interaction	between	dietary	components	including	EEN	and	other	elimination	diets	with	intestinal	
epithelium,	to	device	best	dietary	strategies	to	maintain	remission	in	CD.	(218,	251)	
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APPENDIX	
1.	Patient	Information	Sheet	–	Adolescent	Assent	
	
Study	Title	 “Exclusive	enteral	nutrition	(EEN)	and	mucosal	healing(MH)	in	newly	diagnosed	patients	with	Crohn’s	disease	(CD)	and	
comparison	of	clinical	parameters,	biomarkers,	faecal	microbiome	between	responders	and	non-responders”	
	
Lay	Study	Title		 "Exclusive	enteral	nutrition	(EEN)	and	mucosal	healing	in	newly	diagnosed	patients	with	Crohn’s	disease"		
	
Names	of	Chief	Investigators:	
	
A/	Prof	Peter	Lewindon	 	 	 Dr	Zubin	Grover	 	 			 	A/Prof	Graham	Radford-Smith	
Department	of	Gastroenterology	 	 Department	of	Gastroenterology	 Head	IBD	Research	Group	
Royal	Children’s	Hospital,	Brisbane	 	 Royal	Children’s	Hospital	 		 H	Floor,	Queensland	Institute	Medical	Research	
Tel:	07	3636	5244			 	 	 	 Tel:	0736361909	 	 	
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We	would	like	to	invite	you	to	participate	in	a	study	to	help	us	care	for	children	with	Crohn’s	disease.		This	information	sheet	is	to	explain	why	
we	 are	 performing	 the	 study	 and	what	 is	 involved	 should	 you	wish	 to	 participate.	 	 The	 study	 has	 been	 approved	 by	 the	 Royal	 Children's	
Hospital,	Ethics	Committee.		There	is	no	obligation	to	take	part	in	this	study,	if	you	do	not	wish	to.	
Crohn's	disease	(CD)	is	a	chronic	inflammation	of	the	bowel	that	can	significantly	interfere	with	quality	of	life	and	growth.		When	diagnosed	
before	adulthood	 (25%	of	all	 cases)	 the	disease	 is	more	 severe	with	major	 long	 term	consequences.	 	More	 than	50%	of	 children	will	 have	
surgery	to	remove	damaged	bowel	within	10	years	of	diagnosis.		The	chain	of	events	leading	to	CD	is	unknown	although	an	abnormal	immune	
response	by	white	blood	cells	to	gut	bacteria	is	known	to	play	a	major	role.	The	impact	of	achieving	mucosal	(gut	lining)	healing	early	on	in	the	
course	of	CD	is	now	recognised	as	the	most	important	factor	in	determining	future	quality	of	life,	success	of	subsequent	treatments	and	risk	of	
surgery.	“Clinical	remission”	(feeling	better,	recovery	of	normal	function)	is	not	sensitive	enough	to	predict	mucosal	healing	with	over	70%	of	
patients	on	steroids	reporting	clinical	remission	having	active	damage	of	gut	lining.		Exclusive	Enteral	Nutrition	(EEN)	for	a	minimum	of	8	weeks	
is	recognised	as	not	only	safer,	but	more	effective	than	traditional	treatment	with	steroids	for	inducing	healing	of	the	gut	lining.		However,	the	
mechanisms	by	which	nearly	80%	patients	have	success	with	EEN	is	unknown.		In	this	study,	based	on	the	use	of	EEN	and	routine	re-evaluation	
of	 gut	 lining	 after	 8	 weeks	 treatment,	 we	 expect	 to	 identify	 early,	 those	 not	 adequately	 responding	 to	 treatment	 and	 identify	 the	 key	
parameters	that	predict	those	likely	to	be	poorer	responders	and	those	who	benefit	most	from	EEN.		Poor	responders	need	more	aggressive	
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treatments.	Beneficial	changes	in	the	gut	bacteria	and	immune	regulation	associated	with	healing	of	the	gut	lining	will	direct	future	nutritional	
therapies	and	give	vital	understanding	into	the	causes	of	Crohn’s	disease.		
At	the	time	of	diagnosis	of	your	Crohn’s	disease	you	will	be	offered	treatment	with	EEN,	that	means	consuming	a	special	milk	as	sole	nutrition	
for	8	weeks.		You	can	have	cordial,	lemonade,	boiled	sweets	but	no	other	nutrition.		Many	children	need	a	Nasogastric	tube	to	help	take	all	the	
nutrition	needed	for	recovery	of	health	but	also	to	persist	consuming	the	milk.		The	consultant	supervising	your	care	is	keen	to	offer	you	this	
treatment	 but	will	 discuss	with	 you	 alternative	 treatment	 strategies,	 if	 he/she	 think	 they	 are	 better	 for	 you	 and	 if	 you	wish	 to	 avoid	 EEN	
treatment.		Your	needs	and	wishes	are	more	important	than	study	requirements.		The	other	treatment	traditionally	offered	in	this	setting	is	
steroids.		Steroids	are	easier	to	administer	but	have	more	side	effects	and	are	less	effective	in	treating	the	gut	inflammation.	
If	you	consent	to	take	part	in	the	study,	while	under	anaesthetic	for	the	first,	diagnostic	Endoscopy	and	Colonoscopy	we	will	collect	additional	
blood	and	biopsies	from	you.			We	will	also	ask	for	a	stool	specimen.		The	additional	blood	will	be	approximately	20mls	(4	teaspoonfuls)	to	look	
at	your	CD	genetic	make-up	and	also	to	look	at	the	special	white	blood	cells	(T	regulatory	cells)	that	control	inflammation.		Many	children	have	
already	been	involved	in	Genetic	studies	looking	at	the	causes	of	IBD	in	children	and	this	study	will	dovetail	with	that	one.		Your	DNA	will	not	
be	used	for	any	purpose	other	than	investigation	into	the	causes	and	best	treatments	for	Inflammatory	Bowel	Disease	(IBD)	of	which	Crohn’s	
disease	is	the	major	example.			Additional	biopsies	will	be	taken	from	the	lining	of	the	bowel	to	look	at	the	organisms	that	stick	to	the	bowel	
lining;	to	look	at	the	T	regulatory	white	blood	cells	in	the	bowel	lining	and	to	look	at	the	expression	of	cell	messenger	proteins	(cytokines)	in	
the	bowel	lining.			Normally	we	take	20-30	biopsies	(each	2mm	diameter)	from	children	to	best	assess	the	cause,	severity	and	distribution	of	
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any	disease.	 	 If	 you	 take	part	 in	 the	 study,	 that	 number	will	 increase	by	 an	 extra	 12	biopsies	 to	 gain	 research	 information.	 	 It	will	 add	 an	
additional	5-10minutes	to	the	length	of	the	procedure	but	will	not	cause	any	additional	problems	for	you.		It	will	not	damage	the	gut	and	the	
risk	of	bleeding	from	biopsies	is	minimal.		The	stool	specimen	will	be	analysed	for	the	range	of	organisms	in	it.		
After	 completing	 8	 weeks	 treatment,	 either	 EEN	 or	 an	 alternative	 such	 as	 steroids	 if	 this	 was	 chosen,	 we	will	 repeat	 the	 Endoscopy	 and	
Colonoscopy	to	establish	if	satisfactory	healing	has	taken	place.		We	think	this	is	the	best	way	to	determine	the	next	step	in	management.		You	
are	not	obliged	to	have	the	follow	up	procedures	if	you	do	not	wish	to.		If	you	do,	and	if	you	still	wish	to	be	part	of	the	study,	we	will	again	
collect	additional	biopsies,	an	extra	12,	and	additional	blood	10mls,	to	 look	at	the	T	regulatory	white	blood	cells.	 	Your	treatment	after	this	
second	procedure	will	be	determined	by	your	consultant	in	consultation	with	yourself.		But	if	you	have	had	a	good	response,	it	will	mean	no	
immediate	ongoing	treatment,	as	is	current	best	practice.			
	
Also	during	the	study,	we	will	be	routinely	performing	other	important	clinical	tests;	stool,	blood,	MRI	scan	(special	X-ray)	of	your	gut,	bone	
density)	which	are	good	practice	and	together	with	the	research	information	will	help	give	us	the	very	best	information	to	help	manage	your	
Crohn’s	Disease.		Valuable	information	gained	from	this	study	will	be	published	in	scientific	journals	and	media	but	any	information	relating	to	
you	will	remain	strictly	confidential	and	your	privacy	protected.		In	particular,	any	research	details	will	be	stored	in	a	de-identified	form.				
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There	is	no	obligation	to	take	part	in	the	study,	or	to	have	the	investigations	recommended.		If	you	do	decide	to	take	part,	you	can	change	your	
mind	at	any	time	and	withdraw.		Not	taking	part	or	withdrawing	from	the	study	will	not	affect	your	treatment	or	relationship	with	the	Doctors	
and	the	Hospital	in	anyway.	
	
If	you	have	any	questions	or	concerns	about	the	study	arising	from	this	information	sheet	or	from	what	you	have	heard	about	the	tests	or	the	
study	we	would	be	happy	to	answer	them.		Feel	free	to	discuss	this	study	with	your	parents,	guardians	and	friends.	
	
Thank	you	for	considering	this	study.	
	
Associate	Professor	Peter	Lewindon		 Dr	Zubin	Grover				 Associate	Professor	Graham	Radford-Smith	
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2.CONSENT	FORM	-	Adolescent	Assent	Form	
	
Study	Title	 “Exclusive	enteral	nutrition	 (EEN)	and	mucosal	healing(MH)	 in	newly	diagnosed	patients	with	Crohn’s	disease	 (CD)and	
comparison	 of	 clinical	 parameters,	 biomarkers,	 faecal	 microbiome	 and	 genotype	 between	 responders	 and	 non-
responders”	
	
Lay	Study	Title		 "Exclusive	enteral	nutrition	(EEN)	and	mucosal	healing	in	newly	diagnosed	patients	with	Crohn’s	disease"		
	
Names	of	Chief	Investigators:	
	
A/Prof	Peter	Lewindon	 	 	 Dr	Zubin	Grover	 	 		 	A/	Prof	Graham	Radford-Smith	
Department	of	Gastroenterology	 	 Department	of	Gastroenterology	 	Head	IBD	Research	Group	
Royal	Children’s	Hospital,	Brisbane	 	 Royal	Children’s	Hospital	 			 H	Floor,	Queensland	Institute	Medical	Research	 	
Tel:	07	3636	5244			 	 	 	 Tel:	0736361909	 	 			
If	you	have	read	the	accompanying	information	sheet	and	wish	to	proceed,	please	sign	this	consent	form.	
221 
 
If	you	have	any	further	questions	please	ask	any	of	the	investigators.		Please	also	take	the	opportunity	to	discuss	this	study	with	your	parents	
and	any	of	the	other	clinic	doctors.	
I	have	read	the	parent	/	patient	information	sheet	and	wish	to	take	part	in	this	study	into	Crohn’s	Disease.		I	consent	to	performance	of	the	
following	procedures	by	the	Gastroenterology	consultants;	Drs	PJ	Lewindon,	L	Ee,	G	Withers,	FL	Connor,	E	McIntyre,	Z	Grover	and	R	Muir	on	
my	child	
	____________________________	
1. 12	additional	small	pieces	(2	mm)	of	Intestinal	biopsy	tissue	being	sent	for	research	into	mechanisms	of		mucosal	healing.	
2. Collection	of	blood	(an	extra	20mls)	for	research	purposes,	to	evaluate	special	immune	white	blood	cells	circulating	in	blood	and	CD	
genetic	make-up	
3. Collection	of	stool	to	assess	changes	in	micro	flora.	
4. Storage	of	clinical	and	research	data	 in	a	confidential	 research	database	to	be	used	exclusively	 for	the	better	understanding	and	
treatment	of	Crohn’s	Disease	and	Inflammatory	Bowel	Disease.	
	
I	understand	that	my	child	will	not	be	put	at	additional	risk	by	taking	part	in	this	study	and	that	the	identity/the	identity	of	my	child	will	be	
strictly	protected.	
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Signed:		 	 	 	 	 	 Witnessed	by:	
	
	
Date:	 	 	 	 	 	 	 Date:	 	 	 	 	 	 	
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3.	Patient	and	Parent	Information	Sheet	
Study	Title	 “Exclusive	enteral	nutrition	(EEN)	and	mucosal	healing(MH)	in	newly	diagnosed	patients	with	Crohn’s	disease	(CD)	and	
comparison	 of	 clinical	 parameters,	 biomarkers,	 faecal	 microbiome	 and	 genotype	 between	 responders	 and	 non-
responders”	
	
Lay	Study	Title		 "Exclusive	enteral	nutrition	(EEN)	and	mucosal	healing	in	newly	diagnosed	patients	with	Crohn’s	disease"		
	
Names	of	Chief	Investigators:	
	
Assoc	Prof	Peter	Lewindon	 	 Dr	Zubin	Grover									 	 	 	 	A/	Prof	Graham	Radford-Smith	
Department	of	Gastroenterology	 Department	of	Gastroenterology	 			 Head	IBD	Research	Group	
Royal	Children’s	Hospital,	Brisbane	 Royal	Children’s	Hospital	 			 				 H	Floor,	Queensland	Institute	Medical	Research	 	
Tel:	07	3636	5244			 	 	 	 Tel:	0736361909	 	 			
	 	 	 	 	
We	would	like	to	invite	you	/	your	child	to	participate	in	a	study	to	help	us	care	for	children	with	Crohn’s	disease.		This	information	sheet	is	to	
explain	why	we	are	performing	 the	study	and	what	 is	 involved	should	you	wish	 to	participate.	 	The	study	has	been	approved	by	 the	Royal	
Children's	Hospital,	Ethics	Committee.		There	is	no	obligation	to	take	part	in	this	study,	if	you	do	not	wish	to.	
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Crohn's	disease	(CD)	is	a	chronic	debilitating	inflammation	of	the	bowel.	When	diagnosed	in	childhood	(25%	of	all	cases)	the	disease	is	more	
severe	with	major	consequences	for	life-long	quality	of	life.	More	than	50%	of	children	will	have	surgery	to	remove	damaged	bowel	within	10	
years	of	diagnosis.		Despite	advances	in	knowledge,	the	chain	of	events	leading	to	CD	is	unknown	although	an	abnormal	immune	response	by	
white	blood	cells	to	gut	micro	flora	is	known	to	play	a	major	role.	The	impact	of	achieving	mucosal	(gut	lining)	healing	early	on	in	the	course	of	
CD	is	now	recognised	as	the	most	important	factor	in	determining	future	quality	of	life,	success	of	maintenance	treatments	and	risk	of	surgery.	
“Clinical	remission”	(feeling	better,	recovery	of	normal	function)	is	not	sensitive	enough	to	predict	mucosal	healing	with	over	70%	of	patients	
on	 steroids	 reporting	 clinical	 remission	having	active	mucosal	disease.	 	 Exclusive	Enteral	Nutrition	 (EEN)	 for	 a	minimum	of	8	weeks	 is	now	
recognised	 as	 not	 only	 safer,	 but	 more	 effective	 than	 traditional	 treatment	 with	 steroids	 for	 inducing	 mucosal	 healing.	 	 However,	 the	
mechanisms	by	which	nearly	80%	patients	have	success	with	EEN	is	unknown.		In	this	study,	based	on	use	of	EEN	and	routine	re-evaluation	of	
mucosal	healing	after	8	weeks	treatment,	we	expect	to	identify	early,	those	not	adequately	responding	to	treatment	and	the	key	parameters	
that	predict	those	likely	to	be	poorer	responders	versus	those	who	benefit	most	from	EEN.		Poor	responders	need	more	aggressive	treatment.	
Beneficial	changes	in	gut	microflora	and	immune	regulation	associated	with	mucosal	healing	will	direct	future	nutritional	therapies	and	give	
vital	understanding	into	the	causes	of	Crohn’s	disease.		
	
At	the	time	of	diagnosis	of	your/your	child’s	Crohn’s	disease	you/your	child	will	be	offered	treatment	with	EEN,	that	means	using	a	special	milk	
as	sole	nutrition	for	8	weeks.		You/your	child	child	can	have	cordial,	 lemonade,	boiled	sweets	but	no	other	nutrition.		Many	children	need	a	
Nasogastric	tube	to	help	take	all	the	nutrition	needed	for	recovery	of	health	but	also	to	persist	consuming	the	milk.		The	consultant	supervising	
your/your	 child’s	 care	 is	 keen	 to	 offer	 you	 this	 treatment	 but	 will	 consider	 alternative	 treatment	 strategies,	 if	 he/she	 thinks	 they	 are	 in	
your/your	 child’s	 best	 interests	 and	 this	 takes	 precedence	 over	 any	 study	 requirements.	 	 The	 other	 treatment	 traditionally	 offered	 in	 this	
setting	is	steroid	medication.		Steroids	are	easier	to	administer	but	have	more	side	effects	and	are	less	effective	in	treating	the	inflammation.	
If	you	consent	to	take	part	in	the	study,	while	under	anaesthetic	for	the	first,	diagnostic	Endoscopy	and	Colonoscopy	we	will	collect	additional	
blood	 and	 biopsies	 from	 you/your	 child.	 	 	 We	 will	 also	 ask	 for	 a	 stool	 specimen.	 	 The	 additional	 blood	 will	 be	 approximately	 20mls	 (4	
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teaspoonfuls)	to	look	at	your/your	child’s	CD	genetic	make-up	and	also	to	look	at	the	special	white	blood	cells	(T	regulatory	cells)	that	control	
inflammation.		Many	children	have	already	been	involved	in	Genetic	studies	looking	at	the	causes	of	IBD	in	children	and	this	study	will	dovetail	
with	that	one.		Your/your	child’s	DNA	will	only	be	used	EXCLUSIVELY	for	investigation	into	the	causes	and	best	treatments	for	Inflammatory	
Bowel	Disease	(IBD)	of	which	Crohn’s	disease	is	the	major	example.			Additional	biopsies	will	be	taken	from	the	lining	of	the	bowel	to	look	at	
the	microflora	that	 is	adherent	to	the	bowel	 lining;	to	 look	at	the	T	regulatory	cells	 in	the	bowel	 lining	and	to	 look	at	the	expression	of	cell	
messenger	proteins	(cytokines)	in	the	bowel	lining.			Normally	we	take	20-30	biopsies	(each	2mm	diameter)	from	children	to	best	assess	the	
cause,	severity	and	distribution	of	any	disease.		If	you/your	child	take	part	in	the	study,	that	number	will	increase	by	an	extra	12	biopsies	to	
gain	 research	 information.	 	 It	will	 add	 an	 additional	 5-10minutes	 to	 the	 length	of	 the	procedure	but	will	 not	 significantly	 affect	 your/your	
child’s	health.		It	will	not	damage	the	gut	and	the	risk	of	bleeding	from	biopsies	remains	minimal.		The	stool	specimen	will	be	analysed	for	the	
range	of	organisms	in	it.		
	
After	 completing	 8	 weeks	 treatment,	 either	 EEN	 or	 an	 alternative	 such	 as	 steroids	 if	 this	 was	 chosen,	 we	will	 repeat	 the	 Endoscopy	 and	
Colonoscopy	to	establish	if	satisfactory	healing	has	taken	place.		We	think	this	is	the	best	way	to	determine	the	next	step	in	management.		You	
are	not	obliged	to	have	the	follow	up	procedures	if	you	do	not	wish	to.		If	you	do,	and	if	you	still	wish	to	be	part	of	the	study,	we	will	again	
collect	 additional	 biopsies,	 an	 extra	 12,	 and	 additional	 blood	 10mls,	 to	 look	 at	 the	 T	 regulatory	 cells.	 	 Your	 subsequent	 treatment	will	 be	
determined	 by	 your	 consultant	 in	 consultation	 with	 yourself.	 	 But	 if	 you	 have	 had	 a	 good	 response,	 it	 will	 mean	 no	 immediate	 ongoing	
treatment,	as	is	current	best	practice.			
	
Also	during	the	study,	we	will	be	systematically	performing	other	important	clinical	tests	(stool,	blood,	MRI	abdomen,	bone	density)	which	are	
good	practice	to	manage	the	Crohn’s	disease	and	together	with	the	research	information	will	help	give	us	the	very	best	information	to	help	
manage	your/your	child’s	Crohn’s	Disease.	 	Valuable	 information	gained	from	this	study	will	be	published	in	the	scientific	 literature	but	any	
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information	relating	to	you/	your	child	will	remain	strictly	confidential	and	their	privacy	protected.		In	particular,	any	research	details	will	be	
stored	in	a	de-identified	form.				
There	is	no	obligation	to	take	part	in	the	study,	or	to	have	the	investigations	recommended.		If	you	do	decided	to	take	part,	you	can	change	
your	mind	at	any	time	and	withdraw.		Not	taking	part	or	withdrawing	from	the	study	will	not	affect	your	treatment	or	relationship	with	the	
Doctors	and	the	hospital	in	anyway.	
	
If	you	have	any	questions	or	concerns	about	the	study	arising	from	this	information	sheet	or	from	what	you	have	heard	about	the	tests	or	the	
study	we	would	be	happy	to	answer	them.	
Thank	you	for	considering	this	study.	
	
Dr	Zubin	Grover				
Associate	Professor	Peter	Lewindon		
Associate	Professor	Graham	Radford-Smith	
	
	
	
	
	
	
	
	
	
227 
 
Study	Protocol	
1. Call	65801/0466353242	for	information	sheets	/consent,	although	available	on	J	drive	under	research	folder.	
2. Request	for	Stool	sample	(	before	bowel		washout	,	to	be	stored	at	home	in		refrigerator	)	
Consent	to	participate		
	
	
	
	
	
	 	
	
	
	
	
	
	
	
 Baseline PCDAI, CRP, Iron studies, Calprotectin, Endoscopy, MRE 
Screen for Biological/Immunomodulators –QTB, HBV, HCV, EBV, CMV, Varicella 
*Optimise vaccination, including siblings 
TPMT status  
Early biologics for fistulising CD – Medicare link 
http://www.medicareaustralia.gov.au/provider/pbs/drugs1/files/4237-initial-fistulising-crohn-
disease.pdf 
EEN /Steroids induction therapy 
*Wait 3 weeks after live vaccines (MMR, Varicella) before starting IM/Biologics 
* No Live vaccines with Steroids 
 Those vaccinated/normal screening with severe Phenotype may be started on 6MP/Imuran - < 3 
weeks 
 
 
1st OPD Visit after confirmed diagnosis (2-3 weeks) 
PCDAI, CRP, Iron Studies  
If not already on start 6MP/Imuran (3 weeks after live vaccine) grading up to 2-2.5mg/kg/day  
*Calprotectin –to see early response 
(* evidence that fall > 20% from baseline may predict response to EEN on D30) 
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2nd OPD /Endoscopy visit (End of EEN, usually on 6MP or Imuran) 
  
Follow up – Calprotectin, PCDAI, CRP, Endoscopy, MR Enterography (Usually 8-10 weeks) 
                                                                            
No mucosal remission    Partial Mucosal remission  Mucosal 
remission 
(< 3 months of 6MP/Imuran)   Continue IM     Continue IM 
Continue IM    PBS funded Inflximab/Second Course EEN- Clinical relapse
  
* If severe inflammatory luminal disease, consider Compassionate Infliximab 
**If associated fistulising Peri-anal disease, consider PBS Biologics 
*** If stricturing Ileal disease consider early limited resection and prescribe Post-operative antibiotics for 3 
mo 
****Follow up endoscopy 3 mo post resection to evaluate for endoscopic relapse in terminal ileum 
      
 
 Clinical Follow up – Calprotectin, PCDAI, CRP, BMI Z scores 
   
              Secondary end points:  at 1, 2 years and last follow up 
Hospitalisation    
Disease relapse   
Steroid therapy 
Resection 
Need for Biologics 
Progression of Clinical Phenotype 
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Ph.D.	Portfolio	
Research	School:	Queensland	Children	Medical	Research	Institute	
University	of	Queensland,	School	of	Medicine	
PhD	Tenure:	
Full	time:	18/07/2012-29/05/2013	
Interruption:	29/05/2013	-01/02/2014	
Part	time	Remote	status	(50%)	-	02/02/2014	–	06/2017	
	
PhD	MILESTONES	
	
Confirmation:	November	23.	2012	
Mid-candidature	review:	July	22	2015	
Final	document,	Oral	presentation:	September	2017	
Final	review:	December	2017	
Submission	for	examination:	February	2018	
Post	examination	review	received	Sep	2018	
Post	examination	review	submission	Nov	2018	
	
Awards	and	Scholarship:	
ANZ	Trustees	Clinical	PHD	scholarship	$35,500,	(2	years)		
QCMRI	Clinical	PHD	top	up	scholarship	$14500,	(2	years)	
QCMRI	Clinical	PHD	scholarship	$35,500,	(1	year)	
PMH	Foundation	Grant	$	89,102	(18	months)		
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Invited	National	and	International	Oral	Presentations:	
Long	term	Outcomes	of	EEN	in	CD	
Therapeutic	diets	in	IBD		
Australian	Gastroenterology	
week,	Gold	Coast,	Sep	2017	
The	 Relative	 Abundances	 of	 Dorea	 and	 Faecalibacterium	 spp.	 in	
the	Mucosa	Associated	Microbiome	of	Newly	Diagnosed	Children	
with	 Crohn's	 Disease	 Are	 Differentially	 Affected	 by	 Exclusive	
Enteral	 Nutrition	 (2442760),	 Gastroenterology	 April	 2016	 150,	
Issue	4,	Supplement	1,	Pages	S132–S133	
Digestive	Disease	Week	
San	Diego	May	21-24,	2016.	
Accelerated	 Step	 up	 use	 of	 Infliximab	 is	 associated	 with	 greater	
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